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ABSTRACT 
 
Mahle, Deirdre A., PhD; Biomedical Sciences PhD program, Department of Biochemistry and 
Molecular Biology, Wright State University, 2012. ‘Omic’ Evaluation of the Region Specific 
Changes Induced by Non-Cholinergic Diisopropylfluorophosphate (DFP) Exposure in Fischer 
344 Rat Brain 
 
 
Organophosphorous compounds (OPs) are a class of serine esterase inhibitors that have 
widespread application as pesticides, veterinary pharmaceuticals and chemical warfare agents.  
Environmental contamination is ubiquitous.  The threat of exposure is a concern for both military 
and civilian populations.  Acute inhibition of acetylcholinesterase by OPs triggers a cholinergic 
crisis that results in muscle flaccidity, paralysis, convulsions and death.  At low doses OPs can 
alter neuronal differentiation, cell signaling, behavior and cognition through unknown 
mechanisms.  An imbalance of reactive oxygen species may be implicated in the adverse effects 
of OPs.  An integrated approach using both metabolomic and transcriptomic techniques was used 
to reveal some of the non-cholinergic effects of diisopropylfluorophosphate (DFP), a model OP, 
in rat brain.  Adult male Fischer 344 rats were administered 1 mg/kg DFP or saline via 
subcutaneous injection at 10 mL/kg.  Cortex, brainstem, cerebellum and hippocampus were 
collected at multiple time points ranging from 0.5 - 48 hr.  Total RNA was isolated from each 
region for differential gene expression analysis using the Affymetrix 1.0 ST gene array at 1 hr 
post dose.  Lipid and aqueous extracts were prepared from each brain region at 2 hr post dose, 
and profiles of small molecule metabolites, lipids and phospholipids were measured using 
multinuclear NMR spectroscopy.  Because the dose was below the threshold for cholinergic 
iv 
 
toxicity, it was hypothesized that DFP exposure would up-regulate inflammatory pathways and 
down-regulate processes that result in cellular degradation, such as apoptosis, and that these 
changes would correlate with perturbations in the small molecule and lipid profiles as well as 
gene expression.  All brain regions reached minimum acetylcholinesterase activity (40-55%) at 1-
2 hr post dose with the exception of cortex, which had minimum activity at 12 hr post dose.  No 
brain region showed significant increases in lipid peroxidation.  After 1 hr, pathways associated 
with prostaglandin D2 synthesis were up-regulated in cortex.  Brainstem showed increased 
expression of genes associated with an inflammatory response and ascorbate transport.  Cortex 
showed the most changes in the lipid profile with significant decreases in phosphatidylcholine, 
phosphatidylethanolamine, cholesterol, n3 and n6 fatty acids.  The mitochondrial phospholipid 
cardiolipin was significantly decreased after 2 hr in brainstem.  By evaluating the impact of low 
level OP exposure on the neuronal phenotype of specific brain regions, we hope to gain a greater 
understanding of the non-cholinergic mechanisms of action and sensitive target areas in order to 
improve the development of therapeutic targets for individuals exposed to OPs. 
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I.   INTRODUCTION 
1.1 Background 
Sufficient evidence exists to suggest that organophosphates (OPs), as a class of 
compounds, exert toxicity by mechanisms that are non-cholinergic or are secondary to 
cholinergic activation.  A variety of OPs exhibiting a range of acute toxicities have been reported 
to alter neuronal differentiation and migration, interfere with signaling cascades and impart 
learning and cognitive dysfunction at doses that do not significantly inhibit the enzyme 
acetylcholinesterase.  Knowledge of the mechanisms of action, however, is limited.  This 
dissertation investigates the off-target toxicity of the OP diisopropylfluorophosphate (DFP).  A 
rat model was used to test the following hypothesis:  A non-cholinergic dose of DFP will 
initiate an inflammatory response, possibly mediated by oxidative stress, which perturbs the 
metabolic profile of the central nervous system.  Because of the low level nature of the dose, it 
was expected that the cellular response of the brain would be two-fold:  protection and repair.   
The experimental approach taken for this research relied on ‘omic’ technology, which 
allowed for a systems biology-focused analysis to integrate the complex biological responses in a 
complex biological system.  Both transcriptomics and metabolomics provide a global picture of 
the cellular response to disease, injury or, in this case, toxic insult.  While the transcriptome does 
not define a cell’s physiology it reveals what potentially can happen.  The physiological activity 
of the cell is triggered and regulated at the level of the metabolites.  Therefore, the use of a multi-
omic approach is advantageous since the results can be analyzed and interpreted in an integrated 
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manner.  The etiology of nearly all central nervous system (CNS) diseases and dysfunctions is 
largely unknown but likely is a mix of conditions that are undefined (Kaddurah-Daouk and 
Krishnan, 2009).  Therefore, transcriptomics and metabolomics are powerful and potentially 
synergistic tools that can provide a snapshot of the molecular impact of an OP exposure.  By way 
of example, genomics has successfully been used to link motor neuron disease to a genomic 
mutation in superoxide dismutase (Rosen et al, 1993), while metabolic fingerprints have also 
been identified for the same disease (Rozen et al, 2005).  Using both approaches can potentially 
bridge the gap between the changes in gene expression and the final phenotype of the cell. 
No metabolomic approaches have investigated the changes in the brain’s metabolic 
phenotype after exposure to an OP, though a few have looked at systemic fluids (Bevilacqua et 
al., 2005).  Additionally, few transcriptomic studies have looked at the differential gene 
expression after OP exposure, and the results are incomplete, at best.  However, one study, while 
limited, showed increased expression of both pro- and anti-apoptotic genes (Damodaran et al., 
2006b), supporting the idea that the cellular response to low level exposure of an OP was 
balanced between protection and repair.  The metabolomic and transcriptomic experiments 
described here increase the knowledge base toward improved understanding of the mechanistic 
basis of adverse effects of low level DFP exposure.  
An important characteristic of this research effort is that the brain was not regarded as a 
single organ system.  Because the brain is highly heterogeneous in chemistry, composition and 
function, it was divided into four major regions: cortex, brainstem, cerebellum and hippocampus.  
Each region represented a distinct structure and physiology, chemical and cellular makeup and, 
ultimately, a distinctive function.  Therefore, it was reasonable to assume that each region’s 
response to a low level exposure of DFP would have both characteristic similarities and unique 
differences.  Additionally, investigating specific regions of the brain improved the likelihood of 
detecting slight perturbations that are significant responses for the region but may be diluted by 
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looking at the brain as a whole.  In the rat brain, the hippocampus has been shown to be sensitive 
to nerve agent-induced seizures, while the frontoparietal cortex and cerebellum are sensitive 
regions in monkeys (Spradling et al., 2011).  Because of the nature of nuclear magnetic resonance 
spectroscopy, a primary analytical tool for this research, sufficient tissue is unavailable from 
regions smaller than the hippocampus.  Therefore, the selection of cortex, brainstem, cerebellum 
and hippocampus was based on regional sensitivity to OPs, size and uniqueness of function. 
By understanding the mechanisms of DFP-induced inflammation and its impact on the 
metabolic functioning of specific brain regions, ongoing research can be focused on the sensitive 
areas of the brain to develop more effective therapeutic targets and preventative measures for 
individuals with neural dysfunction caused by OP exposure. 
1.2 Transcriptomics and metabolomics 
The research described here relied on the use of -omic techniques, specifically 
transcriptomics and metabolomics.  A great deal of toxicological research is based on a 
reductionist approach, where a system is broken down to the smallest possible component in 
order to understand the component more fully.  The use of a systems biology approach allowed 
the components to be integrated in order to understand more fully how the system was affected 
(Fig. 1).  For the purpose of studying the mechanistic basis of a toxic insult, both transcriptomics 
and metabolomics can provide data-rich snapshots of the global cellular response.  
Transcriptomics is the study of the transcriptome, or the set of all RNA molecules 
(mRNA, tRNA, rRNA and non-coding RNA) in a group of cells (Fig. 1).  Traditionally, Northern 
blots have been performed to (semi) quantify the amount of mRNA in a biological sample.  With 
the use of specific primers and a radiolabeled probe, RT-PCR (reverse transcriptase-polymerase 
chain reaction), can be employed to amplify a cDNA fragment for quantification.  However, this 
could only be done with one gene at a time, until the advent of the microarray.  Gene expression 
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in a biological sample was first profiled using a microarray in 1995 (Schena et al, 1995).  A 
microarray is, in essence, thousands of Northern blots performed simultaneously in parallel.  
Using a gene array that probes for mRNA transcripts only, analyses can focus on the genes that 
are actively expressed or suppressed as a result of toxic insult.  With the completion of the 
Human Genome Project in 2003, resulting in the identification of approximately 25,000 genes in 
human DNA, publicly available, comprehensive databases have facilitated the analysis and 
interpretation of gene expression data. 
Metabolomics is, simply, the study of the metabolome, or the complete set of metabolites 
in a population of cells (Fig. 1).  While metabolomics is often considered the newest of the ‘omic’ 
technologies, it has, in some sense, been used since the beginning of medicine when physicians 
used color, taste and smell of urine to diagnose disease (Wishart, 2007).  The practice has evolved 
over time through the use of clinical chemistry, metabolic profiling and development of 
instrumentation such as HPLC (high pressure liquid chromatography), GC-MS (gas 
chromatography-mass spectrometry) and electrolyte analyzers.   
Metabolites are intermediates or products of metabolism and are very dynamic.  
Approximately 2900 endogenous or common metabolites are estimated to be detectable in the 
human body, though not all are found in every cell type or fluid.  Metabolomics was initially used 
to monitor specific metabolites or groups of metabolites associated with a known function 
(Wishart, 2007, Sweeley et al, 1974).  This targeted approach has the advantage of being able to 
identify and quantify specific metabolites in order to determine a mechanistic basis of action for a 
disease, pharmaceutical or toxin.  However, as more powerful tools have been developed, such as 
tandem mass spectrometry (MS-MS) and NMR spectroscopy, rapid analysis of hundreds of 
metabolites at a time has led to the popularity of a non-targeted approach, which has been further 
advanced by chemometric and multivariate methods to analyze and interpret spectra without 
identifying individual chemical species in a biofluid (Nicholson et al, 1999).  Clustering 
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algorithms like principal component analysis (PCA) can identify metabolic signatures that 
classify spectra to a unique group.  The benefit of a non-targeted approach is that unknown 
metabolites are not ignored or left out of the analysis, and metabolic patterns including previously 
unidentified metabolites have been successfully used to detect diseases and susceptibility to drug 
toxicity (Smith and Baert, 2003; Nicholson et al., 2002). 
A significant problem for metabolomics is that, unlike the fully sequenced human 
genome, metabolic databases are still in their infancy.  However, in 2007, scientists working 
under the support of Genome Alberta and Genome Canada completed the first draft of the Human 
Metabolome Project (www.metabolomics.ca).  To date, the Human Metabolome Project has 
determined the normal concentration range of hundreds of metabolites specific for tissues, serum, 
urine and cerebrospinal fluid.  Because the metabolic profile at any given time is a snapshot of 
that cell’s physiology, metabolomics provides a unique tool to relate genomic changes to a 
cellular phenotype. 
Both nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography/mass 
spectrometry (LC/MS) are commonly-employed tools for studying and quantifying the 
metabolome.  Each method has its own unique advantages and disadvantages.  High resolution 
NMR-based metabolomics was used for this study because of the ability to capture a specific 
small molecule and lipid metabolite profile from one sample with minimal preparation.  Instead 
of a classical approach of measuring an individual metabolite or a single kinetic parameter, 
NMR-based metabolomics gives a more complete picture of metabolic perturbations that can be 
more closely related to a biological process (Kaddurah-Daouk and Krishnan, 2009). 
 
 
6 
 
 
Figure 1.  Hierarchy of omic techniques, showing the relationships between each discipline.  The omic 
techniques are often described as: genomics – what can happen; transcriptomics – what appears to be 
happening; proteomics – how it happens; metabolomics – what happened. Image taken from the Royston 
Goodacre School of Chemistry, The University of Manchester. 
 
 
1.3 Cholinergic toxicity of OP compounds 
 OPs are tri-ester derivatives of phosphoric or phosphorothioic acid.  They are 
pentavalent tetrahedrons with three singly bound groups and an oxygen or sulfur atom doubly 
bound to a central phosphorous atom (Chambers and Oppenheimer, 2004).  The general structure 
is shown in Figure 2; however, OPs exhibit a wide variety of chemistries as seen in Fig. 3. 
 
  
7 
 
 
 
 
 
 
 
 
Figure 2.  General organophosphate structure.  R1 and R2 are typically alkyl or alkoxy groups.  X 
denotes a leaving group and has diverse chemical identity.  X is lost during the two step reaction with a 
serine esterase, allowing the remaining electrophilic chemical structure to bind with the hydroxyl group of 
a serine residue in the protein’s active site. 
 
 
 
Figure 3.  Examples of the wide variety of OP chemistry. 
 
OPs are inhibitors of serine esterases and, most significantly, acetylcholinesterase 
(AChE).  AChE is widely distributed in the central and peripheral nervous systems and is 
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responsible for the enzymatic cleavage of the neurotransmitter acetylcholine (ACh) to choline and 
acetate, part of the positive control feedback for normal neurological signaling (Figs. 4 and 5).  
The enzyme has a deep active site containing a catalytic triad of serine, histidine and glutamate, 
creating a strong nucleophile (Fig. 5a).  The nucleophilic attack releases the choline group, 
forming an acetate-AChE intermediate (Fig. 5b).  Hydrolysis frees the acetate moiety. 
 
 
Figure 4.  Schematic of cholinergic transmission and mechanism of action of acetylcholinesterase 
(AChE) in the cholinergic synapse.  The neurotransmitter acetylcholine is released by a stimulated 
presynaptic neuron into the synaptic cleft.  Acetylcholine binds to muscarininc or nicotinic receptors on the 
postsynaptic neuron or an end organ, typically muscle.  Muscarininc receptors are metabotropic and use G 
proteins for signaling.  Nicotininc receptors are ionotropic and open channels for Ca
2+
, Na
+
 and K
+
.  AChE 
hydrolyzes acetylcholine to yield choline and acetate.  Choline is taken back up by the presynaptic neuron 
through a high affinity choline transporter where it is recycled for acetylcholine synthesis via the enzyme 
choline acetyltransferase (ChAT).  Image taken from Soreq and Seidman, 2001 
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Figure 5.  Breakdown of the neurotransmitter acetylcholine by acetylcholinesterase.  a. catalytic triad 
of acetylcholinesterase.  b. Hydrolysis of acetylcholine to choline and acetate.  Image taken from Soreq and 
Seidman, 2001. 
 
 
Inhibition of AChE is a two step process that involves the formation of an enzyme∙OP 
complex in a transition state (Fig. 6).  
 
 
Figure 6.  Two step inhibition of acetylcholinesterase, resulting in a phosphorylated enzyme. 
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Phosphorylation of the serine active site of AChE by an OP prevents the hydrolysis of ACh, 
resulting in a buildup of the neurotransmitter in the synapse and hyperstimulation of muscarinic 
and nicotinic receptors in the postsynaptic membrane.  Figures 7 A, B and C show the binding of 
an OP, the transition state and the phosphorylation of the serine active site.  OP binding to AChE 
is not irreversible, but takes hours to days to release; therefore, binding is considered essentially 
irreversible, as new enzymes are synthesized before the bound protein is spontaneously 
regenerated.  However, certain OPs undergo ‘aging’, a process of dealkylation.  The resulting 
monoalkyl renders the enzyme ‘aged’ and completely resistant to regeneration or reactivation. 
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Figure 7.  Mechanism of action of organophosphate (OP) inhibition of the enzyme 
acetylcholinesterase, using a nerve agent as a model OP.  A.)  Initial electrophilic attraction of the 
partially electropositive P of nerve agent to partially electronegative O of serine in the acetylcholinesterase 
active site.  B.)  Formation of OP∙enzyme transition state.  RL is the leaving group.  C.)  Phosphorylation of 
serine active site of acetylcholinesterase.  Binding of nerve agent prevents binding of acetylcholine in 
active site.  Taken from Agency for Toxic Substances and Disease Registry (ATSDR). 
 
 
Symptoms of cholinergic toxicity range from mild to severe and include blurred vision, 
muscle weakness, fasciculations, seizures, paralysis and death from respiratory failure.  ACh 
receptor antagonists such as atropine can reduce or prevent excitotoxicity, while oxime 
A 
B 
C 
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reactivators such as pralidoxime chloride can cleave the OP and restore enzyme activity.  
However, most therapeutically used oximes do not readily cross the blood brain barrier, leaving 
the brain vulnerable to long term effects of AChE inhibition (Garcia et al., 2010).   
Because of the powerful ability to inhibit AChE activity, OPs have been exploited as 
pesticides, pharmaceuticals (treatment of glaucoma, primary degenerative dementia, 
schistosomiasis) and, more insidiously, as chemical warfare agents since the 1930s.  The attacks 
on civilians with sarin (GB) in Japan made it clear that terrorist use of chemical weapons is no 
longer limited to military operations (Yokoyama et al., 1998; Yanagisawa et al., 2006).  As a 
result, the risk of widespread contamination and human exposure, accidental or intentional, is 
high.  
 Cholinergic crisis is a catastrophic event that requires immediate life-saving treatment 
in the form of ACh receptor antagonists and enzyme reactivators.  However, veterans of the Gulf 
War have been exposed to a variety of low level pesticides used in areas designated for eating and 
sleeping.  Some were even exposed to low levels of GB and cyclosarin (GF) during the process of 
destroying a munitions dump (Proctor et al., 2006).  It has been speculated that chronic exposure 
to these low levels of OPs may have contributed to the medically unexplainable physical 
symptoms experienced by many veterans of the first Gulf War.  Indeed, the incidence of a 
neurodegenerative disease that strikingly resembles amyotrophic lateral sclerosis (ALS) was 
significantly increased in this group with onset at ages younger than typically seen with sporadic 
ALS (Haley, 2003; Horner et al., 2003; Weisskopf et al., 2005). 
 It has already been documented that chronic inhibition of the enzyme neurotoxic 
esterase (NTE) by some OPs is associated with OP-induced delayed neuropathy (OPIDN), though 
OP pesticides used in the United States are not significant inhibitors of NTE, and there is limited 
evidence to suggest that nerve agents target NTE (Pope, 1999; Richardson, 1992).  Therefore, 
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OPIDN is not the focus of this research.  However, in addition to anticholinesterase activity, 
evidence is mounting that OPs exert adverse neurological effects that may be secondary to or 
separate from inhibition of AChE with the potential to lead to neuronal dysfunction.   
1.4 Non-cholinergic toxicity of OP compounds 
Based on published data and for the purposes of this research, a non-cholinergic dose was 
considered to be a sub-acute dose that inhibits AChE to a level that does not elicit an overt 
response indicative of cholinergic toxicity such as salivation, lacrimation and seizures 
(muscarininc effects) or muscle weakness, fasciculation and flaccidity/paralysis (nicotinic 
effects).   Substantial evidence exists to indicate that OPs elicit neurotoxic responses at non-
cholinergic doses.  Song et al. (1998) investigated the developmental neurotoxicity of 
chlorpyrifos (CPF), an organophosphothionate, using rat pheochromocytoma (PC12) cells, a cell 
line that can be induced to differentiate into cholinergic neurons.  While the PC12 cells were in an 
undifferentiated state, subtoxic levels of CPF inhibited DNA synthesis in a dose dependent 
manner.  Addition of ACh receptor antagonists had no effect on the inhibition of DNA synthesis, 
indicating that the effects were caused by non-cholinergic mechanisms.  In the same cell line after 
treatment with nerve growth factor (NGF) to induce differentiation, CPF inhibited not only DNA 
synthesis but protein synthesis, as well, with a corresponding decrease in neurite extensions at the 
highest dose. 
In vivo studies have also shown adverse developmental effects of OPs that raise concern 
over pediatric exposure.  Early postnatal rats that were treated daily from postnatal day 1 to 6 by 
oral gavage with either a low or a high dose of CPF were evaluated for markers of neonatal brain 
growth (Betancourt, 2006).  Although the chosen doses caused measurable levels of inhibition of 
brain AChE, they were below the NOEL (no observable effect level) for signs of overt toxicity.  
Both the low and high doses of CPF caused a decrease in the expression of NGF, reelin and 
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myelin-associated glycoprotein (MAG) mRNA.  Because the protein reelin is involved with 
neuronal migration, it is possible that CPF can induce abnormal migration patterns which are 
associated with cognitive and mental dysfunction, as well as motor deficits.  Additionally, 
decreases in MAG, a CNS specific protein, suggest that oligodendrocytes are a target of OPs and 
early formation of myelin in the CNS could be disrupted.  It is important to note that while these 
changes in mRNA expression were dose dependent, the changes were significant from control 
even at the low dose. 
 Diazinon, another organophosphothionate, caused similar restrictive changes in neurite 
outgrowth as CPF in neonatal rats exposed to doses well below the maximum tolerated dose for 4 
days (Slotkin et al., 2006).  Choline acetyltransferase, the enzyme responsible for synthesis of 
ACh, was also decreased, although down regulation of muscarinic ACh receptors, a signal for 
excess cholinergic stimulation, was not evident.  These results suggest that the developmental 
effects were independent from anticholinesterase activity.  Song et al. (1997) compared the 
effects of CPF on adult rat forebrain, an area rich in cholinergic innervation, to the cerebellum, 
which has fewer cholinergic synapses than forebrain and to heart muscle, a non-neuronal tissue.  
The expression and activity of adenylyl cyclase (AC) as well as the activation of the G protein 
receptors coupled to AC were decreased in all three tissues.  Interestingly, the actions of CPF 
were not immediate but were delayed for several days after cessation of treatment.  The 
conclusion was that cholinergic synapses or even the CNS were not the specific target of CPF.    
 Lastly, it was determined from rat hippocampal cultures that nanomolar concentrations 
of the agent VX caused a release of glutamate and γ-aminobutyric acid (GABA) that was 
independent of action potential-induced opening of calcium channels (Rocha et al., 1999).  
Extracellular calcium was required for neurotransmitter release, suggesting that VX could interact 
with the calcium channels directly or through a second messenger.  The release of 
neurotransmitters was unaffected by the complete inhibition of AChE by the nerve agent soman. 
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Therefore, independent of cholinesterase inhibition, VX was able to interfere with neuron to 
neuron communication, establishing dysfunctional transfer of information.  In light of the 
evidence of non-cholinergic toxicity at the cellular level, do these effects translate into a 
phenotype of neurological dysfunction or disease?  
1.5 Altered phenotypes after OP exposure 
Genovese et al. (2006) investigated the effects of low level GF on the learned behavior of 
adult Sprague-Dawley rats that were operantly conditioned to press levers for food pellets.  Rats 
receiving GF by inhalation at doses eliciting only mild signs of toxicity showed a significant 
deficit in the response time as compared to their baseline performances.  However, the effects did 
not persist after 48 hr.  This is in contrast, though, to cognitive studies carried out by Kassa et al. 
(2001).  Learning and spatial memories of adult Wistar rats were significantly influenced by low 
level GB inhalation in a dose dependent manner as compared to control rats exposed to air only.  
Rats in the highest dose group that displayed some mild symptoms of toxicity but were non-
convulsant showed a decrease in their performance for three weeks post exposure.  The 
underlying reason for the deficit in memory, however, is unknown. 
One interesting study investigated the short and long term changes in the hypothalamus-
pituitary-adrenal (HPA) axis after low dose inhalation of GB in adult rats (Peña-Philippides et al., 
2007).  After repeated exposure to GB at doses that did not produce signs of cholinergic toxicity, 
serum cortisol levels decreased significantly and remained lower than control levels at eight 
weeks after treatment.  To correlate the decrease in cortisol to inhibition of the HPA axis and not 
cholinergic toxicity, plasma levels of adrenocorticotropin hormone were measured and were 
found to be significantly decreased, as well.  GB-induced suppression of the HPA axis has the 
potential to disrupt many of the functions under its control.  In light of the fact that cortisol was 
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decreased for at least eight weeks hints at the long lasting effect that GB had on neuroendocrine 
function. 
In 1994 and 1995 terrorists used GB on civilians in a Tokyo subway.  Neurobehavioral 
tests conducted on survivors revealed significantly lower scores on psychomotor performances 
six to eight months after exposure when compared to unexposed individuals, possibly the result 
of permanent damage to the CNS (Yokoyama et al., 1998).  In 1991 US troops destroyed a 
munitions dump that was later discovered in 1996 to have been a depot for the nerve agents GB 
and GF.  Neuropsychological testing was performed to evaluate the impact of the exposure on 
neurobehavioral function on the returning troops (Proctor et al., 2006).  It was found that low 
level exposure to GB and GF was significantly correlated to fine psychomotor dexterity and 
visuo-spatial deficiencies 4-5 years later. 
It is clear that low level exposures to organophosphates have resulted in altered 
behavioral phenotypes, significantly affecting learning and memory functions. These deficits in 
cognitive function indicate the potential for long term damage caused by non-cholinergic doses of 
OPs. 
1.6 OPs and oxidative stress 
It is apparent that OPs can interact with a variety of enzymes and pathways, altering their 
function and changing the phenotype of the targeted cell.  Because OPs are relatively lipophilic 
they can penetrate the blood brain barrier, target neurons and alter neuronal phenotype.  What is 
not clear are the exact, non-cholinergic mechanisms by which OPs affect neural function and 
whether a non-lethal dose can result in adverse changes in brain function.  It is possible that one 
means by which OPs exert non-cholinergic toxicity is through the induction of oxidative stress.  
In the privileged environment of the brain, generating oxidative stress can set off a chain of 
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adverse events that involves peroxidation of structural and signaling lipids, impaired function of 
membrane proteins and inflammation.  
The adult human brain has a tremendously high O2 and glucose consumption rate, using 
20% of basal O2 and 4 X 10
21
 molecules of glucose per min (Emerit et al., 2004).  Mitochondrial 
respiration accounts for the majority of reactive oxygen species (ROS) produced, converting 1-
2% of consumed oxygen into ROS.  The production of ROS is a normal intermediate step of 
mitochondrial oxidation.  However, oxidative stress occurs when there is an imbalance between 
generation and elimination of ROS.  One of the major ROS produced from mitochondrial 
oxidation is superoxide anion, which has one unpaired electron, making it a free radical capable 
of removing an electron from a non-radical species.  Polyunsaturated fatty acids (PUFAs), 
essential components of membranes and signaling lipids and highly abundant in the CNS, are 
sensitive targets of free radicals.  Free radicals such as superoxide can extract hydrogen from a C-
H bond, leaving an unpaired electron on the carbon atom (Fig. 8).  The resulting carbon-centered 
free radical reacts quickly with O2 to form peroxyl radicals.  Peroxyl radicals are highly reactive 
and oxidize adjacent PUFA side chains, membrane proteins and cholesterol, propagating a chain 
reaction that is self sustaining and highly damaging to the cell. 
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Figure 8.  Steps involved in the chain reaction of lipid peroxidation.  PUFA – polyunsaturated fatty 
acid.  Step 1.  Extraction of hydrogen from C-H bond.  Step 2.  Molecular rearrangement  Step 3.  
Generation of lipid peroxyl radical, capable of extracting H from C-H from adjacent PUFA.  Step 4.  
Peroxidized fatty acid.  Taken from Oxidized Phospholipids: Of Whiskers and Razors, Brock, TG. 
 
The adverse effects of lipid peroxidation include a decrease in membrane fluidity with a 
corresponding increase in membrane leakiness, as well as damage to the many membrane 
proteins, including receptors, enzymes and ion channels (Halliwell, 2006).  Many OPs sequester 
in the cellular lipid domains with higher concentrations near the membranes as compared to other 
regions (Bagchi et al., 1995).  Being localized in lipid dense regions provides an ideal 
environment for OPs to have maximum adverse effect, triggering oxidative stress-related impacts 
such as altered membrane structure, compromised membrane proteins or pro-inflammatory 
responses. 
1. 
2. 
3. 
4. 
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1.7 OPs and inflammation 
DFP insult to the brain at a dose below the threshold for cholinergic toxicity would be 
considered an indirect or mild trauma, characterized by expression of M-CSF (macrophage 
colony stimulating factor), TGFβ-1 (transforming growth factor beta) and IL-6 (interleukin-6) 
(Raivich et al., 1999).  Interestingly, an indirect trauma can activate microglia, cells of monocyte 
lineage, to a state of alert, priming them for a more graded response, if necessary (Raivich et al., 
1999).  Multiple reports have shown that acute, seizure-inducing doses of nerve agents elicit pro-
inflammatory responses (Dhote et al., 2007; Chapman et al., 2006; Williams et al., 2003a).  It is 
speculated that pro-inflammatory molecules are responsible for the secondary effects of OP 
poisoning and may be involved in long term neurodegeneration (Spradling et al., 2011).  Limited 
data are available to indicate that non seizure-inducing doses of OPs also trigger inflammatory 
responses.  However, after a 0.5 x LD50 dose of sarin, rat brain showed increased gene expression 
of cytokines that persisted 3 months post exposure (Damodaran et al., 2006a), evidence that low 
level OP exposures do induce an inflammatory response.  It was hypothesized that a non-
cholinergic dose of DFP would initiate an inflammatory response, possible mediated by oxidative 
stress, which would perturb the metabolic profile of the central nervous system.  Because the dose 
level was low, it was expected that this should be a survivable insult and the cellular response 
would focus on protection and repair and the return to homeostasis.  However, in an organ system 
as complex as the nervous system, particularly the brain, initiating an inflammatory cascade can 
set the stage for increased responses that may switch from neuroprotective to neurotoxic, 
resulting in long term dysregulation.  
1.8 Diisopropylfluorophosphate 
The OP selected for this research effort was diisopropylfluorophosphate (DFP).  DFP was 
first synthesized in 1946 as a pesticide (McCombie and Saunders, 1946), though currently it has 
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little commercial value.  This compound was selected because it is both structurally and 
mechanistically similar to highly toxic OPs such as activated insecticides and nerve agents 
(Taylor, 1980).  The chemical structure of DFP is shown in Figure 9.  DFP’s leaving group is 
fluorine, a small, highly electronegative atom.  In the two-step reaction with AChE, the loss of 
fluorine results in a strong electrophile that reacts readily with AChE. 
 
Figure 9.  Chemical structure of the organophosphate diisopropylfluorophosphate (DFP).  The 
leaving group is a fluorine atom, making DFP strongly electrophilic. 
 
It is unclear if DFP-induced oxidative stress is dose-dependent or even if the generation 
of ROS occurs with low level exposure.  Adult male rats exposed to a single dose of DFP had a 
significant increase in lipid peroxidation (measured by thiobarbituric acid-malondialdehyde 
complex) in diaphragm at 30, 60 and 120 minutes after exposure to 1.5 and 2.0 mg/kg but not 1 
mg/kg (Yang and Dettbarn, 1996).  The level of AChE activity after the 1 mg/kg dose was at 
approximately 47% of control while the two higher doses dropped enzyme activity to less than 
15% of control.  The muscle fasciculations caused by the hyperstimulation of ACh receptors 
could account for the increase in ROS (Reid et al., 1992; Yang and Dettbarn, 1996); therefore, it 
is unclear if the source of ROS was receptor hyperstimulation or increased muscle activity that 
correlated to an increase in mitochondrial output.  This study also focused on measurements of 
AChE activity and lipid peroxidation in muscle with no report of brain-specific changes.  In a 
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separate study, rats that were subcutaneously dosed with 1.25 mg/kg DFP in saline showed 
significant increases in cerebral F2-isoprostanes and F4-neuroprostanes, which are sensitive, 
specific markers of oxidative damage to arachidonic acid and docosahexaenoic acid, respectively, 
up to 2 hr post dose (Zaja-Milatovic et al, 2009).  This dose elicited a severe yet nonlethal 
cholinergic response.  Again, it cannot be determined if the generation of ROS was sparked by 
muscle activity or excitotoxicity that results from overstimulation of postsynaptic receptors.  If 
receptor overstimulation was the primary source of oxidative stress, than it is possible that a DFP 
dose that inhibits AChE to a level that does not induce cholinergic crisis may still increase ROS 
through an increase in stimulation of excitatory receptors.  Additionally, measurements of ROS 
for this study were done in whole brain which may mask specific regional changes in lipid 
peroxidation.  To uncover compartmentalized effects and prevent diluted responses this research 
described changes in specific brain regions. 
1.9 Selection of brain regions 
 An important aspect of this research was that the brain was not regarded as a single 
organ system.  Because the brain is highly heterogeneous in chemistry, composition and function, 
it was divided into four major regions: cortex, brainstem, cerebellum and hippocampus.  Each 
region represented a distinct structure and physiology, chemical and cellular makeup and, 
ultimately a distinctive function.  Therefore, it was assumed that each region’s response to a low 
level exposure of DFP would have both characteristic similarities and unique differences.  By 
investigating specific regions of the brain, the likelihood of detecting slight, yet significant 
perturbations for a region was improved.  In the rat brain, the hippocampus has been shown to be 
sensitive to nerve agent-induced seizures, while the frontoparietal cortex and cerebellum are 
sensitive regions in monkeys (Spradling et al., 2011).  DFP has been reported to induce altered 
sleep-wake patterns controlled by the reticular formation in the brainstem (Deurveilher et al., 
1999a, b).  Because of the nature of nuclear magnetic resonance spectroscopy, a primary 
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analytical tool for this proposal, sufficient tissue was unavailable from regions smaller than the 
hippocampus.  Therefore, the selection of cortex, brainstem, cerebellum and hippocampus was 
based on regional sensitivity to OPs, size and uniqueness of function. 
1.10 Thesis focus and significance 
 This research has focused on understanding the mechanism of non-cholinergic toxicity 
and the means by which low level exposure to OPs contributes to long term effects.  The data 
presented here support the hypothesis that a low level exposure to DFP induced an inflammatory 
response that was characterized by a graded cellular response of protection and repair and 
manifested by regional changes in lipid composition and small molecule metabolite profiles.  
Understanding the downstream effects of DFP-induced inflammation on specific regional 
metabolism will provide important knowledge for understanding the mechanistic basis for the 
development of neuroprotectants for individuals exposed to OPs.   
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II. MATERIALS AND METHODS 
2.1 Animals and treatments 
 All animals used in this study were handled in accordance with the principles stated in 
the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996 and the 
Animal Welfare Act of 1966, as amended.  Male Fischer 344 rats (CDF® (F344)/CrlBR; 200-
250g) were received from Charles Rivers Laboratory (Raleigh, NC) and housed individually with 
ad libitum access to food (Purina Certified Rat Chow #5002) and fresh conditioned reverse 
osmosis water.  Rats were given a single subcutaneous injection at the dorsal base of the neck of 
DFP (Sigma Chemical Company) in 0.9% sterile saline at a dose of 1 mg/kg.  Control rats 
received 0.9% sterile saline at 10 mL/kg.  Animals were observed for signs of overt cholinergic 
toxicity for 1 hr post dosing.  These signs included excess salivation, lacrimation, urination and 
defecation (SLUD), as well as the inability to maintain posture.  Control and DFP-treated animals 
(N=5/time point) were euthanized by CO2 inhalation and rapid decapitation at 0.5, 1, 2, 12, 24 or 
48 hr post dose.  One to two drops of trunk blood were collected into tubes containing a heparin 
ring and flash frozen in liquid nitrogen.  Brains were removed, rinsed with ice cold saline and 
dissected on ice to collect cortex, brainstem, cerebellum and hippocampus.  The first dissection 
cut, using a scalpel blade, was a coronal cut between the cerebrum and the cerebellum (Fig. 10 A, 
B).  The portion of the brainstem attached to the cerebellum was gently pulled away to isolate the 
two regions (Fig. 10 C).  A sagittal cut was then made between the two cerebral hemispheres, and 
the two hemispheres were laid medial side up (Fig. 10 A, D).  The thalamus and midbrain were 
gently scraped away and added to the rest of the brainstem.  An ice cold spatula was placed in the 
lateral ventricle underneath the hippocampus (Fig. 10 E).  A cut was made superiorly and 
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inferiorly to free each end of the hippocampus.  The hippocampus was rolled up and away from 
the cortex with the spatula (Fig. 10 F).  It is important to note that because of the dissection 
technique it was undetermined if the corpus callosum was left in the cortex region.  Each section 
was immediately flash frozen in liquid nitrogen and stored at -80°C. 
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Figure 10.  Diagram of rat brain dissection.  A.) Cut 1 separated the cerebellum and portion of the 
brainstem from the rest of the brain.  Cut 2 separated the two cerebral hemispheres to expose the remaining 
brainstem, thalamus and hippocampus. B.) Scalpel blade cutting cerebellum and portion of brainstem from 
cerebrum.  C.) Separation of the cerebellum from portion of the brainstem.  D.) Cerebral hemisphere 
displayed medial side up.  E.) Isolation of the hippocampus.  F.) Hippocampus rolled away from cerebral 
hemisphere.  Photos courtesy of Dr. James Olson. 
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2.2  Biochemical assays 
 AChE activity was measured using a modified version of the Ellman assay (Ellman et 
al., 1961), using dithionitrobenzoic acid (DTNB) and acetylthiocholine as substrate.  Brain 
samples were thawed on ice, and 15-20 mg sections of each region were homogenized in 200 µL 
buffer (0.1 M sodium phosphate, pH 7.4, containing 0.5% Tween-20), using a Dounce 
homogenizer with Teflon pestle.  The homogenates were centrifuged at 13,000 rpm at 4°C for 5 
min and supernatant transferred to a clean tube.  To inhibit butyrylcholinesterase 1µL of 10 mM  
iso-OMPA (tetraisopropyl pyrophosphoramide) was added.  Samples were incubated on ice for 
45 min.  Ten microliters of sample were added to wells of a 96 well flat bottom plate containing 
150 µL of NaPO4, pH 8.0 buffer; samples were run in triplicate.  Each well received 20 µL of 10 
mM DTNB (prepared in 0.1 M NaPO4 buffer, pH 7.0), and the reaction was started with the 
addition of 20 µL of 10 mM acetylthiocholine (prepared in double distilled water).  Blank 
samples contained DTNB only.  Hydrolysis of the acetylthiocholine substrate by AChE in the 
tissue homogenates produces thiocholine.  The rate of this hydrolysis was determined by the 
reaction of thiocholine with dithionitrobenzoic acid to produce 5-thio-2-nitrobenzoate; therefore, 
the rate of hydrolysis was determined by measuring the change in absorbance at 412 nm over 6 
min.  Enzyme activity (µmol/min/ml) was calculated by dividing the slope of the absorbance 
values by the extinction coefficient (13600) and multiplying by the dilution factor (500).  Data 
were normalized to protein concentration, which was determined in each brain region using the 
Pierce BCA method with bovine serum albumin for linear standard calibration (Thermo Fisher 
Scientific, Inc., Rockford, IL).  A Dunnet’s test was used to determine significant changes from 
the control value (averaged from all control animals at all time points).  
 Malondialdehyde (MDA) was determined for cortex samples using the Colorimetric 
Assay for Lipid Peroxidation kit (Oxford Biomedical Research, Oxford, MI) or for brainstem, 
cerebellum and hippocampus using the microplate version.  Each whole brain region was 
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homogenized in ice cold PBS (1:1 w/v) at pH 7.4 with a Dounce homogenizer with Teflon pestle.  
Non-interference in the assay was confirmed for this buffer.  Prior to homogenization, 10 µL of 
0.5 M butylated hydroxytoluene (BHT) per mL of sample were added to prevent artifactual 
oxidation of any lipids.  The samples were centrifuged at 3000 x g at 4°C for 10 min to remove 
large particles.  An aliquot of the sample was removed for protein determination.  The MDA 
standard was provided as a 10mM stock solution of 1, 1, 3, 3-tetramethoxypropane (TMOP) in 
Tris-HCl.  A 20 µM standard stock was prepared from this by diluting the 10 mM stock 1:500 in 
dH2O immediately before use.  Standards for calibration were prepared in microcentrifuge tubes 
as described in Table 1. 
 
Table 1.  MDA standard curve preparation. 
Standard MDA conc 
(µM) 
Vol of 
dH2O (µL) 
Vol of 20 µM MDA 
stock (µL) 
S0 0 200 - 
S1 0.5 195 5 
S2 1.0 190 10 
S3 2.5 175 25 
S4 5.0 150 50 
S5 10.0 100 100 
S6 15.0 50 150 
S7 20.0 - 200 
 
A sample blank was prepared by adding 487.5 µL of acetonitrile and 162.5 µL of Diluent 
(provided in kit) to a microcentrifuge tube.  The sample blank corrected for any contribution to 
the A586 caused by chromophore in the sample.  The Reagent R1 (supplied in kit) was diluted 3:1 
with Diluent immediately before use.  The cuvette assay procedure was started by adding 200 µL 
of sample or standard, 650 µL of the diluted R1 and 150 µL of 12N hydrochloric acid to a 
microcentrifuge tube.  The microplate assay procedure was started by adding 140 µL of sample or 
standard, 455 µL of the diluted R1 and 105 µL of 12N hydrochloric acid to a microcentrifuge 
tube.  Samples and standards were run in triplicate.  Standards, samples and the sample blank 
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were incubated at 45°C for 60 min.  All tubes were centrifuged at 15,000 x g for 10 min to obtain 
a clear supernatant.  For the cuvette assay, the clear supernatant was transferred to a cuvette and 
read at 586 nm.  For the microplate assay, three 150 µL aliquots of the supernatant were 
transferred to the manufacturer supplied microplate and read at 586 nm.  The net A586 for the 
standards were plotted against MDA concentration and a linear regression analysis was 
performed.  The concentration of analyte was calculated for each unknown sample from the net 
A586 of the sample (Equation 1). 
      
   
 
        Equation 1 
 Where: [MDA] = µM concentration of MDA in sample 
 A = Net absorbance at 586 nm of the sample 
m = regression coefficient (slope) 
b = intercept 
df = dilution factor (5) 
 
Sample concentrations were normalized to protein content.  Protein concentration was determined 
using the Pierce BCA method.  Student’s unpaired t-test was used to determine if there were 
significant changes (p ≤ 0.05) in MDA after DFP exposure at each time point. 
2.3 RNA preparation 
2.3.1 RNA isolation 
 Before RNA isolation each brain region from the 1 hr time point was ground under 
liquid nitrogen using an RNase free frozen mortar and pestle to insure a homogeneous mix of the 
tissue sample.  Total RNA was isolated from each brain region using a Qiagen RNeasy Mini Kit 
(Qiagen, Valencia, CA).  Six-hundred microliters of Buffer RLT (from kit) with β-
mercaptoethanol were added to a homogenization tube containing approximately 30 mg of tissue.  
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A stainless steel bead was added to each tube which was then homogenized on a Mix Mill MM 
300 for 2 min at 20 Hz.  The tube was rotated 180° and homogenized for another 2 min at 20 Hz.  
The sample was centrifuged at 15,000 rpm for 3 min.  The supernatant was transferred to a 
QIAshredder spin column and centrifuged at 15,000 rpm for 2 min.  After removing the column, 
the lysate was transferred to a new DNase RNase free microcentrifuge tube.  Six-hundred 
microliters of 70% ethanol were added to the lysate and mixed by pipetting up and down 5 times.  
The sample was transferred to an RNeasy spin column fitted with a 2 mL collection tube and 
centrifuged for 20 sec at 10,000 rpm.  The flow through was discarded.  Seven-hundred 
microliters of Buffer RW1 (from kit) were added to the RNeasy spin column and centrifuged for 
20 sec at 10,000 rpm.  The flow through was discarded.  Five-hundred microliters of Buffer RPE 
(from kit) were added to the RNeasy spin column and centrifuged for 20 sec at 10,000 rpm.  The 
flow through was discarded.  An additional 500 µL of Buffer RPE were added to the RNeasy spin 
column and centrifuged for 20 sec at 10,000 rpm.  The flow through was discarded.  The column 
and collection tubes were centrifuged for 1 min at 15,000 rpm to eliminate any possible carryover 
of Buffer RPE.  The spin column was removed and placed in a new 1.5 mL collection tube.  To 
elute the RNA, 30 µL of DNase RNase free water were added directly to the spin column and 
allowed to sit for 2 min at room temperature.  The column and tube were centrifuged at 13,000 
rpm for 1 min and flow through collected.  The RNA concentration was measured using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE).  In addition, RNA 
quality was determined spectrophotometrically from the A260/A280 ratio (acceptable range of 1.9 
to 2.1) and from gel electrophoretic separation of the 28S rRNA and 18S rRNA bands, using a 
freshly poured 1% agarose gel.  Electrophoretic gel images and A260/A280 ratios are shown in 
Appendix I.  For the synthesis of cDNA through hybridization steps, refer to Figure 11. 
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Figure 11.  WT (Whole Transcript) Sense Target Labeling Assay.  Schematic taken from Affymetrix. 
 
 
2.3.2 1
st
 strand cDNA synthesis 
Amplification and target preparation of the RNA for microarray analysis were completed 
using the Ambion WT Expression Kit (Applied Biosystems), Affymetrix GeneChip WT Labeling 
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Kit and the Poly-A RNA Control kit.  All tubes used were DNase and RNase free.  All enzymes 
and buffers noted in the text were supplied with the kits.  The Poly-A control stock was diluted 
1:10, then 1:50, then 1:50 and finally 1:10 to yield a final 100 ng total RNA in 2 µL.  The 1
st
 
strand master mix was prepared in bulk for all samples using the following mix ratio (for 1 
sample):  4 µL 1
st
 strand buffer mix; 1 µL 1
st
 strand enzyme mix.  The buffer mix contained T7-
(N)6 primers.  Each sample was normalized to 100 ng RNA per 3 µL.  To labeled PCR tubes, the 
following were added:  5 µL 1
st
 strand master mix; 2 µL of the diluted Poly-A spike control; 3 µL 
of RNA-containing sample.  Each tube was gently vortexed, quick spun and incubated in a 
Verti
TM
 thermalcycler (Applied Biosystems) with a heated lid following the 1
st
 Strand cDNA 
synthesis method (Table 2).   
 
Table 2.  Thermal Cycling Methods 
Method Heated Lid 
Temp (°C) 
Step 1 Step 2 Step 3 Step 4 
1
st
 Strand 
cDNA 
Synthesis 
50 25°C, 60 min 42°C, 60 min 4°C, 2 min  
2
nd
 Strand 
cDNA 
synthesis 
Room Temp 16°C, 60 min 65°C, 10 min 4°C, 2 min  
In Vitro 
Transcription 
cRNA 
synthesis 
50 40°C, 16 hrs 4°C, hold   
2
nd
 Cycle 
cRNA 
Denaturation 
75 70°C, 5 min 25°C, 5 min 4°C, 2 min  
2
nd
 Cycle 
cDNA 
synthesis 
75 25°C, 10 min 42°C, 90 min 70°C, 10 min 4°C, 2 min 
RNase H 
Hydrolysis 
75 37°C, 45 min 95°C, 5 min 4°C, 2 min  
Fragmentation 105 37°C, 60 min 93°C, 2 min 4°C, 2 min  
Labeling 105 37°C, 60 min 70°C,10 min 4°C, 2 min  
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2.3.3 2nd strand cDNA synthesis 
The 2
nd
 strand master mix was prepared on ice using the following mix ratio (for 1 
sample):  32.5 µL DNase RNase free water; 12.5 µL 2
nd
 strand buffer mix; 5 µL 2
nd
 strand 
enzyme mix.  Fifty microliters of the 2
nd
 strand master mix were added to each of the 1
st
 strand 
synthesis samples, gently vortexed, quick spun and incubated in a thermalcycler using the 2
nd
 
Strand Synthesis method (Table 2).  At the end of the program, samples were removed, quick 
spun and placed on ice for 5 min before proceeding directly to in vitro transcription cRNA 
synthesis.  
2.3.4 Synthesis of cRNA using in vitro transcription (IVT) 
  The IVT master mix was prepared at room temperature using the following mix ratio 
(for 1 sample):  24 µL IVT buffer mix; 6 µL IVT enzyme mix.  Thirty microliters of the IVT 
master mix were added to each of the 2
nd
 strand cDNA samples, gently vortexed, quick spun and 
incubated in a thermalcycler using the IVT method (Table 2).  At the end of the IVT program, the 
samples were placed on ice before purification of the cRNA. 
2.3.5 Purification of cRNA 
The Elution Solution (provided with kit) was preheated at 55°C for at least 10 min before 
use.  The cRNA binding master mix was prepared at room temperature using the following mix 
ratio (for 1 sample): 10 µL nucleic acid binding beads; 50 µL nucleic acid binding buffer.  Sixty 
microliters of the cRNA binding master mix were added to each sample, pipetting up and down 
three times to mix.  The samples were then transferred to a U-bottom plate.  Sixty microliters of 
100% isopropanol were added to each sample, pipetting up and down three times to mix.  The 
plate was gently shaken on a plate shaker (Boekel Scientific) for 2 min and then moved to a 
magnetic stand for 5 min while the mixture became clear and the beads formed pellets against the 
magnets.  The supernatant was removed and discarded.  One-hundred microliters of nucleic acid 
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wash solution were added to each sample.  The plate was shaken for 1 min, and the wash process 
was repeated a second time.  The residual ethanol was allowed to evaporate by shaking the plate 
an additional minute at high speed. Forty microliters of the heated elution solution were added to 
each sample and allowed to incubate at room temperature for 2 min.  The plate was vigorously 
shaken for 3 min and then moved to the magnetic stand for 5 min.  The supernatant containing the 
cRNA was transferred to clean tubes, and cRNA yield was determined using a Nanodrop 
spectrophotometer and stored at -20°C before proceeding to the 2
nd
 Cycle cDNA Synthesis. 
2.3.6 2
nd
 Cycle cDNA synthesis 
Each sample was normalized to 455 ng/µL (equal to a total of 10 µg cRNA in a volume 
of 22 µL).  Twenty-two microliters of the sample and 2 µL of Random Primers (from kit) were 
added to clean PCR tubes on ice.  The samples were gently vortexed, quick spun and incubated in 
the thermalcycler, using the 2
nd
 Cycle cRNA Denaturation program. The 2
nd
 Cycle master mix 
was prepared at room temperature using the following mix ratio (for 1 sample): 8 µL of 2
nd
 cycle 
buffer mix; 8 µL of 2
nd
 cycle enzyme mix.  At the end of the thermalcycler program, 16 µL of the 
2
nd
 Cycle master mix were added to the 2
nd
 Cycle cRNA Denaturation product, gently vortexed, 
quick spun and incubated in the thermalcycler using the 2
nd
 Cycle cDNA Synthesis program. The 
synthesis of second cycle cDNA in the presence of random primers and dUTP was performed to 
assure that regions encoded by all the exons on the gene were equally synthesized and that 
deoxyuridine was incorporated into the single-stranded DNA at pre-defined ratios relative to 
thymidine.  Upon completion the samples were placed on ice for hydrolysis of the cRNA 
template.  Two microliters of RNase H were added to each sample and mixed by pipetting up and 
down 3 times.  Each sample was gently vortexed, quick spun and incubated on the thermalcycler 
using the RNase H program.  The samples were removed and placed on ice for purification of the 
cDNA and removal of unincorporated nucleotides following the same procedure as in section 
2.3.5.   
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2.3.7 Fragmentation, labeling and hybridization of single stranded cDNA 
Fragmentation required the use of the Affymetrix GeneChip® WT Terminal Labeling kit.  
Each sample was normalized to 5.5 µg in 31.2 µL, using DNase RNase free water.  
Fragmentation master mix was prepared at room temperature using the following mix ratio (for 1 
sample): 10 µL DNase RNase free water; 4.8 µL of 10X cDNA Fragmentation buffer; 1.0 µL of 
UDG (uracil-DNA glycosylase); 1.0 µL APE (apurinic/apyrimidinic endonuclease).  Each sample 
tube containing 31.2 µL of normalized single stranded cDNA received 16.8 µL of fragmentation 
master mix.  Tubes were gently vortexed, quick spun and incubated on the thermalcycler using 
the Fragmentation program.  After the cDNA was fragmented 45 µL were transferred to clean 
PCR tubes, and 2 µL were used for gel electrophoresis to verify fragmented samples.  
Electrophoretic gel images are shown in Appendix I. 
The labeling procedure required the use of the GeneChip® WT Terminal Labeling kit.  
Labeling master mix was prepared at room temperature using the following mix ratio (for 1 
sample):  12 µL of 5X TdT (Terminal deoxynucleotidyl Transferase) buffer; 2 µL of TdT; 1 µL 
of 5 mM DNA labeling reagent (containing biotin label).  Fifteen microliters of the master mix 
were added to the 45 µL aliquot of fragmented single-stranded DNA, gently vortexed, quick spun 
and incubated on the thermalcycler using the Labeling program.  
Hybridization required the use of the GeneChip® Hybridization, Wash and Stain kit.  
The 20X GeneChip® Eukaryotic Hybridization Control stock was heated to 65°C for 5 min to 
resuspend the cRNA completely.  The Hybridization Cocktail was prepared at room temperature 
using the following mix ratio (for 1 sample):  60 µL of fragmented and labeled DNA; 3.7 µL of 
control oligonucleotide B2 (3 nM); 11 µL of 20X Eukaryotic Hybridization controls (bioB, bioC, 
bioD, cre); 110 µL of 2X Hybridization mix; 15.4 µL of DMSO (dimethylsulfoxide); 19.9 µL of 
DNase RNase free water.  The Hybridization Cocktail was heated at 99°C for 5 min and then 
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cooled to 45°C for 5 min.  The samples were centrifuged at 15,000 rpm for 1 min.  The 
Affymetrix GeneChip® Exon 1.0 ST (Sense Target) Arrays were equilibrated to room 
temperature and then injected with 200 µL of the sample for hybridization for 16 hr at 45°C using 
a rotating hybridization oven (Affymetrix) at 60 rpm.  Using an Affymetrix Fluidics Station, the 
chips were washed and stained and then scanned with an Affymetrix GeneChip Scanner 3000.  
Expression Console
TM
 software (Affymetrix) was used to evaluate overall quality of the arrays 
and to detect outliers.   
2.38 Data processing procedures 
Data processing required multiple steps to insure significant changes in gene expression 
in brain regions from DFP-treated rats as compared to control (Montgomery, 2006; Irizarry et al., 
2003a; Irizarry et al, 2003b; Glantz, 1996; Holm, 1979).  The following steps were used to 
process the gene array data. 
Array Normalization:  Normalization was performed using full quantile normalization (Irizarry et 
al., 2003).  Each input array was normalized to the sum of the intensity from the 16
th
 to the 85
th
 
percentile (removing higher level of noise from each end).  
Probe Score Transformation and GC Filtering:  The 4,021,734 probes on each array were filtered 
and transformed.  Probes with a GC count less than 6 and greater than 17 were excluded from the 
analysis.  Probe scores were then transformed by taking the Base-2 logarithm. 
Background Correction:  The background of each exon array was established from a pool of 
probes with no authentic hybridization targets.  Each probe score was corrected for background 
by subtracting the median expression score of background probes with similar GC content. 
Probe Summarization and Transformation:  The Rat Exon 1.0 ST array contains 1,044,122 probe 
sets (4 probes/set).  The expression score for each set was derived via the application of RMA 
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(Robust Multi-array Average) to the probe scores across all input hybridizations.  Probe sets with 
fewer than three probes were excluded from further analysis. 
Mixed model, nested analysis of variance was used to identify the genes with group specific 
expression (Montgomery, 2006).  For the mixed model, the CEL file (stores the results of 
intensity calculations) is the random factor.  The exons and the groups are the fixed effects.  The 
data are then analyzed by ANOVA according to a linear model.  For each gene tested, the 
probability of a false-positive was 0.05.  Because a large number of independent genes were 
tested, this significance value was misleading since the probability of finding a false-positive 
grows as more genes are tested (Glantz, 1996).  To correct for this, the Holm’s method (step-
down Bonferroni) was used. 
2.4 GeneChip analysis 
The gene chip data were stringently evaluated by a variety of quality assessment metrics 
before statistical analysis was completed (Affymetrix, Gentleman et al., 2005).  Quality 
assessment measures included: (i) comparison of the mean raw intensity for all probes to the 
background intensity, (ii) a Pearson’s correlation to check for variability in gene expression 
relative to other chips, and (iii) evaluation of the polyA spike probeset to confirm expected 
behaviors, such as constant expression levels and rank order of signals between spike sets, were 
observed.  Cell intensities of the genechip arrays were evaluated and statistical analyses were 
performed using XRAY for Exon and GeneArray analysis software (Biotique Systems, Inc., 
Reno, NV) with a significance threshold of p<0.05 and an initial stringency filter of fold change > 
1.15x.  To determine the presence or absence of expression for a particular gene in a group, the p-
value was derived to test the null hypothesis that the average of the CEL files (intensity files) 
belonging to the group was not above background.  Rejection of the null hypothesis occurred 
when the p-value was less than the significance level of 0.05, in which case it is inferred that the 
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gene was expressed in the given group.  The NIH NIAID DAVID (Database for Annotation, 
Visualization and Integrated Discovery, http://david.abcc.ncifcrf.gov/tools.jsp ) database was 
used to generate the lists of pathways and biological processes with significant enrichment of up- 
and down-regulated genes to infer modulation/perturbation of specific biological pathways and 
processes in DFP-treated brain regions as compared to control (Dennis et al., 2003; Huang et al., 
2009a, b).  Significance was determined using a modified (more conservative) Fisher Exact test 
which subtracted one from the total number of genes affected by treatment.  The Gene Ontology 
website (http://www.geneontology.org) was used in conjunction with DAVID to characterize the 
biological processes, molecular functions and cellular components that had altered regulation as a 
result of DFP exposure.  PubMed Gene (www.ncbi.nlm.nih.gov/pubmed/) was used to identify 
specific gene functions and descriptions. To visualize the biological interactions of the significant 
genes, pathway analysis on the combined lists of up and down regulated genes for each brain 
region was performed using GeneSpring bioinformatic software (version 11.5.1; Agilent 
Technologies, Santa Clara, CA). 
The low stringency filter was justifiable and even preferred over a higher fold change 
(FC) threshold.  Because gene chips and RNA preparation chemistry have substantially improved, 
noise in the microarray is minimal, alleviating the need for a high FC filter which would lose true 
positives while reducing false positives.  Also, the degree of fold change does not correlate to 
biological significance linearly, emphasizing the need for pathway analysis and determining 
biological interactions.  The datasets went through a second level of filtering with the pathway 
analyses, making the need for a high stringency FC filter unnecessary.   Use of the DAVID 
database shifted the analysis of the microarray from individual genes changes to changes in 
pathways. 
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2.5 NMR sample preparation 
Each brain region from the 2 hr time point and cortex samples from the 48 hr time point 
were extracted by the dual phase method of Tyagi et al. (1996).  Frozen brain sections were 
ground to a fine powder under liquid nitrogen using a frozen mortar and pestle.  The frozen 
powder was quickly transferred to a tared 20 mL glass homogenizer tube, and the weight 
recorded.  Ice cold methanol (MeOH) was immediately added to the tube at 0.7 mL/100 mg 
tissue, and the mixture was homogenized on ice with a chilled Teflon pestle in reverse mode at 20 
rpm.  The homogenate was allowed to stand on ice for 15 min.  Chilled chloroform (CHCL3) at 
0.7 mL/100 mg tissue was added, and the mixture was homogenized at 20 rpm.  Chilled double 
distilled water (ddH2O) was added at 0.7 mL/100 mg tissue, and the mixture was homogenized at 
20 rpm.  The mixture was transferred to an ice cold 50 mL glass centrifuge tube and allowed to 
stand on ice for 15 min before centrifuging at 2000 x g for 25 min at 4°C.  In the meantime, a 
separatory flask and funnel were placed in a refrigerator at 4°C.  A #1 filter paper disc was placed 
in the funnel and primed with 0.5 mL each of MeOH, CHCL3 and ddH2O, in that order.  The 
supernatant was transferred to the flask.  The homogenizer tube was washed with 0.5 mL each of 
MeOH, CHCL3 and ddH2O and the mixture was re-homogenized.  The mixture was allowed to 
stand on ice for 5 min, transferred to the same centrifuge tube and centrifuged at 2000 x g for 5 
min at 4°C, transferring the supernatant to the separatory funnel. This procedure was repeated 2 
more times.  After the supernatant was completely filtered, the mixture was allowed to stand at 
4°C for 17-24 hr to allow complete separation of the 2 liquid phases. 
Once separation was complete, the funnel was moved to room temperature and allowed 
to sit for 2 hr.  The upper aqueous phase was carefully aspirated with a disposable pipet and 
transferred to a 60 mL lyophilizer flask.  The lower organic phase was drained into a pre-weighed 
10 mL amber vial.  The funnel was washed 3 times with 0.5 mL each of ddH2O, CHCL3 and 
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MeOH (in this order), allowing funnel to sit for 45 min between each wash to allow the phases to 
separate.  Aqueous and organic phases were removed each time as before.   
The lyophilizer flask containing the aqueous extract and the amber vial containing the 
organic extract were attached to clamps and placed in a 25°C water bath.  A gentle stream of 
nitrogen was blown over the top of the flask or vial to evaporate the MeOH or CHCL3.  After 
most of the MeOH was evaporated the lyophilizer flask was placed in liquid nitrogen to freeze the 
aqueous extract and then lyophilized to dryness overnight.  After the CHCL3 was evaporated the 
vial was sealed with a black Viton septum (Fisher Scientific) and placed on vacuum overnight 
and then weighed.  The lipid sample was reconstituted in 600 µL of 99.8% deuterated chloroform 
(CDCl3) or, if the lipid weight was greater than 30 mg, then enough CDCl3 was added to yield a 
lipid concentration of 50 mg/ml.  Each vial was then crimp-sealed and stored at -20°C until 
analysis. 
The dried aqueous sample was reconstituted in 2 mL of ddH2O, and 5 g/100 mL of 
Chelex 100 were added to remove divalent ions.  The mixture was stirred at 4°C for 1 hr, then 
transferred to a 15 mL disposable centrifuge tube and centrifuged at 2000 x g for 10 min at 4°C to 
remove the Chelex.  The supernatant was transferred to a pre-weighed 20 mL clear serum vial 
and covered with filter paper.  The lyophilizer flask was rinsed 3 times with 2 mL of ddH2O, 
transferring each washing to the same centrifuge tube.  The tube was centrifuged at 2000 x g for 5 
min at 4°C, transferring the supernatant to the same vial each time.  The vial was placed in liquid 
nitrogen to freeze the aqueous extract and placed on a lyophilizer overnight.  Once dry, the dried 
sample was weighed, crimp-sealed and stored at -20°C for subsequent NMR analysis.   
The dried aqueous extracts were reconstituted in 750 µL of 1.04 mM 2, 2`, 3, 3`-
deuterotrimethylsilylpropionic acid (TSP) solution prepared in 99.99% deuterium oxide (D2O).  
TSP was added as a chemical shift reference (set at 0.0 ppm) and internal standard for metabolite 
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quantification (
1
H NMR).  For 
1
H analysis, 650 µL of the reconstituted solution were added to a 5 
mm NMR tube.  Upon completion of 
1
H acquisition, 75 µL of 30.4 mM methylene diphosphonic 
acid (MDPA) in a 141.5 mM Na2(EDTA) solution were added to the NMR tube as a standard for 
31
P NMR analysis of aqueous samples.  For NMR analysis, lipid extracts were prepared in a 
three-part solvent system consisting of CDCl3, MeOH and 90 mM aqueous Cs2(EDTA) (Meneses 
and Glonck, 1988).  The final lipid sample composition was 12/4/1 CDCl3:MeOH:H2O (v/v/v).  
Samples were placed into 5 mm NMR tubes. 
2.6 NMR analyses 
All NMR analyses were performed using a Varian INOVA 600 MHz spectrometer (14.1 
T).  High-resolution 
1
H and proton-decoupled 
31
P and 
13
C NMR spectra of brain region extracts 
were acquired in field-lock mode using a 5 mm broadband probe operating at 600, 243 and 151 
MHz, respectively.  The sample temperatures were maintained at 20°C for lipid extracts to 
optimize spectral resolution and 25°C for aqueous extracts.  Data acquisition parameters for 
1
H 
included 8000 Hz spectral bandwidth, 4 s acquisition time, 1 s interpulse delay and 45 min of 
signal averaging.  C-13 parameters included a 70° pulse, 35 kHz spectral bandwidth and 2 s 
acquisition time, using a waltz 
1
H-decoupling sequence with nuclear Overhauser enhancement 
(NOE) and approximately 20 hr of signal averaging.  P-31 aqueous data were acquired using a 
1
H-decoupling sequence with NOE using a 70° pulse, 12 kHz bandwidth, 1.6 s acquisition time, 2 
s interpulse delay and 20 hr of signal averaging.  P-31 lipid data were acquired using a 90° pulse, 
800 Hz bandwidth, 1.6 s acquisition time, 13 s interpulse delay and 6 hr of signal averaging (full 
T1 relaxation and no NOE). 
2.7 NMR data analysis and quantification of specific metabolites 
Using a Sun Microsystems computer and VNMR v6.1 software, NMR data were 
processed using exponential multiplication, Fourier transformation, manual phasing and baseline 
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correction (5
th
 order polynomial and spline correction).  The 
1
H and 
13
C NMR spectra were 
adaptively binned using a dynamic programming technique in MATLAB
®
 (MathWorks, Inc., 
R2011b) that sets the minimum distance between peaks to 0.002 ppm and the maximum distance 
between peaks in a bin to 0.04 ppm (Anderson et al., 2010).  Adaptively binned spectra were then 
deconvolved, if necessary, and integrated for quantification of individually identified metabolites.   
NMR chemical shift assignments for lipid resonances in the 
13
C spectrum were taken 
from Forgacs et al. (2012), Halliday et al. (1988) and Sillerud et al. (1986).  The CDCl3 signal 
was set at 77.79 ppm for reference and was used as the internal standard for quantification.  The 
C18, C19 and C14 carbons of cholesterol at 12.5, 19.7 and 57.2 ppm, respectively, were averaged 
for quantification.  The signal in the range of 20.9 – 21.03 ppm represented the n2 carbon from all 
n3-fatty acids (FA), and the signal within the range of 32.03 – 32.29 ppm represented the n3 
carbon of the n6-FA.  These carbon signals shift slightly within this range because of the 
differences in carbon chain lengths of these fatty acids. The signal generated from the 
magnetically equivalent resonances of the 3 methyl carbons of the choline headgroup of 
phosphatidylcholine (PtdC), (CH3)3N-, at 54.4 ppm was used to quantify PtdC.  This 
concentration of PtdC was then used as the internal standard for quantification of the 
31
P lipid 
spectra.  The terminal methyl carbon of fatty acids at 14.8 ppm was used as a measure of total 
FA.  The signal at 27.3 ppm represented the polyunsaturated fatty acids (PUFA), specifically 
allylic carbons, C=C-CH2- C=C.  While this signal was integrated for a quantitative value of 
PUFA, it is important to note that its intensity is dependent upon both concentration and 
composition, and, therefore, is not an accurate measure of concentration. 
For quantification purposes the 
1
H, 
31
P and 
13
C NMR signal intensities were corrected for 
T1 saturation and NOE, when necessary.  To correct for T1saturation and NOE data were acquired 
for a representative cortex and brainstem sample under fully relaxed conditions (5T1 with no 
NOE; interpulse delay of 250 µsec for 
13
C and 59 µsec for 
1
H).  The ratio of the intensity of each 
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signal selected to the CDCl3 or TSP intensity was calculated for both fully relaxed (RFR) and 
partially saturated (RPS) spectra.  Calculation of the RFR/RPS ratio provided the saturation factor 
for each signal of interest.  For all analyses metabolite concentrations were normalized to tissue 
weight. 
Principal component analysis (PCA) was used as an unsupervised method to visualize 
NMR-derived data from control animals by transforming the data into a new coordinate system, 
where each new dimension was computed as a linear combination of the original values in order 
to demonstrate the uniqueness and/or similarities of each brain region best explained by the 
overall variance in the data (Jolliffe, 1986; Mahle et al., 2010).  For PCA, adaptively binned 
1
H 
aqueous spectra were normalized to tissue weight and autoscaled to the mean and standard 
deviation of the control spectra, equalizing the importance of small and large signal metabolites 
(Van den Berg et al., 2006).  The signals for water and TSP were removed before autoscaling.   
In order to evaluate differences between metabolites from each group, a targeted 
approach was used to focus on the NMR signals that were identifiable as known metabolites, 
making a direct comparison between control and DFP-treated groups.  Because the NMR spectra 
represented individual rat metabolite profiles and were independent measures, Student’s 2-tailed t 
test (unpaired) was used to determine significant differences in metabolite concentration between 
treatment and control groups.   
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III. RESULTS 
3.1 Basal regional differences 
3.1.1 Basal AChE activity 
 AChE data from control animals were compiled in order to provide comparative 
information regarding the normal, basal activity of the enzyme in each brain region measured 
(Fig. 12).  AChE activity in brainstem was significantly higher than all other brain regions, while 
activity in cerebellum was significantly lower than all other brain regions (p<0.01).  Enzyme 
activity levels in cortex and hippocampus were not different from each other.   
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Figure 12.  Basal acetylcholinesterase activity in measured brain regions.  Abbreviations:  CX – cortex; 
BS –brainstem; CB – cerebellum; HP - hippocampus.  Data are from all control animals averaged over all 
time points (Mean ± SE; n=30).  *Significantly different from all other regions (p<0.01). 
 
 
3.1.2 Basal lipid profiles 
The normal regional composition of several measured lipid species in cortex, brainstem, 
cerebellum and hippocampus are shown in Figure 13.  The brainstem had the greatest amount of 
FA per g tissue and was significantly higher than all other regions measured.  The hippocampus 
had the least amount of FA per g tissue and was significantly lower than all other regions.  Cortex 
was lower than cerebellum.  The brainstem also had the greatest amount of cholesterol, averaging 
about 145, 120 and 230% greater than cortex, cerebellum and hippocampus, respectively.  The 
hippocampus had the lowest amount of cholesterol as compared to the other three regions.  
Cholesterol in the cerebellum was 13% higher than cortex.  The intensity of the NMR signal at 
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27.3 ppm (PUFA) can be altered by changes in concentration and composition (number of double 
bonds in the FA); therefore, changes in the intensity of this NMR signal are not truly reflective of 
PUFA concentration alone.  Overall, PUFA differences between regions were minimal.  The 
hippocampus had lower levels of PUFA than cortex, brainstem and cerebellum, while the cortex 
had lower levels than brainstem and cerebellum.  There was no statistical difference in PUFA 
levels between brainstem and cerebellum. 
 
Figure 13.  Normal regional composition of lipid species in measured brain regions from vehicle-
treated control rats.  Significant differences (p≤0.05) noted as: 
a
different than all other regions; 
b
less than 
BS, CB; 
c
greater than CX, HP; 
d
greater than BS, HP; 
e
less than CX, CB; 
f
greater than CB, HP, 
g
less than 
CX, BS. *PUFA signal intensity is subject to changes in both concentration and composition.  **Average 
of 3 cholesterol carbon signals (C18 at 12.5 ppm, C19 at 19.7 ppm and C14 at 57.2 ppm).  Abbreviations:  
CX – cortex; BS – brainstem; CB – cerebellum; HP – hippocampus; FA – fatty acid; PUFA – 
polyunsaturated fatty acid.  A) full scale profile  B) expanded scale for display of n3 and n6 FA. 
 
 
The n3 and n6 FA data are displayed at an expanded scale in the inset of Figure 13.  The 
levels of n3 FA in the hippocampus were approximately 35% of cortex and cerebellum levels and 
65% of brainstem.  Brainstem levels of n3 FA were also significantly lower than cortex and 
cerebellum.  There was no statistical difference in n3 FA levels between cortex and cerebellum.  
The levels of n6 FA in both the cerebellum and the hippocampus were about half the levels in the 
A B 
46 
 
cortex and brainstem.  There was no difference in n6 FA levels between cortex and brainstem or 
cerebellum and hippocampus. 
Figure 14 shows the normal regional composition of the major phospholipids in cortex, 
brainstem, cerebellum and hippocampus from vehicle-treated control animals.  With the 
exception of phosphatidylethanolamine (PtdE) and phosphatidylinositol (PtdI), brainstem had 
significantly higher levels of all phospholipids than cortex, cerebellum and hippocampus.  Levels 
of phosphatidic acid (PA) were 6-10 fold greater in the brainstem than the other three regions, 
while levels of PtdC were 2-4 fold greater.  On average, brainstem levels of all other 
phospholipids averaged about 3, 3 and 5 fold greater than cortex, cerebellum and hippocampus, 
respectively.  The hippocampus had significantly lower levels of sphingomyelin (SM), PtdI, 
choline plasmalogen (ChPl), ethanolamine plasmalogen (EthPl), PtdE and PtdC and 
phosphatidylserine (PtdS) than all other brain regions (inset of Fig. 14).  The levels of PtdI, ChPl, 
PtdE, PtdS and PtdC were significantly lower in cerebellum as compared to cortex and brainstem 
and higher than hippocampus.  There was no significant difference in levels of PA between cortex 
and cerebellum or hippocampus.  No differences existed between cortex and cerebellum or 
cerebellum and hippocampus for cardiolipin (CL).  Levels of SM were also the same in cortex 
and cerebellum. 
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Figure 14.  Normal regional composition of major phospholipids in measured brain regions from 
vehicle-treated control rats.  Significant differences (p≤0.05) noted as: 
a
different than all other regions; 
b
less than CX; 
c
greater than CB, HP.  Abbreviations:  CX – cortex; BS – brainstem; CB – cerebellum; HP – 
hippocampus; PA – phosphatidic acid; CL – cardiolipin; SM – sphingomyelin; PtdI – phosphatidylinositol; 
ChPl – choline plasmalogen; EthPl – ethanolamine plasmalogen; PtdE – phosphatidyethanolamine; PtdS – 
phosphatidylserine; PtdC – phosphatidylcholine.  A) full scale profile  B) expanded scale for display of PA, 
CL, SM, PtdI and ChPl. 
 
 
3.1.3 Aqueous metabolite profile 
The intensities from adaptively binned 
1
H-NMR spectra of aqueous extracts of each brain 
region from control animals provided multivariate data input to principal component analysis 
(PCA).  The PCA scores plot (PC1 vs. PC2) for the four brain regions is shown in Figure 15.  
Differences in the mapping position on the plot reflect differences in the biochemical composition 
of the aqueous extract.   
1
H-NMR spectra for each brain region displayed tight clustering in PC 
space with distinct grouping within and between each region.  No region overlapped with another 
region. 
  
A B 
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Figure 15.  Principal component plot of 
1
H-NMR spectra of aqueous metabolites from control 
animals.  Abbreviations:  CX – cortex; BS – brainstem; CB – cerebellum; HP – hippocampus.  Data are 
plotted as the mean value for the first two principal components (PC1 vs. PC2) ± 1 SE (ellipse).  
Adaptively binned 
1
H aqueous spectra were normalized to tissue weight and autoscaled to the mean and 
standard deviation of the control spectra specific to each brain region. 
 
3.2 Cortex 
3.2.1 Biochemical assays 
 Inhibition of AChE in the cortex reached a maximum at 12 hr post dose with activity 
levels at 55% of control activity (Fig. 16).  The cortex showed a trend toward recovery by 48 hr 
post dose; however, enzyme activity levels did not reach control levels by 48 hr post dose. 
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Figure 16.  Inhibition of acetylcholinesterase activity reported as a percentage of the control value in 
cortex after a single subcutaneous dose of 1 mg/kg DFP. Data are mean ± SE;  n=5/time point.  
*Significantly different from control at p<0.05. 
 
 
MDA was measured in the cortex at 0.5, 1, 2, 12, 24 and 48 hr post DFP dose.  None of 
the cortex samples from rats treated with DFP showed any significant change in the level of 
MDA at any time point post dose (Fig. 17). 
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Figure 17.  Time course measurement of levels of malondialdehyde in cortex.  Data are Mean ± SE;  
n=5/time point. 
 
 
3.2.2 Differential gene expression in cortex 
 Complete results of the quality control analysis of the gene arrays are shown in 
Appendix II.  Based on the quality control analyses, the data from the gene chip from one cortex 
sample (animal #72, DFP group, n = 4 for this group) was excluded from the dataset.  The final 
differential gene expression changes in the cortex 1 hr post DFP exposure included 28 up and 319 
down-regulated genes (p<0.05 with fold change > 15% regardless of annotation status).  The total 
number of annotated genes that were differentially expressed was 319 (genes with a known 
protein product are designated as annotated).  The expression of 20 genes was present in the 
control group but absent in the DFP group, while 5 genes were not expressed in the control group 
but were in the DFP group.  The full list of differentially expressed genes in the cortex can be 
found in Appendix III.  Only the genes that were annotated were included in the final list. 
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In order to understand the biological relevance of the many gene expression changes 
caused by DFP exposure, complete lists of up- and down-regulated genes were used separately to 
search the DAVID web site.  This analysis produced a large number of biological processes, 
cellular components and molecular functions that were affected by DFP exposure.  The results of 
the database search are summarized in Table 3.  Among the many down-regulated biological 
processes were: protein localization and transport, regulation of apoptosis/ programmed cell 
death, cellular signaling, synaptic transmission, regulation of neurotransmitter levels and 
secretion of neurotransmitters.  The database search also identified down-regulated cellular 
components, specifically plasma membrane, synapse and cellular projections.  The molecular 
function termed ‘disulfide bond’ was significantly up-regulated and consisted of the genes coding 
for neuromedin U receptor (Nmur2) and prostaglandin D2 synthase (Ptgds).  The molecular 
functions of ATP and nucleotide binding were significantly down-regulated. 
Table 3.  Gene expression changes in specific cellular pathways of the cortex 1 hr post 1 mg/kg 
DFP exposure. 
Category
 
Pathway Regulation 
# genes 
changed 
%
a p-
value* 
Biological 
Process 
cell-cell signaling Down 13 5.1 0.0038 
cellular protein catabolic process Down 10 3.9 0.0450 
establishment of protein 
localization 
Down 19 7.5 0.0014 
generation of a signal involved in 
cell-cell signaling 
Down 7 2.7 0.0052 
intracellular protein transport Down 10 3.9 0.0270 
memory Down 4 1.6 0.0500 
mRNA transport Down 4 1.6 0.0480 
neurotransmitter secretion Down 5 2.0 0.0073 
protein amino acid 
phosphorylation 
Down 17 6.7 0.0190 
protein localization Down 22 8.6 0.0007 
protein modification by small 
protein conjugation or removal 
Down 7 2.7 0.0094 
protein transport Down 19 7.5 0.0013 
protein ubiquitination Down 5 2.0 0.0340 
regulation of apoptosis Down 17 6.7 0.0400 
regulation of cell death Down 17 6.7 0.0460 
regulation of neuron 
differentiation 
Down 7 2.7 0.0360 
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regulation of neurotransmitter 
levels 
Down 6 2.4 0.0084 
regulation of programmed cell 
death 
Down 17 6.7 0.0450 
regulation of protein catabolic 
process 
Down 5 2.0 0.0063 
response to electrical stimulus Down 3 1.2 0.0180 
RNA localization Down 5 2.0 0.0150 
synaptic transmission Down 11 4.3 0.0015 
transmission of nerve impulse Down 12 4.7 0.0031 
Cellular 
Component 
cell junction Down 14 5.5 0.0068 
cell projection Down 19 7.5 0.0096 
cell projection part Down 10 3.9 0.0070 
cell soma Down 10 3.9 0.0069 
cortical actin cytoskeleton Down 3 1.2 0.0410 
dendrite Down 9 3.5 0.0140 
dendritic spine Down 7 2.7 0.0002 
endosome Down 10 3.9 0.0052 
filopodium Down 4 1.6 0.0039 
Golgi apparatus part Down 9 3.5 0.0220 
intracellular organelle lumen Down 26 10.2 0.0190 
late endosome Down 4 1.6 0.0360 
membrane-enclosed lumen Down 26 10.2 0.0380 
neuron projection Down 12 4.7 0.0350 
nuclear lumen Down 21 8.2 0.0300 
nuclear pore Down 4 1.6 0.0360 
nucleolus Down 12 4.7 0.0015 
plasma membrane Down 48 18.8 0.0037 
plasma membrane part Down 30 11.8 0.0080 
postsynaptic membrane Down 9 3.5 0.0006 
synapse Down 15 5.9 0.0006 
synapse part Down 12 4.7 0.0008 
Molecular 
Function 
Disulfide bond Up 3 50 0.0220 
adenyl nucleotide binding Down 37 14.5 0.00005 
adenyl ribonucleotide binding Down 37 14.5 0.00002 
ATP binding Down 37 14.5 0.00001 
ATPase activity Down 10 3.9 0.01100 
ATPase activity, coupled Down 8 3.1 0.02000 
ATP-dependent helicase activity Down 4 1.6 0.04300 
ephrin receptor activity Down 3 1.2 0.01000 
helicase activity Down 8 3.1 0.00025 
ion channel activity Down 10 3.9 0.03900 
nucleoside binding Down 38 14.9 0.00004 
nucleotide binding Down 49 19.2 0.00002 
phosphatase binding Down 4 1.6 0.02000 
protein complex binding Down 8 3.1 0.03600 
protein kinase activity Down 18 7.1 0.00190 
protein phosphatase binding Down 4 1.6 0.01500 
protein tyrosine kinase activity Down 6 2.4 0.02700 
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purine NTP-dependent helicase 
activity 
Down 
4 1.6 0.04300 
purine nucleoside binding Down 37 14.5 0.00008 
purine nucleotide binding Down 43 16.9 0.00003 
purine ribonucleotide binding Down 43 16.9 0.00001 
substrate specific channel activity Down 10 3.9 0.04600 
DEAD-like helicase, N-terminal Down 4 1.6 0.02100 
DNA/RNA helicase, C-terminal Down 5 2.0 0.00460 
DNA/RNA helicase, 
DEAD/DEAH box type, N-
terminal 
Down 4 1.6 0.00760 
Ephrin receptor, ligand binding Down 3 1.2 0.00570 
Fibronectin, type III subdomain Down 3 1.2 0.02300 
Helicase, superfamily 1 and 2, 
ATP-binding 
Down 4 1.6 0.02100 
RNA helicase, ATP-dependent, 
DEAD-box, conserved site 
Down 3 1.2 0.03700 
RNA helicase, DEAD-box type, 
Q motif 
Down 4 1.6 0.00450 
Tyrosine-protein kinase, ephrin 
receptor 
Down 3 1.2 0.00570 
Axon guidance Down 6 2.4 0.04100 
*p-value derived from modified Fisher’s Exact test.   
a
Percentage calculated by number of genes differentially expressed/total number of genes 
involved in process, cellular component or molecular function*100. 
 
3.2.3 Metabolic changes in cortex 
 Lipid metabolite changes at 2 hr post DFP exposure are detailed in Table 4.  In cortex, 
all lipid species measured decreased significantly after DFP treatment, except phosphatidic acid 
and cardiolipin.  The lipids showing the greatest decreases were EthPl and ChPl (45 and 56%), as 
well as n3 fatty acids (48%).  The n6 fatty acids were also decreased by 43%.  The average 
decrease after DFP exposure for the remaining lipid species was about 30%, ranging from 16% 
for sphingomyelin to 44% for phosphatidylinositol.  Lipid metabolite changes at 48 hr post DFP 
exposure were also measured.  However, the decoupling parameters used were no longer accurate 
for the 
13
C acquisition, making the 
13
C lipid spectra difficult to quantify.  The remaining lipids in 
CDCl3 were re-analyzed, although the total amount of lipid was small and did not necessarily 
correlate back to the original lipid weight.  Therefore, while lipid signals were quantified the 
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results are only qualitative.  The qualitative results reveal no significant differences in any of the 
measured lipids.  The quantified results are available in Appendix IV.   
 
Table 4.  Changes in lipid metabolite concentrations in the cortex 2 hr post 1 mg/kg DFP dose. 
 Metabolite Concentration (µmol/g tissue) 
Metabolite Control DFP 
Total Tissue Weight (g) 0.841 ± 0.036 0.808 ± 0.043 
Phosphatidic acid 0.7 ± 0.3 0.5 ± 0.0 
Cardiolipin 2.3 ± 0.6 2.2 ± 0.5 
Ethanolamine  
plasmalogen 
25.6 ± 5.2 14.2 ± 1.3
* 
Choline plasmalogen 2.5 ± 0.5 1.1 ± 0.4
** 
Phosphatidylserine 12.7 ± 1.2 8.4 ± 0.2
** 
Phosphatidyl- 
ethanolamine 
27.8 ± 2.0 16.8 ± 0.5
** 
Phosphatidylinositol 2.7 ± 0.3 1.5 ± 0.1
** 
Phosphatidylcholine 50.8 ± 5.3 33.3 ± 1.6
** 
Sphingomyelin 5.6 ± 0.4 4.7 ± 0.1
* 
Cholesterol
a 
77.5 ± 3.3 57.9 ± 4.1
** 
n3 Fatty acids 25.4 ± 7.1 13.2 ± 5.1
* 
n6 Fatty acids 30.9 ± 4.0 17.7 ± 2.4
** 
Polyunsaturated  
fatty acids
b 205.2 ± 14.1 155.2 ± 3.3
** 
Total fatty acids 261.1 ± 27.4 200.2 ± 17.4
* 
Control n = 4; DFP n = 3 
* p<0.05 
**p<0.01 
a
Average of 3 cholesterol carbon signals (C18 at 12.5 ppm, C19 at 19.7 ppm and C14 at 57.2 
ppm. 
b
Polyunsaturated fatty acid signal intensity is subject to changes in both concentration and 
composition  
 
Aqueous, small molecule metabolites were measured in extracts of the cortex at the 2 hr 
time point by 
1
H and 
31
P NMR.  N-acetylaspartate (NAA) was decreased by approximately 11% 
in response to DFP treatment (Table 5).  Small molecule metabolites from extracts of the cortex 
at 48 hr post dose were also measured (Table 5).  The amino acids valine and isoleucine were 
increased 4 and 5 fold, respectively.  GABA was increased by 55%.  G3P and dihydroxyacetone 
55 
 
phosphate (DHAP) were both decreased 2 fold.  Decreases in phosphocholine, glucose and G6P 
were approximately 25-35%. 
Table 5.  Changes in aqueous metabolite concentrations in the cortex 2 and 48 hr post 1 mg/kg 
DFP dose. 
 Metabolite Concentration (µmol/g tissue) 
Metabolite 
(chem. shift in 
ppm) 
2 hr post dose 48 hr post dose 
Control DFP Control DFP 
Valine (0.98) 0.03 ± 0.01 0.08 ± 0.06
 
0.05 ± 0.03 0.26 ± 0.08
** 
Isoleucine (1.01) 0.08 ± 0.01 0.07 ± 0.01 0.09 ± 0.01 0.38 ± 0.13
** 
β-hydroxybutyrate 
(1.24) 
0.44 ± 0.05 0.44 ± 0.00 0.66 ± 0.27 0.58 ± 0.07 
Lactate
a
 (1.33, 4.11) 12.3 ± 1.1 11.9 ± 0.7 12.8 ± 1.6 13.6 ± 1.8 
Alanine (1.41) 0.51± 0.03 0.48 ± 0.02 2.0 ± 0.5 0.69 ± 0.05
** 
NAA (2.02) 8.7 ± 0.3 7.7 ± 0.2
** 
8.7 ± 1.0 9.4 ± 1.2
 
Methionine (2.13) 0.09 ± 0.01 0.08 ± 0.01 ND ND 
Succinate (2.41) 0.75 ± 0.05 0.74 ± 0.02
 
0.71 ± 0.11 0.74 ± 0.20 
Trimethylamine 
(2.92) 
0.05 ± 0.00 0.04 ± 0.00 0.09 ± 0.01 0.09 ± 0.02 
GABA (2.98) 2.6 ± 0.3 2.1 ± 0.8 2.6 ± 0.2 3.7 ± 0.3
* 
Ornithine (3.07) 1.3 ± 0.23 0.95 ± 0.04 1.21 ± 0.29 1.28 ± 0.20 
Cis-aconitate (3.21) 0.39 ± 0.08 0.27 ± 0.01 1.2 ± 0.8 2.7 ± 1.1
* 
Choline (3.22) 0.52 ± 0.02 0.47 ± 0.06 0.51 ± 0.06 0.43 ± 0.18 
Phosphocholine 
(3.23) 
0.94 ± 0.06 0.87 ± 0.02 0.89 ± 0.13 0.66 ± 0.08
* 
Myo-inositol
a
 (3.53, 
4.06) 
6.4 ± 0.8 5.8 ± 0.8 8.1 ± 1.4 7.8 ± 0.5 
Glucose (3.41) 3.86 ± 3.80 3.07 ± 0.21 3.5 ± 1.3 2.2 ± 0.1
* 
Fumarate (6.52) 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 
Tyrosine (7.13) 0.1± 0.04 0.05 ± 0.05 0.14 ± 0.02 0.18 ± 0.07 
Formate (8.46) 1.4 ± 0.4 1.2 ± 0.1 0.59 ± 0.37 0.44 ± 0.13 
Nicotinate
a
 (8.71, 
8.94) 
0.10 ± 0.06 0.04 ± 0.03 0.2 ± 0.04 0.2 ± 0.04 
GPC
b
 (3.06) 0.59 ± 0.02 0.55 ± 0.06 0.52 ± 0.07 0.49 ± 0.07 
GPE
b
 (3.73) 0.28 ± 0.01 0.27 ± 0.02 0.29 ± 0.03 0.28 ± 0.02 
G3P
b
 (7.05) 3.95 ± 0.18 3.85 ± 0.19 3.6 ± 0.6 1.7 ± 1.3
* 
G6P
b
 (7.11) 3.34 ± 0.2 3.28 ± 0.05 3.0 ± 0.5 2.2 ± 0.3
* 
DHAP
b
 (8.04) 0.09 ± 0.03 0.06 ± 0.00 0.13 ± 0.04 0.07 ± 0.02
* 
Control n = 5; DFP n = 2 
*p<0.05 
**p<0.01 
a
average of multiple signals 
b
metabolite signals are from 
31
P aqueous spectra.  GPC set at 3.082 ppm for reference 
 Abbreviations:  NAA – N-acetylaspartate; GABA – γ-aminobutyric acid; GPC – 
glycerophosphocholine; GPE – glycerophosphoethanolamine; G3P – glycerol-3-phosphate; G6P 
– glucose-6-phosphate; DHAP – dihydroxyacetone phosphate; ND – Not detectable 
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3.3 Brainstem 
3.3.1 Biochemical assays 
 Inhibition of AChE in the brainstem reached a maximum at 1 hr post dose with activity 
levels at 40% of control activity (Fig. 18).  The cortex showed a trend toward recovery by 48 hr 
post dose; however, enzyme activity levels did not reach control levels by 48 hr post dose. 
 
 
Figure 18.  Inhibition of acetylcholinesterase activity reported as a percentage of the control value in 
brainstem after a single subcutaneous dose of 1 mg/kg DFP. Data are mean ± SE; n=5/time point.  
*Significantly different from control at p<0.05. 
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MDA was measured in the brainstem at 0.5, 1, 2, 12, 24 and 48 hr post DFP dose.  None 
of the brainstem samples from rats treated with DFP showed any significant change in the level of 
MDA at any time point post dose (Fig. 19). 
 
 
Figure 19.  Time course measurement of levels of malondialdehyde in brainstem.  Data are Mean ± 
SE; n=5/time point. 
 
 
3.3.2 Differential gene expression in brainstem 
 Complete results of the quality control analysis of the gene arrays are shown in 
Appendix II.  Based on the quality control analyses, the data from all gene chips were included in 
the dataset.  However, one array from the DFP group was lost during preparation (n=4 for DFP 
group).  The final differential gene expression changes in the brainstem 1 hr post DFP exposure 
included 57 up and 107 down-regulated genes (p<0.05 with fold change > 15% regardless of 
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annotation status).  The total number of annotated genes that were differentially expressed was 
121.  The expression of 19 genes was present in the control group but absent in the DFP group, 
while 19 genes were not expressed in the control group but were in the DFP group.  The full list 
of differentially expressed genes in the brainstem can be found in Appendix III.  Only the genes 
that were annotated were included in the final list. 
In order to understand the biological relevance of the many gene expression changes 
caused by DFP exposure, complete lists of up- and down-regulated genes were used separately to 
search the DAVID web site.  The results of the database search are summarized in Table 6.  In the 
brainstem vitamin transport was up-regulated.  Among the down-regulated biological processes 
were protein localization, regulation of exocytosis and cellular homeostasis.  The database search 
identified cellular components that were up-regulated (brush border and cell projections) and 
down-regulated (nucleus and synapse associated components).  As in the cortex, the molecular 
functions of ATP and nucleotide binding were down-regulated in the brainstem. 
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Table 6.  Gene expression changes in specific cellular pathways of the brainstem 1 hr post 1 
mg/kg DFP exposure. 
Category Pathway Regulation 
# genes 
changed 
%
a 
p-value* 
Biological 
Process 
vitamin transport Up 2 12.5 0.0200 
cellular homeostasis Down 6 7.5 0.0500 
establishment of protein localization Down 7 8.8 0.0370 
intracellular receptor-mediated 
signaling pathway 
Down 
3 3.8 0.0220 
modification-dependent protein 
catabolic process 
Down 
5 6.2 0.0390 
nuclear import Down 3 3.8 0.0360 
protein folding Down 4 5.0 0.0170 
protein import into nucleus Down 3 3.8 0.0330 
protein localization in nucleus Down 3 3.8 0.0420 
regulation of exocytosis Down 3 3.8 0.0200 
regulation of secretion Down 5 6.2 0.0240 
steroid hormone receptor signaling 
pathway 
Down 
3 3.8 0.0110 
ubiquitin-dependent protein catabolic 
process 
Down 
4 5.0 0.0390 
Cellular 
Component 
brush border Up 3 18.8 0.0016 
cell projection Up 4 25.0 0.0440 
nuclear lumen Down 10 12.5 0.0098 
nuclear matrix Down 3 3.8 0.0150 
synapse Down 6 7.5 0.0160 
synaptic vesicle Down 3 3.8 0.0400 
Molecular 
Function 
vitamin transporter activity Up 2 12.5 0.0120 
ATP binding Down 12 15.0 0.0150 
heat shock protein binding Down 3 3.8 0.0420 
purine ribonucleotide binding Down 15 18.8 0.0048 
*p-value derived from modified Fisher’s Exact test 
a
Percentage calculated by number of genes differentially expressed/total number of genes 
involved in process, cellular component or molecular function*100. 
 
 
 
3.3.3 Metabolic changes in brainstem 
Lipid metabolite changes in the brainstem at 2 hr post DFP exposure are detailed in Table 
7.  In brainstem cardiolipin was significantly decreased by 38% (p<0.05).  No other measured 
lipids were significantly changed after DFP exposure. 
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Table 7.  Changes in lipid metabolite concentrations in the brainstem 2 hr post 1 mg/kg DFP 
dose. 
 Metabolite Concentration (µmol/g tissue) 
Metabolite Control DFP 
Total Tissue Weight (g) 0.523 ± 0.017 0.529 ± 0.043 
Phosphatidic acid 4.9 ± 1.7 2.9 ± 1.2 
Cardiolipin 5.6 ± 1.8 3.5 ± 0.8
* 
Ethanolamine  
plasmalogen 
63.7 ± 11.7 54.0 ± 13.1 
Choline plasmalogen 6.7 ± 2.4 5.1 ± 0.8 
Phosphatidylserine 30.0 ±11.2 26.7 ± 3.7 
Phosphatidyl- 
ethanolamine 
45.5 ±  9.4 38.1 ± 7.1 
Phosphatidylinositol 5.2 ± 2.3 4.7 ± 0.8 
Phosphatidylcholine 81.4 ± 5.5 71.2 ± 9.5 
Sphingomyelin 16.1 ± 6.0 14.3 ± 2.0 
Cholesterol
a 
189.8 ± .9 184.0 ± 8.6 
n3 Fatty acids 14.0 ± 2.4 13.3 ± 2.6 
n6 Fatty acids 31.7 ± 3.4 35.0 ± 5.0 
Polyunsaturated  
fatty acids
b 229.5 ± 9.5 230.3 ± 20.9 
Total fatty acids 419.3 ± 28.5 457.6 ± 88.1 
Control n = 5; DFP n = 5 
*Denotes significance at p<0.05 
a
Average of 3 cholesterol carbon signals (C18 at 12.5 ppm, C19 at 19.7 ppm and C14 at 57.2 
ppm. 
b
Polyunsaturated fatty acid signal intensity is subject to changes in both concentration and 
composition  
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Aqueous, small molecule metabolites were measured in extracts of the brainstem at the 2 
hr time point by 
1
H and 
31
P NMR.  Brainstem showed no significant changes in any measured 
small molecule metabolites 2 hr post 1 mg/kg DFP exposure (Table 8).   
 
Table 8.  Changes in aqueous metabolite concentrations in the brainstem 2 hr post 1 
mg/kg DFP dose. 
Metabolite 
(chem. shift in ppm) 
Metabolite Concentration (µmol/g tissue) 
2 hr post dose 
Control DFP 
Valine (0.98) 0.01 ± 0.00 0.02 ± 0.01 
Isoleucine (1.01) 0.08 ± 0.02 0.10 ± 0.04 
β-hydroxybutyrate (1.24) 0.33 ± 0.08 0.5  ± 0.2 
Lactate
a
 (1.33, 4.11) 11.7 ± 2.7 13.6 ± 0.8 
Alanine (1.41) 0.11 ± 0.05 0.12 ± 0.03 
NAA (2.02) 6.8 ± 1.6 7.8 ± 0.9 
Methionine (2.13) 0.06 ± 0.01 0.07 ± 0.00 
Succinate (2.41) 0.69 ± 0.21 0.85 ± 0.13 
Trimethylamine (2.92) 0.05 ± 0.05 0.02 ± 0.01 
GABA (2.98) 2.4 ± 0.7 3.0 ± 0.4 
Ornithine (3.07) ND ND 
Cis-aconitate (3.21) 0.3 ± 0.2 0.3 ± 0.03 
Choline (3.22) 0.6 ± 0.2 0.7 ± 0.1 
Phosphocholine (3.23) 1.2 ± 0.3 1.4 ± 0.1 
Myo-inositol
a
 (3.53, 4.06) 8.0 ± 2.2 9.2 ± 1.3 
Glucose (3.41) 3.6 ± 3.0 1.5 ± 0.8 
Fumarate (6.52) 0.03 ± 0.01 0.03 ± 0.01 
Tyrosine (7.13) 0.15 ± 0.03 0.09 ± 0.05 
Formate (8.46) 1.4 ± 0.9 1.6 ± 0.5 
Nicotinate
a
 (8.71, 8.94) 0.11 ± 0.03 0.21 ± 0.18 
GPC
b
 (3.06) 0.89 ± 0.33 1.19 ± 0.28 
GPE
b
 (3.73) 0.35 ± 0.14 0.42 ± 0.22 
G3P
b
 (7.05) 2.7 ± 1.2 3.4 ± 1.0 
G6P
b
 (7.11) 8.7 ± 3.8 10.9 ± 3.4 
DHAP
b
 (8.04) 0.05 ± 0.06 0.08 ± 0.06 
Control n = 5; DFP n = 5 
a
average of multiple signals 
b
metabolite signals are from 
31
P aqueous spectra.  GPC set at 3.082 ppm for reference 
 Abbreviations:  NAA – N-acetylaspartate; GABA – γ-aminobutyric acid; GPC – 
glycerophosphocholine; GPE – glycerophosphoethanolamine; G3P – glycerol-3-phosphate; G6P 
– glucose-6-phosphate; DHAP – dihydroxyacetone phosphate; ND – Not detectable 
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3.4 Cerebellum 
3.4.1 Biochemical assays 
 Inhibition of AChE in the cerebellum reached a maximum at 2 hr post dose with 
activity levels at 50% of control activity (Fig. 20).  The cerebellum showed a trend toward 
recovery by 48 hr post dose; however, enzyme activity levels did not reach control levels by 48 hr 
post dose. 
 
 
Figure 20.  Inhibition of acetylcholinesterase activity reported as a percentage of the control value in 
cerebellum after a single subcutaneous dose of 1 mg/kg DFP. Data are mean ± SE; n=5/time point.  
*Significantly different from control at p<0.05. 
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MDA was measured in the cerebellum at 0.5, 1, 2, 12, 24 and 48 hr post DFP dose.  None 
of the cerebellum samples from rats treated with DFP showed any significant change in the level 
of MDA at any time point post dose (Fig. 21). 
 
 
Figure 21.  Time course measurement of levels of malondialdehyde in cerebellum.  Data are mean ± 
SE; n=5/time point. 
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3.4.2 Differential gene expression in cerebellum 
 Complete results of the quality control analysis of the gene arrays are shown in 
Appendix II.  Based on the quality control analyses, the data from two gene chips (one control 
and one DFP-treated; n = 4 for each group) were excluded from the dataset.  The final differential 
gene expression changes in the cerebellum 1 hr post DFP exposure included 65 up and 158 down-
regulated genes (p<0.05 with fold change > 15% regardless of annotation status).  The total 
number of annotated genes that were differentially expressed was 163.  The expression of 12 
genes was present in the control group but absent in the DFP group, while 17 genes were not 
expressed in the control group but were in the DFP group.  The full list of differentially expressed 
genes in the cerebellum can be found in Appendix III.  Only the genes that were annotated were 
included in the final list. 
In order to understand the biological relevance of the many gene expression changes 
caused by DFP exposure, complete lists of up- and down-regulated genes were used separately to 
search the DAVID web site.  The results of the database search are summarized in Table 9.  
Among the many up-regulated biological processes in the cerebellum were anti-apoptosis, 
response to stimuli, response to oxidative stress and regulation of gene expression/ RNA 
metabolism/ RNA polymerase.  Down-regulated biological processes included negative 
regulation of apoptosis, protein folding/ catabolism, purine nucleoside triphosphate synthesis and 
ribosome synthesis.  Cellular components were down-regulated and consisted of intracellular 
organelles and the nucleus.  Phosphatase activity associated with the mitogen activated protein 
kinase (MAPK) pathway was up-regulated.  ATPase activity and DNA repair processes were 
down-regulated. 
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Table 9.  Gene expression changes in specific cellular pathways of the cerebellum 1 hr post 1 
mg/kg DFP exposure. 
Category Pathway Regulation 
# genes 
changed 
%
a 
p-value* 
Biological 
Process 
adult behavior Up 3 16.7 0.0052 
behavior Up 5 27.8 0.0012 
negative regulation of transcription 
factor activity 
Up 2 11.1 0.0470 
positive regulation of anti-apoptosis Up 2 11.1 0.0320 
positive regulation of gene expression Up 4 22.2 0.0250 
positive regulation of RNA metabolic 
process 
Up 4 22.2 0.0160 
positive regulation of transcription from 
RNA polymerase II promoter 
Up 4 22.2 0.0096 
regulation of anti-apoptosis Up 2 11.1 0.0430 
regulation of cell proliferation Up 4 22.2 0.0410 
regulation of RNA metabolic process Up 6 33.3 0.0110 
regulation of transcription Up 7 38.9 0.0064 
response to endogenous stimulus Up 4 22.2 0.0270 
response to extracellular stimulus Up 4 22.2 0.0048 
 response to oxidative stress Up 3 16.7 0.0180 
 transcription Up 5 27.8 0.0070 
 cellular protein catabolic process Down 6 5.5 0.0280 
 cellular response to stress Down 7 6.4 0.0300 
 chromatin organization Down 5 4.5 0.0450 
 DNA repair Down 7 6.4 0.0005 
 
modification-dependent protein 
catabolic process 
Down 6 5.5 0.0190 
 negative regulation of apoptosis Down 8 7.3 0.0020 
 negative regulation of cell death Down 8 7.3 0.0023 
 
negative regulation of programmed cell 
death 
Down 8 7.3 0.0022 
 
nucleoside triphosphate biosynthetic 
process 
Down 4 3.6 0.0190 
 nucleotide-excision repair Down 3 2.7 0.0290 
 positive regulation of ligase activity Down 4 3.6 0.0044 
 
positive regulation of ubiquitin-protein 
ligase activity 
Down 3 2.7 0.0410 
 protein catabolic process Down 6 5.5 0.0350 
 protein folding Down 5 4.5 0.0041 
 
proteolysis involved in cellular protein 
catabolic process 
Down 6 5.5 0.0270 
 
purine nucleoside triphosphate 
biosynthetic process 
Down 4 3.6 0.0180 
 
purine ribonucleoside triphosphate 
biosynthetic process 
Down 4 3.6 0.0180 
 regulation of apoptosis Down 9 8.2 0.0280 
 regulation of cell death Down 9 8.2 0.0300 
 regulation of ligase activity Down 4 3.6 0.0058 
 regulation of programmed cell death Down 9 8.2 0.0300 
 regulation of ubiquitin-protein ligase Down 3 2.7 0.0490 
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activity 
 response to DNA damage stimulus Down 7 6.4 0.0027 
 ribonucleoprotein complex biogenesis Down 4 3.6 0.0350 
 ribosome biogenesis Down 4 3.6 0.0130 
 rRNA metabolic process Down 3 2.7 0.0450 
 rRNA processing Down 3 2.7 0.0420 
 sulfur metabolic process Down 4 3.6 0.0210 
 
transcription-coupled nucleotide-
excision repair 
Down 2 1.8 0.0330 
 transmembrane transport Down 4 3.6 0.0330 
Cellular 
Component 
chromosome Down 7 6.4 0.0380 
intracellular organelle lumen Down 19 17.3 0.0016 
membrane-enclosed lumen Down 20 18.2 0.0013 
nuclear lumen Down 15 13.6 0.0062 
nucleolus Down 7 6.4 0.0140 
nucleoplasm Down 11 10.0 0.0270 
organelle lumen Down 20 18.2 0.0009 
 mitochondrion inner membrane Down 5 4.5 0.0120 
Molecular 
Function 
MAP kinase phosphatase activity Up 2 11.1 0.0120 
MAP kinase tyrosine/serine/threonine 
phosphatase activity 
Up 2 11.1 0.0120 
protein heterodimerization activity Up 3 16.7 0.0300 
protein tyrosine/serine/threonine 
phosphatase activity 
Up 2 11.1 0.0350 
transcription activator activity Up 3 16.7 0.0450 
transcription factor activity Up 4 22.2 0.0360 
transcription regulator activity Up 5 27.8 0.0300 
Dual specificity protein phosphatase 
(MAP kinase phosphatase) 
Up 2 11.1 0.0110 
MAP kinase phosphatase Up 2 11.1 0.0110 
MAPK signaling pathway Up 3 16.7 0.0210 
PIRSF002524:nerve growth factor IB-
like nuclear receptor 
Up 2 11.1 0.0063 
ATPase activity Down 6 5.5 0.0190 
ATPase activity, coupled Down 5 4.5 0.0290 
hydrogen ion transmembrane 
transporter activity 
Down 4 3.6 0.0140 
Chaperone Down 4 3.6 0.0390 
DNA damage Down 4 3.6 0.0290 
DNA repair Down 4 3.6 0.0190 
*p-value derived from modified Fisher’s Exact test 
a
Percentage calculated by number of genes differentially expressed/total number of genes 
involved in process, cellular component or molecular function*100. 
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3.4.3 Metabolic changes in cerebellum 
Lipid metabolite changes in the cerebellum at 2 hr post DFP exposure are detailed in 
Table 10.  In cerebellum phosphatidylinositol was 11% lower in the DFP-treated group as 
compared to control while n3 fatty acids were about 33% lower.   
 
Table 10.  Changes in lipid metabolite concentrations in the cerebellum 2 hr post 1 mg/kg DFP 
dose. 
 Metabolite Concentration (µmol/g tissue) 
Metabolite Control DFP 
Total Tissue Weight (g) 0.249 ± 0.032 0.218 ± 0.022 
Phosphatidic acid 0.8 ± 0.1 0.8 ± 0.2 
Cardiolipin 2.1 ± 0.4 1.9 ± 0.3 
Ethanolamine  
plasmalogen 
18.5 ± 3.9 17.0 ± 2.2 
Choline plasmalogen 1.4 ± 0.4 1.4 ± 0.1 
Phosphatidylserine 8.6 ± 0.8 8.2 ± 0.7 
Phosphatidyl- 
ethanolamine 
15.9 ± 1.7 15.0 ± 2.4 
Phosphatidylinositol 1.8 ± 0.1 1.6 ± 0.2
* 
Phosphatidylcholine 33.2 ± 3.2 32.5 ± 1.6 
Sphingomyelin 4.9 ± 0.6 4.9 ± 0.3 
Cholesterol
a 
87.7 ± 2.2 81.8 ± 2.8 
n3 Fatty acids 26.7 ± 5.1 17.8 ± 6.3
** 
n6 Fatty acids 16.3 ± 1.9 15.6 ± 2.3 
Polyunsaturated  
fatty acids
b 240.1 ±  18.7 221.3 ± 10.0 
Total fatty acids 308.9 ± 25.6 289.1 ± 13.3 
Control n = 5; DFP n = 5 
*
Denotes significance at p<0.05 
**
Denotes significance at p<0.01 
a
Average of 3 cholesterol carbon signals (C18 at 12.5 ppm, C19 at 19.7 ppm and C14 at 57.2 
ppm. 
b
Polyunsaturated fatty acid signal intensity is subject to changes in both concentration and 
composition  
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Aqueous, small molecule metabolites were measured in extracts of the cerebellum at the 
2 hr time point by 
1
H and 
31
P NMR.  Alanine was increased 3 fold in cerebellum while succinate 
was increased by about 30%.  Trimethylamine was decreased by approximately 50% (Table 11).   
 
Table 11.  Changes in aqueous metabolite concentrations in the cerebellum 2 hr post 1 
mg/kg DFP dose. 
Metabolite 
(chem. shift in ppm) 
Metabolite Concentration (µmol/g tissue) 
2 hr post dose 
Control DFP 
Valine (0.98) ND ND 
Isoleucine (1.01) ND ND 
β-hydroxybutyrate (1.24) 0.16 ± 0.03 0.16 ± 0.02 
Lactate
a
 (1.33, 4.11) 15.8 ± 1.9 17.3 ± 2.3 
Alanine (1.41) 0.02 ± 0.00 0.06 ± 0.00
* 
NAA (2.02) 6.3 ± 0.9 7.0 ± 0.8 
Methionine (2.13) 0.05 ± 0.01 0.05 ± 0.01 
Succinate (2.41) 0.7 ± 0.1 0.9 ± 0.2
** 
Trimethylamine (2.92) 0.007 ± 0.001 0.004 ± 0.00
* 
GABA (2.98) ND ND 
Ornithine (3.07) ND ND 
Cis-aconitate (3.21) 0.09 ± 0.03 0.1 ± 0.06 
Choline (3.22) 0.56 ± 0.17 0.56 ± 0.04 
Phosphocholine (3.23) 0.78 ± 0.09 0.93 ± 0.12 
Myo-inositol
a
 (3.53, 4.06) 7.6 ± 4.2 6.3 ± 6.3 
Glucose (3.41) 0.36 ± 0.3 0.16 ± 0.04 
Fumarate (6.52) 0.01 ± 0.01 0.01 ± 0.01 
Tyrosine (7.13) 0.02 ± 0.01 0.02 ± 0.01 
Formate (8.46) 3.2 ± 2.5 3.7 ± 0.4 
Nicotinate
a
 (8.71, 8.94) 0.15 ± 0.03 0.16 ± 0.05 
GPC
b
 (3.06) 0.58 ± 0.08 0.71 ± 0.11 
GPE
b
 (3.73) 0.13 ± 0.03 0.29 ± 0.11 
G3P
b
 (7.05) 2.6 ± 0.5 2.8 ± 0.2 
G6P
b
 (7.11) 1.1 ± 0.2 1.0 ± 0.1 
DHAP
b
 (8.04) 0.05 ± 0.04 0.07 ± 0.05 
Control n = 5; DFP n = 5 
*
Denotes significance at p<0.01 
**
Denotes significance at p<0.05 
a
average of multiple signals 
b
metabolite signals are from 
31
P aqueous spectra.  GPC set at 3.082 ppm for reference 
 Abbreviations:  NAA – N-acetylaspartate; GABA – γ-aminobutyric acid; GPC – 
glycerophosphocholine; GPE – glycerophosphoethanolamine; G3P – glycerol-3-phosphate; G6P 
– glucose-6-phosphate; DHAP – dihydroxyacetone phosphate; ND – Not detectable 
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3.5 Hippocampus 
3.5.1 Biochemical assays 
 Inhibition of AChE in the hippocampus reached a maximum at 2 hr post dose with 
activity levels at 55% of control activity (Fig. 22).  The hippocampus showed a trend toward 
recovery by 48 hr post dose; however, enzyme activity levels did not reach control levels by 48 hr 
post dose. 
 
 
Figure 22.  Inhibition of acetylcholinesterase activity reported as a percentage of the control value in 
hippocampus after a single subcutaneous dose of 1 mg/kg DFP. Data are mean ± SE; n=5/time point. 
*Significantly different from control at p<0.05. 
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MDA was measured in the hippocampus at 0.5, 1, 2, 12, 24 and 48 hr post DFP dose.  
None of the hippocampus samples from rats treated with DFP showed any significant change in 
the level of MDA at any time point post dose (Fig. 23). 
 
 
Figure 23.  Time course measurement of levels of malondialdehyde in hippocampus.  Data are Mean ± 
SE; n=5/time point. 
 
 
3.5.2 Differential gene expression in hippocampus 
 Complete results of the quality control analysis of the gene arrays are shown in 
Appendix II.  Based on the quality control analyses, the data from one gene chip (DFP-treated; 
n=4 for DFP group) were excluded from the dataset.  One sample was lost during preparation 
(n=4 for control group).  The final differential gene expression changes in the hippocampus 1 hr 
post DFP exposure included 18 up- and 105 down-regulated genes (p<0.05 with fold change > 
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15% regardless of annotation status).  The total number of annotated genes that were 
differentially expressed was 105.  The expression of 22 genes was present in the control group 
but absent in the DFP group, while 9 genes were not expressed in the control group but were in 
the DFP group.  The full list of differentially expressed genes in the hippocampus can be found in 
Appendix III.  Only the genes that were annotated were included in the final list. 
In order to understand the biological relevance of the many gene expression changes 
caused by DFP exposure, complete lists of up- and down-regulated genes were used separately to 
search the DAVID web site.  The results of the database search are listed in Table 12.  All 
biological processes and cellular components in the hippocampus were down-regulated.  The 
cellular pathways affected by DFP exposure were I-kappaB kinase cascade and Wnt signaling 
pathways.  The down-regulated cellular components were cytoplasmic vesicles. 
 
Table 12.  Gene expression changes in specific cellular pathways of the hippocampus 1 hr post 1 
mg/kg DFP exposure. 
Category Pathway Regulation 
# genes 
changed 
% p-value* 
Biological 
Process 
I-kappaB kinase/NF-kappaB 
cascade 
Down 3 3.8 0.0110 
Protein kinase cascade Down 5 5.2 0.035 
Cellular 
Component 
cytoplasmic vesicle Down 7 8.8 0.0300 
Molecular 
Function 
Wnt signaling pathway Down 5 5.2 0.0055 
*p-values derived from modified Fisher’s Exact test 
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3.5.3 Metabolic changes in hippocampus 
Lipid metabolite changes in the hippocampus at 2 hr post DFP exposure are detailed in 
Table 13.  The hippocampus had no significant changes after DFP treatment in any of the lipid 
species measured. 
 
Table 13.  Changes in lipid metabolite concentrations in the hippocampus 2 hr post 1 mg/kg DFP 
dose. 
 Metabolite Concentration (µmol/g tissue) 
Metabolite Control DFP 
Total Tissue Weight (g) 0.113 ± 0.031 0.130 ± 0.017 
Phosphatidic acid 0.5 ± 0.2 0.3 ± 0.2 
Cardiolipin 1.2 ± 0.7 1.5 ± 0.6 
Ethanolamine  
plasmalogen 
11.3 ± 2.6 10.0 ± 4.2 
Choline plasmalogen 0.8 ± 0.2 0.7 ± 0.4 
Phosphatidylserine 6.3 ± 2.0 5.4 ± 1.7 
Phosphatidyl- 
ethanolamine 
11.3 ±1.9 10.5 ± 2.9 
Phosphatidylinositol 1.1 ± 0.3 1.1 ± 0.4 
Phosphatidylcholine 22.9 ± 4.0 20.8 ± 6.2 
Sphingomyelin 3.0 ± 0.4 2.8 ± 0.7 
Cholesterol
a 
58.1 ± 2.2 55.1 ± 3.6 
n3 Fatty acids 9.1 ± 4.7 8.8 ± 2.3 
n6 Fatty acids 14.0 ± 1.9 12.1 ± 5.6 
Polyunsaturated  
fatty acids
b 181.0 ± 11.6 175.8 ± 49.1 
Total fatty acids 218.1 ± 20.4 199.6 ± 50.9 
Control n = 5; DFP n = 4 
a
Average of 3 cholesterol carbon signals (C18 at 12.5 ppm, C19 at 19.7 ppm and C14 at 57.2 
ppm. 
b
Polyunsaturated fatty acid signal intensity is subject to changes in both concentration and 
composition  
 
Aqueous, small molecule metabolites were measured in extracts of the hippocampus at 
the 2 hr time point by 
1
H and 
31
P NMR (Table 14).  In the hippocampus, the amino acids valine, 
isoleucine and alanine were increased 4-5 fold, while cis-aconitate, fumarate and nicotinate were 
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increased 2-3 fold after exposure to DFP.  Succinate and γ-aminobutyric acid (GABA) were 
decreased approximately 57%. 
 
Table 14.  Changes in aqueous metabolite concentrations in the hippocampus 2 hr post 1 
mg/kg DFP dose. 
Metabolite 
(chem. shift in ppm) 
Metabolite Concentration (µmol/g tissue) 
2 hr post dose 
Control DFP 
Valine (0.98) 0.05 ± 0.01 0.26 ± 0.05
** 
Isoleucine (1.01) 0.11 ± 0.06 0.43 ± 0.06
** 
β-hydroxybutyrate (1.24) 0.51 ± 0.42 0.38 ± 0.21 
Lactate
a
 (1.33, 4.11) 11.1 ± 2.0 12.1 ± 1.5 
Alanine (1.41) 0.03 ± 0.01 0.16 ± 0.02
** 
NAA (2.02) 5.2 ± 1.3 5.4 ± 0.6 
Methionine (2.13) ND ND 
Succinate (2.41) 0.69 ± 0.01 0.27 ± 0.01
** 
Trimethylamine (2.92) ND ND 
GABA (2.98) 1.3 ± 0.3 0.6 ± 0.5
* 
Ornithine (3.07) ND 0.28 ± 0.17 
Cis-aconitate (3.21) 0.36 ± 0.2 0.83 ± 0.24
* 
Choline (3.22) 0.53 ± 0.13 0.51 ± 0.07 
Phosphocholine (3.23) 0.53 ± 0.07 0.48 ± 0.04 
Myo-inositol
a
 (3.53, 4.06) 3.9 ± 0.9 3.9 ± 0.4 
Glucose (3.41) 1.3 ± 0.2 1.6 ± 0.6 
Fumarate (6.52) 0.04 ± 0.03 0.1 ± 0.03
* 
Tyrosine (7.13) 0.06 ± 0.04 0.1 ± 0.02 
Formate (8.46) 3.2 ± 2.8 8.3 ± 6.5 
Nicotinate
a
 (8.71, 8.94) 0.10 ± 0.04 0.19 ± 0.06
**
 
GPC
b
 (3.06) 0.43 ± 0.16 0.42 ± 0.06 
GPE
b
 (3.73) 0.28 ± 0.01 0.26 ± 0 
G3P
b
 (7.05) ND ND 
G6P
b
 (7.11) ND ND 
DHAP
b
 (8.04) ND ND 
Control n = 4; DFP n = 4 
*
Denotes significance at p<0.05 
**
Denotes significance at p<0.01 
a
Average of multiple signals 
b
Metabolite signals are from 
31
P aqueous spectra.  GPC set at 3.082 ppm for reference 
 Abbreviations:  NAA – N-acetylaspartate; GABA – γ-aminobutyric acid; GPC – 
glycerophosphocholine; GPE – glycerophosphoethanolamine; G3P – glycerol-3-
phosphate; G6P – glucose-6-phosphate; DHAP – dihydroxyacetone phosphate; ND – Not 
detectable 
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IV. DISCUSSION 
The aim of this research was to gain insight into the possible mechanistic basis of non-
cholinergic toxicity induced by the OP, DFP, in the rat brain.  The –omic approach to 
investigating the off-target toxicity of DFP provided a global picture of the effects triggered by 
low level exposure.  The use of a multi-omic approach was advantageous since the results could 
be analyzed and interpreted in an integrated manner.  It was expected that the cellular response to 
a low dose insult of DFP would be protection and repair with an effort to return to homeostasis.  
The greatest effects at 1 hr (gene expression) and 2 and 48 hr (metabolic) after DFP exposure 
were seen in the cortex, although each region had similar and distinctive changes in metabolic 
and gene expression profiles. 
4.1 Normal regional lipid composition 
The use of NMR to generate full lipid profiles of the cortex, brainstem, cerebellum and 
hippocampus provided an insightful view of the normal regional lipid differences (Figs 13, 14).  
The brainstem showed the most unique lipid profile as compared to the other three regions, being 
much higher in all measured phospholipids and cholesterol.  With the exception of the substantia 
nigra, red nucleus and olivary and cranial nuclei, the brainstem is predominantly white matter, 
corresponding to the increased levels of these lipids.  Interestingly, the levels of n6 fatty acids 
were comparable in brainstem relative to other regions, but the level of n3 fatty acids was 
significantly lower than in cortex and cerebellum.  In the 
13
C spectrum of all brain extracts, the n3 
fatty acid signal was a single peak, likely representing a single lipid species, presumably 
docosahexaenoic acid (DHA), the major n3 fatty acid in mammalian brain.  Though not a single 
peak, the n6 fatty acid signal was dominated by one peak and assumed to be arachidonic acid 
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(AA).  These signals corresponded to NMR spectra from reference standards of DHA and AA 
that were acquired in this laboratory.  DHA is specific to the CNS and is particularly enriched in 
grey matter (Halliwell and Whiteman, 2004; Milatovic et al., 2006).  Approximately 50% of CNS 
plasma membrane PUFAs is DHA, with a concentration in the synapses (Bazan et al., 2011).  AA 
is a known precursor of pro-inflammatory eicosanoids and also increases production of 
interleukins 1 and 6 as well as TNF-α (tumor necrosis factor alpha) (Yao et al., 2009).  n3 fatty 
acids such as DHA, however, suppress the production of AA-derived eicosanoids by 
competitively inhibiting cyclooxygenase and through a negative feedback mechanism on Δ-
desaturase, the rate limiting enzyme in the formation of AA; n3 fatty acids thus are considered to 
be anti-inflammatory or immunosuppressive (Muakkassa et al., 1991; Yao et al., 2009).  It is 
unknown if the brainstem has higher levels of most lipid species solely because of greater 
myelination or if there is functional importance associated with these elevated lipid species.  It 
has been thought that the high levels of ethanolamine plasmalogen in the brainstem may serve as 
scavengers for ROS, protecting critical membrane phospholipids from peroxidation (Brosche and 
Platt, 1998; Engelmann et al., 1994; Hahnel et al., 1999; Kuczynski and Reo, 2006).  The high 
n6:n3 (or AA:DHA) FA ratio, calculated to be 2.32 ± 0.51, in the brainstem would favor a pro-
inflammatory response.  Irrespective, the high lipid density of the brainstem does create an 
attractive target for lipid soluble toxins, such as OPs.  Correspondingly, this region was also 
found to have the highest basal level of AChE activity (Fig. 12) 
Cortex, cerebellum and hippocampus were relatively similar and unremarkable in the 
lipid profiles with the exception of the n3 and n6 FA which, again, may reflect the inflammatory 
response tendencies of those regions.  The calculated n6:n3 ratios for the cortex, cerebellum and 
hippocampus were 1.26 ± 0.27, 0.62 ± 0.08 and 2.07 ± 1.4, respectively.  The relatively equal 
ratio between AA and DHA in the cortex would balance the pro- and anti-inflammatory response, 
while the hippocampus may behave similarly to the brainstem with a pro-inflammatory tendency.  
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With an AA:DHA ratio less than 1, the cerebellum was unique and likely favors an anti-
inflammatory response.   
4.2 Regional metabolomes 
 PCA is a commonly used unsupervised method to visualize NMR-derived metabolomic 
data.  Various reports have described the use of PCA to illustrate the clustering of NMR spectral 
intensities using top principal components (Anthony et al, 1994; Holmes et al, 1992, 1998a,b; 
Williams et al., 2003b).  One of the stated reasons for the selection of cortex, brainstem, 
cerebellum and hippocampus as the brain regions for the investigation of low level OP toxicity 
was because of the assumption that each region had distinct function, and therefore, would have 
distinct chemical makeup.  Since the physiological activity of the cell is defined and regulated by 
the metabolites, then the cellular chemistry would be a driver of that region’s specific physiology.  
PCA of the 
1
H NMR spectra of control brain extracts illustrated the biochemical uniqueness of 
the four brain regions investigated (Fig. 15).  Each region displayed tight clustering within each 
group and no overlap between regions.  This result demonstrates that, unlike the lipid 
composition which was relatively similar for cortex, cerebellum and hippocampus, the 
biochemical makeup of each region was unique.  The systemic distribution of DFP delivered 
enough dosage to cause comparable and significant levels of inhibition of AChE in each region 
(Figs. 16, 18, 20, 22).  With such different metabolic profiles each region’s cellular response to 
the insult would be expected to reflect these variations. 
4.3 Acetylcholinesterase inhibition 
For the purposes of this research, a non-cholinergic dose was considered to be a sub-
acute dose that inhibited AChE to a level that did not elicit an overt response indicative of 
cholinergic toxicity such as salivation, lacrimation and seizures (muscarinic effects) or muscle 
weakness, fasciculation and flaccidity/paralysis (nicotinic effects).  All animals showed none of 
these cholinergic symptoms post dosing.  The inhibition of AChE in each of the brain regions was 
positive indication of systemic distribution of DFP to the brain.  The large amount of variability 
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in the cortex likely stems from non-homogeneous sampling of the large cortical region.  All other 
regions were subsequently homogenized before removal of sample for analysis.  Knowing that 
the level of maximum inhibition for all four regions was approximately 50%, and that the 
brainstem had the highest level of basal activity, more of the DFP dose reached the brainstem.  
Because of the substantially higher lipid content in the brainstem this may be caused, in part, by 
higher partitioning of DFP in this region.  Many OPs are highly lipophilic, although DFP is water 
soluble, as well.  The Kow (octanol/water partition coefficient) of DFP is 14.8, compared to the 
highly lipid soluble soman which has a Kow of 66.1. This increased affinity for lipids may make 
the brainstem a target for OPs.  Each brain region showed a trend toward recovery by 48 hr which 
is similar to previous reports in whole brain (Gearhart et al., 1990; Martin, 1985), though none of 
the regions reached control levels by 48 hr.  New enzyme production depends on protein 
synthesis only and not mRNA synthesis, and the appearance of new AChE occurs over a period 
of days to weeks (Chippendale et al., 1974; Lanks et al., 1974) which is consistent with the lack 
of complete recovery seen at 48 hr.  Therefore, even in the absence of cholinergic symptoms, 
delayed synthesis of AChE can prolong mild hyperstimulation of postsynaptic receptors.  In 
addition to this, it is important to note that while neuronal and astrocytic metabolism differ, 
neuronal health and function is dependent on the surrounding astrocytes.  While the initial 
response may occur at the synapse, the cascade of effects is not limited to the neuron. 
4.4 Determination of oxidative stress 
It has not been previously shown if a 1 mg/kg dose of DFP would trigger oxidative stress 
through the formation of ROS.  We were unable to measure any significant increases in MDA, 
the selected marker of lipid peroxidation, in any of the four brain regions.  The MDA assay itself 
may also be unreliable, as there were significant differences between data generated from the 
cuvette method and the microplate method (Figs. 17, 19, 21, 23), although it is believed that 
comparisons between treated and control for each tissue were valid as they were run together with 
linear standard calibration.  If mild lipid peroxidation occurs at this dose of DFP, then more 
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sensitive markers, such as F2-isoprostane and F4-neuroprostane, which are the products of 
peroxidation of AA and DHA, respectively, would be required for detection (Halliwell and 
Whiteman, 2004; Milatovic et al., 2006; Reich et al., 2001).  For the purposes of this study, we 
have no definitive proof of oxidative stress manifested in the form of lipid peroxidation.  
However, differential gene expression results suggest that one of the early cellular responses to 
DFP was to ameliorate increases in ROS.  Up-regulation of genes associated with vitamin C 
transport in the brainstem and response to oxidative stress and myeloperoxidase (mpo) in the 
cerebellum indicated that there was cellular detection of an imbalance of ROS that triggered an 
early gene response in these regions (differential gene expression data is available in Appendix 
III).  It is probable that the gene expression changes are more sensitive markers of oxidative stress 
than MDA, and that a 1 mg/kg dose of DFP was enough to induce a level of oxidative stress that 
was low, yet significant enough to bring about a change in gene expression.  However, induction 
of oxidative stress did not appear to be a major contributor to the overall mechanistic basis of low 
level toxicity of DFP. 
4.5 Biological interactions in the cortex 
The cortex had the most changes in gene expression, with the majority of genes being 
down-regulated.  Three general processes were the focus of down-regulation in the cortex: 
apoptosis, synaptic functions and protein transport (Table 6).  The down-regulation of two of 
these, apoptosis and synaptic functions, supported the concept of protection and repair.  While the 
low dose of DFP likely caused a mild, yet sustained increase in postsynaptic stimulation, the level 
should not be enough to cause extensive excitotoxicity.  Induction of apoptosis would be a gross 
overt response that would elicit more damage than the initial insult.  The gene expression changes 
shown here are at 1 hr post-dose, representing an early response that enables the protection of 
survivable cells and allows for activation of mechanisms to repair damage.   
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Multiple processes involving synaptic functions were down-regulated, particularly those 
that regulate the levels and secretion of neurotransmitters.  All brain regions were shown to have 
a maximum inhibition of AChE of approximately 50% with a slow trend toward recovery by 48 
hr. As previously stated, losing function of up to half of the AChE would result in an increase in 
the available ACh in the synaptic space with a subsequent overstimulation of postsynaptic 
receptors.  Although DFP, for the most part, does not age, the binding to AChE is essentially 
irreversible and reactivation would take longer than the formation of new protein, which is on the 
order of days to weeks.  With diminished hydrolysis of ACh in the synaptic space, the two 
options for attenuating the postsynaptic stimulation are to: 1) reduce the number of postsynaptic 
ACh receptors and/or 2) reduce the amount of ACh being released into the synapse.  In the cortex 
the differential gene expression data suggest that the synaptic structure is being modified to 
moderate the transmission of excitatory neurotransmitters.  Using GeneSpring software, the 
biological interactions of down-regulated genes associated with synaptic functions in the cortex 
revealed the potential effect of DFP on the synapse (Fig. 24).   
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Figure 24.  Biological interactions of synapse-related gene protein products and functions in the 
cortex (GeneSpring).  Gene product legend: green – down-regulated; grey – unchanged.   Interaction 
legend: blue square – binding; purple square – regulation; cyan diamond – metabolism.  Rab3c is 
associated with the plasma membrane.  All other genes/proteins are associated with cytosol. 
 
 
The gene expression of the family of RIM-binding proteins, Erc1, Erc2, Rab3 and Cast were all 
down-regulated in the cortex.  RIMs are proteins specific to the presynaptic active zone that serve 
to regulate neurotransmitter release and control membrane traffic (Wang et al., 2002).  These 
proteins interact with Bsn, Rims1, Pclo and Unc13a, all of which are responsible for synaptic 
cytoskeleton organization, regulation of exocytosis, regulation of presynaptic cytomatrix proteins 
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and synaptic vesicle maturation with the ultimate outcome being the regulation of 
neurotransmitter secretion.  A down-regulation in the expression of this protein family has the 
potential to induce further modulation of these genes and proteins to reduce the amount of 
excitatory neurotransmission, ultimately serving a neuroprotective role.  Additionally, the 
expression of grik2, the gene coding for an ionotropic glutamate receptor specific to the synaptic 
membrane was also down-regulated.  After acute doses of OPs, particularly nerve agents, severe 
AChE inhibition is quickly succeeded by activation of NMDA (N-methyl-D-aspartate) glutamate 
receptors, causing intracellular accumulation of Ca
2+
.  NMDA receptor activation is considered to 
be responsible for the induction of seizures and status epilepticus which cause the profound 
neuronal damage seen following acute exposure (McDonough and Shih, 1997).  While the gene 
that codes specifically for subunits of the NMDA glutamate receptor, grin, did not have altered 
expression, the down-regulation of grik2 is further evidence of neuroprotective changes in gene 
expression after a sub-acute dose.  Finally, the inhibitory neurotransmitter GABA was increased 
at 48 hr post DFP, also promoting neuromodulation of excessive excitatory transmission.  The 
release of GABA has been shown to be a neuronal defense mechanism in response to glutamate 
exposure (Sapolsky, 1998). 
Expression of Ptgds was up-regulated and expression of Nmur2 was not detectable in 
control cortical samples but was significantly up-regulated after DFP exposure.  The search in 
DAVID linked these genes with the biological function termed ‘disulfide bond’, likely referring 
to three conserved cysteine residues in the prostaglandin D2 (PGD2) protein, one of which, Cys
65
, 
is critical for catalytic activity (Liu et al, 2008).  Nmur2 is a G-protein coupled receptor that is 
expressed mainly in the CNS and, in particular, the hypothalamus (Zeng et al., 2006).  The 
significance of Nmur2 is unclear, though it may be involved in adrenocorticotrophin-mediated 
stress response (Zeng et al., 2006).  Interestingly, some studies have discovered that 
glucocorticoids impair neuronal defenses by inhibiting the release of extracellular adenosine 
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during an insult to the neurons (Sapolsky, 1998).  Quantifying adenosine from the NMR spectrum 
is difficult because the best resolved signals arise from adenosine associated with ATP and not 
free adenosine.  The protein product of Ptgds, however, catalyzes the synthesis of PGD2 from 
PGH2.  PGD2 is the most abundant prostaglandin in the brain (Saleem et al., 2009).  Inflammation 
in the CNS is known to increase the synthesis of PGD2.  An up-regulation in Ptgds is a good 
indication of inflammatory processes in the cortex and correlates with the loss of membrane 
phospholipids and specifically n6 FA (AA) seen in the NMR lipid metabolite data. 
The third down-regulated process, protein transport, is likely a result of injury and has the 
potential to be harmful to the cell.  In a scenario where the cellular response is protection and 
repair, one of the means by which the cell accomplishes this task is to synthesize and localize 
proteins.  As discussed earlier, the synthesis of new AChE is critical to re-establishing normal 
synaptic function and returning the cell to homeostasis.  In the CNS, de novo synthesis of AChE 
occurs in the neuronal cell body and is then transported through the axon to the nerve terminal 
(Chippendale et al., 1974).  If the mechanisms of protein transport are dysfunctional, then the 
localization of newly synthesized enzyme to the synapse will quite likely be delayed, prolonging 
the period of postsynaptic hyperstimulation.  In fact, Chippendale et al. (1974) suggested that the 
delivery of new AChE after inhibition with 1 mg/kg DFP was via slow axoplasmic flow and not 
any rapid flow.  However, it is possible that the protein transport mechanisms associated with 
rapid axoplasmic flow were disabled.  Therefore, while cellular responses are focused on 
minimizing and repairing damage from the toxic insult, the secondary effects of the exposure are 
creating a roadblock for these mechanisms.  Prolonging the repair process has the potential to 
lead to long-term neural dysfunction. 
Finally, the molecular functions of nucleotide and ATP binding were significantly down-
regulated, with the expression of a large number of genes being affected.  The functions of 
nucleotide and ATP binding are broad, as they apply to nearly every process in the cell.  
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However, the overall message is that the energy status of the cell has been affected as a result of 
the DFP insult.  An impairment of the ability to bind ATP impedes cellular progress toward 
homeostasis, just as down-regulation of protein transport does. 
The signal representing NAA was significantly lower in the DFP-treated cortex samples 
as compared to control at 2 hr post-dose.  NAA is specific to the nervous system and is 
considered to be a marker of neuronal health.  Decreases in NAA have been shown to correlate to 
axonal degradation or dysfunctional metabolism, and nearly all brain diseases or disorders, with 
the exception of Canavan disease, have decreased levels of NAA (Moffett et al., 2007).  It is 
important to note that neuronal dysfunction associated with decreases in NAA can be reversible 
and does not indicate a permanent loss of neurons (De Stephano et al., 1995; Moffett et al., 
2007).  The change in NAA seen at 2 hr was significant, yet returned to control levels by 48 hr.  
However, the decrease at 2 hr can be interpreted as a neuron-specific perturbation seen only in the 
cortex (Table 5). 
Because of the changes seen in the cortex at 2 hr, we chose to look at the cortex at 48 hr 
post dose to determine if there was a progression of metabolic perturbation.  At 48 hr post DFP 
exposure, the data reveal a perturbation in glycolysis (Figure 25).   
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Figure 25.  Schematic representation of glycolytic pathway and TCA cycle, showing changes in small 
molecule metabolites in the cortex at 48 hr post DFP exposure with associated gene expression 
changes at 1 hr post DFP exposure.  Increases in measured metabolites are shaded red and decreases are 
shaded green.  Metabolites that were measured from the NMR spectra but did not change after DFP 
exposure are shaded grey.  Unshaded metabolites were not measured.  Genes are denoted by lower case text 
in italics.  Down-regulated genes are in green.  Abbreviations:  G6P – glucose-6-phosphate; GA3P – 
glyceraldehyde-3-phosphate; DHAP – dihydroxyacetone phosphate; G3P – glycerol-3-phosphate; OAA – 
oxaloacetate; αKG – α-ketoglutarate. 
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Differential gene expression data showed that expression of slc2a3 was down-regulated 
at 1 hr with a subsequent decrease in glucose and G6P levels observed at 48 hr.  Slc2a3 codes for 
GLUT3, the primary neuronal glucose transporter, and is found predominantly in axons and 
dendrites of neurons (Vannucci et al., 1998).  The change in expression of the gene for GLUT3 
but not GLUT1, the astrocytic glucose transporter, localized the site of injury to the neuron.  
Down-regulation for expression of gyk (glycerol kinase) at 1 hr was followed by a decrease in 
G3P and DHAP at 48 hr.  The decreases in these metabolites are likely to alter the level of 
glyceraldehyde-3-phosphate (GA3P) and, ultimately, the amount of pyruvate available for the 
TCA cycle.  Unfortunately, the signals for GA3P and pyruvate were not detectable in the NMR 
spectrum.  The chemical shift for pyruvate in the spectrum was unobstructed by other signals; 
therefore, the levels of pyruvate are simply below the limit of detection.  The decrease in DHAP 
was likely caused by decreases in both G6P and G3P, offsetting the equilibrium between DHAP 
and GA3P.  Interestingly, gene expression for lactate dehydrogenase (ldha) was down-regulated 
at 1 hr, though no corresponding changes in levels of lactate were measured at either 2 or 48 hr.  
Lactate dehydrogenase is a tetrameric enzyme, containing either M and/or H subunits.  Ldha 
codes for the M subunit, while ldhb codes for the H subunit.  The LDH-1 isozyme, found mainly 
in neurons, is composed of 4 H subunits, while LDH-5, specific to astrocytes, contains M 
subunits only.  Therefore, the down-regulation of ldha, which codes for the M subunit, localizes 
this change in gene expression to the astrocyte.  Additionally, slc16a1 and slc16a7, which code 
for MCT (monocarboxylate transporter) 1 and 2, respectively, were also down-regulated.  MCT1 
is the major lactate transporter of the BBB and is found in significant quantities in astrocytes.  
MCT2 is the major isoform for neurons and has high affinity for pyruvate.  Taken together, these 
changes have the potential to impact energy production in the neuronal environment.  Lactate as 
an alternative energy source for the neuron has been proposed (Pellerin and Magistretti, 1994); 
however, the astrocyte-neuron lactate shuttle hypothesis is quite controversial and is refuted by 
substantial data regarding the lactate dehydrogenase enzymes and lactate transporters.  Glycolytic 
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enzymes are tightly regulated by cellular energy status.  LDH, however, is not regulated by 
energy status; the rate and direction of the reaction catalyzed by LDH is controlled by the 
concentration of the substrates and products, lactate and pyruvate, as well as the NADH/NAD
+
 
ratio.  Therefore, neuronal levels of pyruvate at rest or during increased neural activation drive 
the LDH reaction toward lactate.  Also, both glycolysis and lactate dehydrogenation require 
NAD
+
, which means that if lactate is used as an energy source, it is done at the expense of 
glucose.  Finally, in order for the LDH reaction to shift towards pyruvate production, the levels of 
lactate must be excessively high.  Lactate transport across the BBB, however, follows a 
concentration gradient facilitated by the MCTs.  This process is relatively slow in the absence of 
a dramatic event such as seizure induced increases in brain lactate concentration.  With the 
decrease in glucose, G6P, G3P and DHAP and the down-regulation of genes indicative of energy 
status, it is probable that the glycolytic rate was down, although the glycolytic metabolites may 
simply be depleted by increased energy demands.  If the equilibrium reaction catalyzed by LDH 
normally favors the direction of lactate production, then the down-regulation of the astrocyte-
specific LDH would reduce the conversion of pyruvate to lactate in the astrocyte, likely insuring 
that the available pyruvate from glucose is fully oxidized.  It is interesting that this is localized to 
the astrocyte and not the neuron, where the conversion of energy substrate to ATP is critical.  
Gene array data do not show a change in the expression of GLUT1, only GLUT3.  Based on this, 
glucose transport to the astrocyte is not compromised.  This is compelling evidence to indicate 
that lactate from the astrocyte is not an alternative energy substrate.  Because glycolytic ATPs are 
linked to ion transport (Dienel and Cruz, 2003; Roberts, 2007; Wu et al., 1997), the energy 
derived from glycolysis is essential, particularly for synaptic function as few to no mitochondria 
are found in the synaptic region.  It is very unfortunate that pyruvate was not quantifiable from 
the NMR spectrum and future studies should include specific analysis of this metabolite.  
Additionally, time course measurement of lactate may reveal the temporal relationship between 
the gene expression change and any changes in lactate levels. 
87 
 
There was limited indication that the disruption in glycolysis translated to the TCA cycle 
at this time point.  Only succinate and fumarate could be quantified from the NMR spectra, and 
the concentration of these two metabolites did not change after DFP exposure.  Cis-aconitate was 
measured, and being in equilibrium with citrate, should be an indicator of citrate levels which 
were not quantifiable.  Cis-aconitate levels were decreased at 48 hr, though this was not 
statistically significant.  Expression of the gene coding for iso-citrate dehydrogenase (idh3a) was 
down-regulated at 1 hr with no apparent impact on the TCA cycle that is reflected later in the 
metabolites succinate and fumarate.  What is known, though, is that the cell was responding to the 
DFP insult as early as 1 hr post dose, and glycolysis was impacted by 48 hr.  These changes in the 
glycolytic pathway may mark the cellular attempt to return to homeostasis, which increases the 
demand for ATP.  Based on gene expression data, the ability to use ATP has been compromised.  
In an environment where the demand for glucose and oxygen is already high, even a slight 
perturbation in glucose metabolism and energy usage can have deleterious effects for the neuron.  
The increases in the BCAAs valine and isoleucine in cortex at 48 hr represent a potential 
impact on the TCA cycle.  As essential amino acids, the sole source for BCAAs is dietary; 
therefore, the increase in these levels must be caused by decreased metabolism.  Catabolism of 
valine in brain slices ultimately forms succinyl-CoA; this conversion has the potential to serve an 
anaplerotic function to the TCA cycle (Murin et al, 2009a).  Glial metabolism of isoleucine yields 
acetyl-CoA and propionyl-CoA, the latter being catalyzed by propionyl-CoA carboxylase to 
succinyl-CoA for TCA cycle anaplerosis (Murin et al., 2009b).  Gene array results showed no 
change in the expression of any genes associated with enzymes of these metabolic pathways.  
Impairment of valine and isoleucine metabolism potentially reduces this point of entry into the 
TCA cycle.  At the 48 hr time point, however, there is no indication of any impact on metabolites 
within the TCA cycle.  Future studies should investigate later time points to determine if the 
perturbation in BCAA metabolism translates to a change in TCA cycle metabolites. 
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The changes in these BCAAs may have broader implications than solely a connection to 
the TCA cycle.  In addition to this function, BCAAs act as nutritional signals for cellular growth 
pathways through protein synthesis, specifically the mammalian Target of Rapamycin (mTOR) 
pathway.  Increases in these amino acids stimulate the mTOR complex, triggering protein 
synthesis.  If the neuronal response was to protect and repair, while returning to homeostasis, 
cellular growth in the form of increasing axon length and dendritic outgrowth would be 
counterproductive.  Cell signaling cascades are complex and have many points of positive and 
negative feedback; however, the gene expression data showed down-regulation of several ephrin 
receptor tyrosine kinases (epha6, epha7, ephb6), as well as ephrin B2 ligand (efnb2).  Ephrin 
receptors have been shown to inactivate mTOR by increasing upstream repressor activity (Nie et 
al, 2010).  A down regulation of these receptors has the potential to stimulate mTOR activity 
further to the detriment of the neuron. Ephrin signaling is known to control growth cone 
dynamics such as axon branching and retraction and work through a variety of downstream 
effectors such as GTPases, phosphatases and guanine nucleotide exchange factors.  There is no 
indication that the signaling pathway is linked to BCAA metabolism.  As signaling molecules, 
BCAAs are specific to the mTOR complex itself, triggering the localization of the complex to a 
molecular scaffold of activating proteins.  Therefore, it is unlikely that the down-regulation of 
ephrin gene expression is responsible for the increase in valine and isoleucine. 
At 2 hr post dose, the cortex showed the greatest changes in the lipid profiles, with 
decreases in lipids and phospholipids associated with the plasma membrane.   Cardiolipin, a 
phospholipid specific to the inner mitochondrial membrane, was not affected by DFP exposure.  
This seems to correlate with the lack of any observed impact on the TCA cycle at 48 hr that may 
have been caused by an earlier disruption in the mitochondrial membrane.  The targeting of the 
plasma membrane may be related to the level of inhibition of AChE.  Significant inhibition of 
enzyme was seen as early as 30 min after DFP dosing, reducing the amount of free choline from 
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ACh hydrolysis, and, therefore, the amount available for re-uptake by the presynaptic neuron.  
Under normal conditions, the presynaptic neuron uses the recycled choline as substrate for the 
synthesis of ACh (via choline acetyltransferase) and phosphocholine (via choline kinase) for 
phospholipid synthesis and incorporation into the membrane.  The demand for this choline for 
ACh synthesis far exceeds that for PtdC synthesis, as very little dietary choline is used for ACh 
(Cansev et al., 2008; Zeisel, 2006).  The impact on the membrane is two-fold: the incorporation 
of choline-containing phospholipids into the membrane decreases while the breakdown of 
choline-containing phospholipids increases.  Choline deficiency has been shown to create a loss 
of PtdC from the membrane, although the levels of PtdE were reported to increase (Zeisel, 1997).   
However, PtdE-N-methyltransferase, the enzyme responsible for the synthesis of PtdC from PtdE 
using S-adenosylmethionine as a methyl donor, has been shown to have activity in the brain, 
particularly when PtdC breakdown increases during excessive neuronal firing (Blusztajn et al., 
1986; Lakher and Wurtman, 1987; Zeisel, 1997).  The majority of activity is located in the nerve 
terminal, corresponding to the region most immediately affected by excess neuronal stimulation 
(Blusztajn et al, 1986; Parducz et al., 1976; Zeisel, 1997).  Therefore, lack of replenishment of 
the choline pool could explain the decreases in PtdC, PtdE and SM, which is another choline-
containing phospholipid.  The measured levels of choline did not change significantly from 
control at either 2 or 48 hr post dose, though this may be attributable to choline being both a 
breakdown product and synthetic precursor.  However, phosphocholine, a precursor to PtdC 
synthesis, was decreased at 48 hr, suggesting that the rate of PtdC synthesis was being up-
regulated in order to restore membrane phospholipids, and, therefore, membrane stability (Fig. 
26).  In fact, qualitative analysis of the phospholipid metabolites at 48 hr revealed that the levels 
of PtdC, PtdE and ChPl from control cortex were no longer significantly different than DFP-
treated cortex, suggesting that the cellular environment in the cortex had recovered membrane 
phospholipids (Figs. 26, 27; data in Appendix IV).  It should be noted that the expression of 
phospholipase C, which hydrolyzes PtdC to DAG and phosphocholine, and phospholipase D, 
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which hydrolyzes PtdC to PA and choline, was not changed.  However, smpd3 gene, which codes 
for sphingomyelinase, was down-regulated at 1 hr post dose.  This could account for the decrease 
in phosphocholine since this enzyme catalyzes the hydrolysis of SM to phosphocholine and 
ceramide.  However, it is also possible that this gene was down-regulated in order to prevent the 
hydrolysis of SM in order to preserve membrane integrity.  Indeed, levels of SM from DFP-
treated cortex were not significantly different than control at 48 hr post dose. 
 
 
Figure 26.  Schematic representation of interaction of glycolytic pathway and lipid metabolism, 
showing changes in small molecule metabolites in the cortex at 48 hr post DFP exposure with 
associated gene expression changes at 1 hr post DFP exposure.  Decreases in measured metabolites are 
shaded green.  Metabolites that were measured from the NMR spectra but did not change after DFP 
exposure are shaded grey.  Unshaded metabolites were not measured.  Genes are denoted by lower case text 
in italics.  Down-regulated genes are in green.  Abbreviations:  G6P – glucose-6-phosphate; DHAP – 
dihydroxyacetone phosphate; G3P – glycerol-3-phosphate; Eth Pl – ethanolamine plasmalogen; Ch Pl – 
choline plasmalogen; PA – phosphatidic acid; DAG – diacylglycerol; PtdE – phosphatidylethanolamine; 
PtdC – phosphatidylcholine; CDP – cytidine diphosphate; PLC – phospholipase C; SM - sphingomyelin. 
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Figure 27.  Temporal changes in phosphatidylcholine and related small molecule metabolites.  
Decreases in measured metabolites are shaded green.  Metabolites that were measured from the NMR 
spectra but did not change after DFP exposure are shaded grey.  Unshaded metabolites were not measured.  
Abbreviations:  PA – phosphatidic acid; PLD – phospholipase D; DAG – diacylglycerol; PLC – 
phospholipase C; AA – arachidonic acid; GPC – glycerophosphocholine; CDP – cytidine diphosphate; 
PtdC – phosphatidylcholine; PLA2 – phospholipase A2. 
 
 
The decrease in membrane phospholipids and n6 FA also provided additional evidence 
that the low level exposure to DFP induced an inflammatory response.  Prostaglandin synthesis 
would require cleavage of membrane phospholipids to supply the required precursor, AA, leading 
to a loss of the phospholipids.  Gene expression data do not show any change in phospholipase 
A2.  This does not explain, however, why the inflammatory response would be localized to just 
the cortex.  Further evidence would be needed to determine if inflammation played a role in the 
mechanistic basis of effects caused by low level DFP exposure. 
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Because phospholipid metabolism, specifically fatty acid synthesis and turnover, in the 
brain consumes ATP at a high rate, restoring membrane integrity would also require a dramatic 
increase in ATP consumption (Purdon and Rapoport, 2007).  Therefore, the loss of membrane 
phospholipids, either for replenishing the choline pool or for supplying AA, will generate an 
increased demand for energy in the neuronal environment.  This may account for the perturbation 
in metabolites associated with the glycolytic pathway.  Additionally, DHAP is the precursor for 
de novo synthesis of the ether-linked plasmalogens (Lee, 1998; Pollock et al., 1976; Purdon and 
Rapoport, 2007).  The decrease in DHAP at 48 hr may be indicative of an up-regulation in 
synthesis of EthPl and ChPl, both of which had comparable levels in control and DFP-treated 
groups at 48 hr post dose (Fig. 26; data in Appendix IV).   
 Finally, the decrease in n3 FA cannot be overlooked and has unique significance to the 
CNS.  As previously stated, the NMR signal for the n3 FA was a single peak and presumed to be 
DHA.  This is consistent with reports that DHA is the most abundant long chain n3 PUFA in the 
CNS.  Therefore, the decrease in the n3 FA signal in the cortex can be attributed to a loss of 
DHA.  In addition to being a key component of membrane phospholipids (levels of unesterified 
DHA are negligible as free DHA is rapidly incorporated into the sn2 position of phospholipids), 
DHA may play a critical neuroprotective role in the CNS.  A bioactive derivative of DHA, 
neuroprotection D1 (NPD1, 17S-docosatriene), has been shown to induce homeostasis and pro-
survival signaling after insult by up-regulating anti-apoptotic proteins and down-regulating pro-
apoptotic proteins (Bazan et al., 2011).  NPD1 is considered to be anti-inflammatory.  It is 
possible that the low level exposure to DFP induced the conversion of DHA to NPD1 for the 
promotion of cell survival.  Gene array data do not show a change in the expression of 15-
lipoxygenase-1, the enzyme responsible for conversion of DHA to NPD1, though this does not 
imply that the enzyme is not already active.  However, the loss of DHA leads to potentially 
adverse implications for the cell. The phospholipid PtdS is rich in DHA and is a key player in Akt 
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signaling for promoting cell survival (Bazan et al., 2011).  Because of the tight regulation 
between DHA and PtdS, a loss of DHA results in a preferential loss of PtdS.  The data reported 
here show a significant decrease in PtdS, which could correlate to the decrease in n3 FA.  This 
loss can translate to a deficit in Akt signaling, hampering the cellular attempt to return to 
homeostasis.  DHA-rich membranes have also been linked to G protein coupled receptor (GPCR) 
signaling pathways, suggesting that GPCRs are located in DHA-rich regions of the cell 
membrane.  Interestingly, muscarinic ACh receptors are GPCRs.  Disruption in this region of the 
membrane can further challenge neuronal communication and function via impaired signaling 
pathways.  It is obvious that future studies should further investigate the role of DHA in OP-
mediated toxicity.  Neuroprostane, the peroxidation product of DHA, and NPD1 levels are 
important markers for understanding the mechanisms of action within the CNS, and particularly, 
the cortex.  
4.6 Biological interactions in the brainstem 
 The brainstem was the most unique of the four brain regions investigated, in terms of 
composition and response to the low level exposure to DFP.  As previously stated, the brainstem 
was much higher in all measured phospholipids and cholesterol, relative to cortex, cerebellum 
and hippocampus, a finding that is not unusual considering the large degree of myelination in the 
brainstem.  This lipid-rich environment makes the brainstem an attractive target site for lipophilic 
compounds such as OPs.  DFP’s large Kow of 14.8 indicates that the compound will partition 
readily into the brainstem region.  This was reflected in the AChE inhibition data.  The maximum 
inhibition of AChE in the brainstem was at 40% of control activity, the greatest amount of 
inhibition of the four regions investigated.  The basal level of enzyme activity in the brainstem 
was higher than cortex, cerebellum and hippocampus.  Taken together, the brainstem received the 
largest dose of DFP.  However, the lipid and small molecule metabolite profiles at 2 hr post DFP 
exposure were negligibly affected by the insult.  Only the mitochondrial phospholipid cardiolipin 
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was decreased at 2 hr post dose.  Of the small molecule metabolites that were identifiable from 
1
H 
and 
31
P NMR spectra, none were altered.  PCA of the binned 
1
H spectra revealed an overlap of 
control and DFP-treated groups, positive indication that no variables existed in the spectra, 
known or unknown, that contributed to separation of the two groups (Fig 28).  Based on the 
metabolic data, it appeared that a 1 mg/kg DFP dose had no effect on the brainstem at 2 hr post 
dose. 
 
Figure 28.  Principal components scores plot (PC1 vs. PC2) of 
1
H-NMR spectra of aqueous 
metabolites from brainstem. 
 
 Gene expression data at 1 hr post dose did suggest that multiple processes could be 
occurring early on in the brainstem.  As in the cortex, the expression of several genes encoding 
for proteins associated with synaptic function were down-regulated, including Rab5a, Rab3b and 
stx1a.  Rab5a and Rab3b are specific to synaptic vesicles and synaptosomes and serve to regulate 
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vesicle transport and exocytosis at the synapse.  Stx1a encodes for syntaxin, a protein which 
interacts with SNAP (soluble NSF-attachment proteins) and synaptobrevin proteins to form a 
macromolecule complex between the membrane of a synaptic vesicle and the synaptic membrane, 
allowing them to come together and fuse.  Down-regulation of the expression of these genes 
allows the presynaptic neuron to modulate the amount of neurotransmitter being released into the 
synaptic space, attenuating the postsynaptic hyperstimulation caused by excess ACh.   
 The brainstem also showed gene expression up-regulation that indicated an early and 
immediate response to address the DFP insult and associated oxidative stress.  The expression of 
slc23a1 was up-regulated; in fact, slc23a1 expression was only detectable after DFP exposure.  
The protein product of Slc23a1 is an ascorbate/sodium symporter.  Vitamin C, as ascorbate, 
provides antioxidant defense and reduces oxidized tocopherol (vitamin E), which is highly 
efficient at protecting against lipid peroxidation.  Vitamin E, mainly as α-tocopherol, is critical to 
brain health, as long term deficiency induces neurological disease (Muller and Goss-Sampson, 
1990).  However, the concentration of α-tocopherol in the CNS is tightly regulated, and the levels 
do not change dramatically in short periods of time (Halliwell, 2001).  Therefore, ascorbate is 
essential to reduce oxidized vitamin E.  The CNS maintains high concentrations of ascorbate in 
grey and white matter and in cerebral spinal fluid (Halliwell, 2001).  Ascorbate is actively 
transported by both neurons and glia to increase the intracellular concentration to millimolar 
levels (Siushansian and Wilson, 1995).  Therefore, the up-regulation in the expression of the 
ascorbate transporter is good indication that the brainstem was responding to an increase in 
oxidative stress.     
  It is interesting to note that aanat was up-regulated and arntl was down-regulated.  The 
protein product of aanat is arylalkylamine N-acetyltransferase (AANAT), which is the enzyme 
that catalyzes the conversion of serotonin to N-acetylserotonin in the synthetic pathway for 
melatonin.  AANAT activity positively correlates to and is an important regulator of melatonin 
synthesis (Iuvone et al., 2005).  Circadian clocks are set by melatonin, and Iuvone et al (2005) 
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reported that the rhythmicity of melatonin production is controlled by AANAT activity.  The 
arntl gene codes for aryl hydrocarbon receptor nuclear translocator-like protein.   The protein 
arntl forms a heterodimer complex with CLOCK, another circadian rhythm associated protein, to 
activate downstream genes that drive circadian cycles (Xu et al., 2010).  The change in 
expression of these two genes in the brainstem provides the potential to disrupt circadian-
controlled mechanisms.  In a separate study, adult male rats that were subcutaneously dosed with 
0.2 mg/kg/day of DFP showed disturbances in sleep/wake patterns (Deurveilher et al, 1999a).  
The contention of the authors was that changes in sleep patterns correlated directly to the 
inhibition of AChE.  Indeed, as inhibition initially increased, the behavioral patterns worsened.  
However, while serum cholinesterase activity was inhibited by 70% of control 6 hr after the first 
dose, in the pontomesencephalic tegmentum, the region of interest for sleep behavior, 
cholinesterase activity was reduced only 40% after 3 days of DFP dosing, while differences in 
wakefulness and slow-wave sleep had reached a maximum (Deurveilher et al., 1999b).  
Cholinesterase activity in this region was reduced to as low as 25% of control with no 
corresponding increase in the changes in wakefulness and slow-wave sleep. This implies the 
possibility that the behavioral changes in the rats may have been caused by a mechanism other 
than AChE inhibition.  It is possible that the exposure to DFP caused changes in the expression of 
genes associated with the regulation of circadian cycles within the brainstem, thus inducing a 
disruption in sleep patterns. 
 Just as was seen in the cortex, the processes and molecular functions of protein 
localization and ATP/ribonucleotide binding were down-regulated, potentially creating similar 
opportunities for neuronal dysfunction that may be manifested at later time points.  Early gene 
expression changes associated with the disruption of protein localization implicate the axonal 
transport mechanisms.  Kif12, encoding for a member of the kinesin superfamily of microtubule-
based molecular motors, was up-regulated.  Kinesin motors aid in the transport of vesicles along 
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microtubules by hydrolyzing ATP (Dagenbach and Endow, 2004).  Increasing the transcription of 
mRNA for this protein would improve the ability to move vesicles containing newly synthesized 
proteins to the necessary regions, particularly the synapse.  However, the down-regulation of ATP 
binding functions and utilization of ATP as an energy source would impede the motor function, 
and thus the ability to transport proteins effectively.   
 Finally, analysis of the lists of up- and down-regulated genes using GeneSpring 
software revealed a biological interaction pathway that suggests the exposure to DFP induced an 
inflammatory response in the brainstem (Fig. 29).  Table 15 describes each gene/protein 
identified in the biological interaction pathway. 
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Figure 29.  Biological interactions of inflammation pathway-associated gene protein products and 
functions in the brainstem (GeneSpring).  Gene legend: red – up-regulated; green – down-regulated; grey 
– unchanged.   Interaction legend: blue square – binding; purple square – regulation; cyan triangle – 
transport; cyan diamond – metabolism; pink symbol – protein modification.  Connector legend: blue line – 
regulator; pink line – target; red line – catalyst/modulator; gold line – participant; cyan line – reactant.  All 
genes/proteins are associated with cytosol. 
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Table 15.  List of up- and down-regulated genes in the brainstem and associated protein products. 
Gene 
PMID 
# 
Name Description Function 
Ccl11 6356 
Chemokine (C-C 
motif) ligand 11 
Cytokine involved in 
immunoregulation and 
inflammation, eosinophil-
specific 
+ regulation/ 
transport of 
eosinophils, + 
regulation of 
dpp4 
Jak2 3717 Janus kinase 2 
Protein tyrosine kinase 
involved in cytokine receptor 
signaling pathways 
multiple 
Dpp4 1803 
Dipeptidyl-peptidase 
4 
Regulation of T-cell mediated 
immunity 
Regulates ccl11 
Il25 64806 Interleukin 25 Induce NF-κB activation Regulates ccl11 
Il13 3596 Interleukin 13 
B-cell maturation/ 
differentiation 
+ regulation of 
Jak2 
Il5 3567 Interleukin 5 
Colony stimulating factor, 
eosinophils 
+ regulation of 
Jak2, regulated 
by Jak2 
Stat1 6772 
Signal transducer and 
activator of 
transcription 1 
Transcription factor, cell 
viability in response to stimuli 
and pathogens 
Regulated and 
modified by Jak2 
Stat5a 6776 
Signal transducer and 
activator of 
transcription 5a 
Response to cytokines, 
transcription activator, anti-
apoptosis 
+ and – regulated 
by Jak2 
Ptpn11 5781 
Protein tyrosine 
phosphatase, non-
receptor type 11 
Signaling molecule regulating 
cell growth and differentiation 
Regulates Jak2, 
+ and – regulated 
by Jak2 
Csf2 1437 
Colony stimulating 
factor 2 (granulocyte-
macrophage) 
Cytokine that control 
production, differentiation and 
function of granulocytes and 
macrophages 
+ regulates Jak2 
Irs1 3667 
Insulin receptor 
substrate 1 
Protein phosphorylated by 
insulin receptor tyrosine kinase 
Binds with Jak2 
 
The up-regulated gene, ccl11, encodes for C-C motif chemotactic chemokine ligand and 
is involved in inflammatory and immune responses.  This chemokine has chemotactic activity 
specifically for eosinophils, efficiently recruiting the inflammatory cells to sites of acute 
inflammation, often leading to a hyper-response (Ishii et al, 1998).  Up-regulation of ccl11 was a 
positive indication of an inflammatory response.  The down-regulation of jak2, however, suggests 
a modulatory effect for the immune response.  Both jak2 and ccl11 either regulate or are 
regulated by many proteins associated with immune responses involving T-cells, B-cells, 
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eosinophils, macrophages and cytokine signaling pathways.  Changes in the expression of these 
two genes have the potential to impact a dynamic range of immunological mediators and 
effectors.  A full time course metabolomic study would be an effective way to determine if the 
gene expression changes translated to a perturbation in the metabolome at a later time point. 
4.7 Biological interactions in the cerebellum 
The cerebellum had the lowest amount of basal activity of AChE as compared to the 
other three regions measured.  This corresponded to reports that  while levels of choline 
acetyltransferase (ChAT) and expression of nicotinic ACh receptor subunits are high during 
postnatal cerebellar ontogenesis, immunoreactivity and levels of transcripts for the receptor 
subunits are much lower in adulthood (De Filippi et al., 2005).  The conclusion is that the 
cholinergic system is critical for development of the cerebellum, particularly for neuronal 
differentiation and migration.  However, in adult rats, nearly all lobules of the cerebellum receive 
cholinergic afferents with higher density of labeling in the vestibulo-cerebellum in the vermis (De 
Filippi et al., 2005).  The primary function of nicotinic ACh receptor activation in the cerebellum 
is to modulate neurotransmitter release, indicating that the cholinergic system has a unique 
function in the cerebellum beyond simple neuronal communication.  The diffuse distribution of 
cholinergic synapses coupled with a neuromodulatory function could have implications for the 
cerebellar response to a low level exposure of a cholinergic inhibitor.  While the metabolic 
response at 2 hr post dose was minimal, the transcriptomic response was diverse and unique from 
the other brain regions investigated. 
Few correlative changes were seen in the lipid or small molecule metabolites in the 
cerebellum.  The loss of n3 fatty acids in the cerebellum, however, may mark an oxidative attack 
on DHA.  This may become more evident at later time points, which should be considered for 
future studies.  Gene expression changes seen at 1 hr post dose indicated that there was an early 
cellular response to oxidative stress.  It is worth noting that NAA levels were stable at 2 hr post 
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dose, indicating that neuronal integrity had not been significantly affected.  The increases in 
alanine and succinate may mark an initial adjustment in glycolysis or the TCA cycle that could be 
elucidated by investigation of later time points.  As seen in the cortex, slight changes in small 
molecule metabolites at 2 hr were followed by a progression of increased glycolytic perturbation 
at 48 hr.   
The cerebellum had the second most changes in gene expression after the cortex.  DFP 
exposure had an effect on diverse biological processes in the cerebellum.  Similar to the cortex, 
apoptotic pathways were down-regulated, while anti-apoptotic pathways were up-regulated.  As 
anticipated, the cellular response was protection and repair, not self-destruction, as the injury 
induced by the low level exposure should have been survivable.  The neuromodulatory nature of 
cholinergic transmission in the cerebellum may have further attenuated the extent of injury 
caused by AChE inhibition.  Indeed, the extent of depression of gene expression associated with 
synaptic transmission was not seen in the cerebellum, unlike the cortex and the brainstem.  This 
mode of protection and repair was also reflected in the down-regulation of processes associated 
with protein degradation, minimizing catabolic pathways and preserving cellular integrity. 
In spite of protein catabolic processes being down-regulated, it appeared that protein 
synthesis was negatively impacted.  Several transcription-related processes were up-regulated but 
translation was down-regulated, particularly ribosomal biogenesis.  Impairment of the protein 
synthetic machinery would impede the cell’s ability to repair cellular damage, as well as restore 
functional AChE to the synapse, delaying the return to homeostasis. 
It is unclear if the down-regulation of DNA repair processes was a result of cellular 
injury or a cellular response of protection.  No conclusive evidence exists that definitively 
supports OP-induced DNA damage, although the OP pesticide phorate was shown to cause DNA 
breaks in the sentinel fish species rohu (Mohanty et al, 2011).  DFP has not been reported to 
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cause DNA damage.  It seems possible that down-regulation of DNA repair was a cellular 
response of protection, possibly to conserve sources of energy for the restoration of cellular 
homeostasis.  A low level exposure of the nerve agent GB (similar in structure to DFP) in rat 
hepatocytes also caused a down-regulation of DNA repair that was unrelated to cell death (Klein 
et al, 1987).  However, in a study with the same agent, the hippocampus showed up-regulation of 
DNA repair processes 6 hr post low level treatment (Dr. Victor Chan, personal communication).  
Therefore, it is unclear if these OPs, at low level, are either inhibiting DNA repair or, possibly, 
protecting DNA from damage.  It is also impossible to determine if the DNA repair is for nuclear 
DNA, mitochondrial DNA or both.  Most DNA repair processes are shared by both mitochondrial 
and nuclear DNA, with the exception of nucleotide excision repair which is specific to nuclear 
DNA (Larsen et al, 2005).  Differential gene expression data do not indicate the exact pathways 
of DNA repair that were down-regulated.  What is clear, however, is that the expression of 
processes that are both pro and anti-cell survival have been altered, and these processes are likely 
competing with each other, prolonging the disruption in the neuronal environment and hindering 
the return to homeostasis.  Additional metabolomic studies should include later time points to 
determine if the cellular phenotype continues to reflect a progression of metabolic disruption. 
Despite the lack of any measureable increases in the lipid peroxidation marker MDA, 
gene expression data suggested that the cerebellum was responding to an early detection of 
oxidative stress.  From the DAVID database search, response to reactive oxygen species was an 
up-regulated process and included the genes dusp, fos, and hdac6 (dual specificity phosphatase, 
FBJ osteosarcoma oncogene and histone deacetylase 6).  Response to oxidative stress was also 
up-regulated and included the same genes, as well as mpo (myeloperoxidase), which is located in 
the mitochondrion.  Interestingly, the mitochondrion was identified as a down-regulated cellular 
component with some specificity for the inner membrane.  Changes in expression of genes 
associated with the inner mitochondrial membrane include key components of the mitochondrial 
103 
 
electron transport chain (Table 16).  Atp5f1 and atp5c1 encode for the membrane proton channel 
linked to the F1 complex by central and peripheral stalks and the extramembranous catalytic core 
(F1 complex) of the ATP synthase complex, respectively.   The protein product of cox4i2 
(cytochrome c oxidase) is the terminal oxidase in the electron transport chain, while surf1 
proteins are involved in the biogenesis of the cytochrome c oxidase complex.  The gene for the 
acylcarnitine transporter (slc25a20) was also down-regulated.  Acylcarnitines of various lengths 
are transported across the inner mitochondrial membrane from the cytosol to the mitochondrial 
matrix via this transporter for fatty acid oxidation.  A down-regulation in the expression of these 
genes indicates a loss of critical energy-producing capabilities.  The up-regulation of 
myeloperoxidase and the down-regulation of energy producing pathways make the cerebellar 
mitochondria a clear target of the exposure to DFP.  Future studies should include a temporal 
investigation of the metabolic profiles of this region, particularly those metabolites associated 
with mitochondrial function, including TCA cycle metabolites and the phospholipid cardiolipin.  
Future studies should also include in vitro metabolic measurements of basal oxygen consumption 
and glycolytic rates, as well as metabolic respiration and ATP usage in order to assess any 
mitochondrial damage. 
  
104 
 
Table 16.  Functional annotation clustering of inner mitochondrial membrane associated genes 
down-regulated in the cerebellum. 
Affymetrix 
Exon Gene 
ID 
Entrez 
Gene ID 
Official 
Gene 
Symbol 
ID GENE NAME 
7212517 171375 Atp5f1 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit B1 
ATP synthase, H+ 
transporting, 
mitochondrial F0 
complex, subunit B1 
7159732 116550 Atp5c1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, 
gamma polypeptide 1 
ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, gamma 
polypeptide 1 
7233997 84683 Cox4i2 
cytochrome c oxidase subunit IV 
isoform 2 
cytochrome c 
oxidase subunit IV 
isoform 2 
7340393 117035 Slc25a20 
solute carrier family 25 
(carnitine/acylcarnitine 
translocase), member 20 
solute carrier family 
25 
(carnitine/acylcarnit
ine translocase), 
member 20 
7237053 619346 Surf1 surfeit 1; surfeit 4 surfeit 1; surfeit 4 
  
Finally, it is worth noting the increase in expression of two specific genes that may have 
significance in the cerebellum: tnfrsf4 and npas4.  The protein encoded by tnfrsf4 is a member of 
the superfamily of tumor necrosis factor receptors, integral to the plasma membrane.  The 
receptor ligand, TNF-α, is a pro-inflammatory cytokine that is released by microglia primarily in 
response to brain injury such as ischemia, trauma and excitotoxicity (Raivich et al., 1999).  
Injured neurons have been shown to up-regulate receptors for TNF-α (Knott et al, 2000).  
However, TNF-α may be a driver of neuroinflammation and contribute to the pathology of 
neurological diseases.  TNF-α alone was able to promote motor neuron death in vitro (He et al., 
2002), and induction of apoptosis by TNF-α related ligands has been shown to be involved in 
both HIV-1 dementia and Alzheimer’s disease (Huang et al., 2005).  Up-regulation of receptors 
for TNF-α at 1 hr post exposure was a neuroprotective response that has the potential to 
contribute to long term neuronal dysfunction.   
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 Npas4 (neuronal PAS domain protein 4) is a brain-specific transcription factor complex 
localized in the nucleus.  It has been hypothesized that this protein serves as an “on demand” 
neuroprotectant in response to neurodegenerative stimuli (Ooe et al., 2009).  These authors 
describe the effects of multiple neuronal stress inducers and have shown that kainate-induced 
glutamate excitotoxicity was fatal for npas4 knockout mice but not for wild type littermates.  As 
previously stated, activation of NMDA glutamate receptors plays a key role in the 
neuropathology associated with acute OP exposure (McDonough and Shih, 1997).  Additionally, 
expression of npas4 was up-regulated in mouse hippocampal cells that survived transient global 
ischemia (as a stroke model), while the nearby dying cells had little expression of the protein.  
Npas4 has also been reported to regulate the expression of genes that control the quantity of 
GABAergic synapses in order to modulate the activity of excitatory neurons (Lin et al, 2008).  
Up-regulation of this gene in the cerebellum was good indication that neuroprotective pathways 
were being activated.  Ooe et al (2009) proposed a hypothetical model of the neuroprotective 
response of npas4 that included downstream regulation of expression of stress-inducible enzymes, 
including glutathione peroxidase, X-box binding protein and heat shock protein 5 as potential 
target genes.  While none of these genes showed a change in expression at 1 hr, these are notable 
targets for investigation at later time points. 
4.8 Biological interactions in the hippocampus 
The hippocampus is a subcortical structure that is associated with mechanisms of learning 
and memory, specifically spatial memory and the consolidation of short to long term memory.  
Numerous studies have reported that OP exposure creates deficits in behavior and cognition, 
indicating that the hippocampus is affected by OPs.  Cholinergic projections to the hippocampus 
come primarily from the medial septum by way of the fimbria-fornix (Alonso and Amaral, 1995; 
Placzek et al., 2009; Yoshida and Oka, 1995), and both nicotinic and muscarinic receptors are 
expressed throughout the hippocampus (Grybko et al., 2010; Jerusalinsky et al., 1997; Placzek et 
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al, 2009).  ACh is considered to be involved in a variety of cognitive functions, and antagonists 
for both receptors diminish long term potentiation and cause deficits in learning and memory 
(Jerusalinsky et al., 1997; Tai and Leung, 2012).  Given the wide distribution of ACh receptors 
and importance of cholinergic innervation in the hippocampus, it is not surprising that exposure 
to an OP, a cholinergic disruptor, would cause a deficit in the cognitive functions of this brain 
region. 
In terms of AChE, the hippocampus had levels of basal enzyme activity similar to the 
cortex, being significantly greater than the cerebellum and less than the brainstem (Fig. 12).   This 
level of activity corresponds to literature reports of the distribution of cholinergic synapses in the 
hippocampus.  AChE activity reached a maximum inhibition of 55% of control at 2 hr post 
exposure, a moderate loss of enzyme function that would not be cholinergically toxic but 
certainly cause sustainment of ACh in the synaptic space and hyperexcitation of postsynaptic 
receptors.  However, unlike the cortex and brainstem, gene expression data demonstrated little to 
no down-regulation of synaptic functions as a means to attenuate excess postsynaptic stimulation.  
Because ACh receptor activity is linked to cognitive functions in the hippocampus, excess 
receptor binding may not cause an immediate neuromodulatory response.  In fact, 
pharmaceuticals used for the treatment of Alzheimer’s disease and dementia are often 
anticholinergic compounds (Howard et al., 2012).  However, persistent ACh in the synapse will 
eventually upset the homeostatic regulation of the neuronal environment.  It is possible that 
synaptic functions would be altered at a later time point.  The expression of rab3b was down-
regulated at 1 hr, indicating that a cellular response to decrease the synaptic docking function may 
have been initiated, and further transcriptomic changes associated with the synapse could occur 
after the 1 hr time point. 
An unexpected gene expression change was the down-regulation of the Wnt signaling 
pathway (Fig. 30).  This pathway has long been known to play a key role in neuronal 
development in the CNS.  However, Wnt has been shown to be active in adult hippocampal 
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dentate gyrus (Garbe and Ring, 2012; Lie et al., 2005), possibly playing a role in cognitive 
functions associated with the hippocampus.  Considering the number of reports of cognitive 
deficits occurring after exposure to OPs, it is quite conceivable that down-regulation of 
neurogenesis is part of the mechanistic basis of the deficits.  Five genes associated with the Wnt 
signaling pathway were down-regulated.  Sfrp4 encodes for a cysteine-rich domain that is the 
putative binding site of Frizzled proteins and is considered to be a modulator of Wnt signaling.  
The protein product of dvl1 is a cytoplasmic phosphoprotein that is directly downstream of 
frizzled receptors.  Ctnnbip1 is encoded to a protein that binds catenin and prevents interaction 
with a specific family of transcription factors, negatively regulating the Wnt signaling pathway 
(Daniels and Weis, 2002).  The protein product of ctbp1 is a transcriptional repressor (PubMed 
Gene ID 1488).  Finally, camk2d is part of the Wnt/Ca
2+
 signaling pathway.  Down-regulation of 
the expression of these genes hints at a modulatory effect on the pathway.  Just as with the 
potential involvement of the mTOR pathway in the cortex, neurogenesis would be an energy-
demanding process at a time when cellular functions are focused on returning to homeostasis.  
Therefore, down-regulation of the Wnt pathway appears to promote this goal.  Future studies 
should include time course investigation of components of this pathway to determine if the 
perturbation in the signaling cascade progresses or subsides. 
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Figure 30.  KEGG schematic for the Wnt Signaling pathway.   Red stars mark genes that were down-
regulated 1 hr after 1 mg/kg DFP exposure.  Gene symbol identifications:  sfrp4 (FRP) – secreted frizzled-
related protein 4; dvl1 – disheveled, dsh homolog 1; ctnnbip1 (ICAT) – catenin, beta interacting protein 1; 
camk2d (CAMKII) – calcium/calmodulin-dependent protein kinase II delta; ctbp2 (loc685847, CtBP) – c-
terminal binding protein 2. 
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The I-kappaB kinase/NF-kappaB cascade was also down-regulated in the hippocampus.  
Activation of the I-kappaB kinase (interferon-kappaB kinase, IKK) complex triggers 
phosphorylation events that release an inhibitory protein that complexes with NF-κB (nuclear 
factor kappa light chain enhancer of activated B cells) and localizes it in the cytosol.  Release of 
the protein allows the NF-κB dimer to translocate to the nucleus where it binds DNA response 
elements to induce expression of proteins associated with immune and pro-inflammatory 
responses.  Inducers of NF-κB include ROS and TNF-α (Chandel et al., 2000).  Activation of NF-
κB transcription factors is caused by nearly all receptors of the innate and adaptive immune 
system (Ruland, 2011).  Because it is important for the effects of this cascade to be transient, 
modulation and termination of the cascade are as important for the cell as the initial activation.  
Uncontrolled activity of NF-κB can lead to inflammation and tumor development (Ruland, 2011).  
Therefore, negative regulation of the pathway is essential for normal cell maintenance.  The 
expression of three genes from this cascade was affected: traf2, irak1bp1 and nfkbib.  The Traf2 
protein is part of the canonical NF-κB pathway activated by TNF.  Upon TNF receptor activation, 
traf2, among other proteins, is recruited to the receptor in order to induce recruitment of IKK.  
Irak1bp1 encodes for a protein within the cascade initiated by activation of toll-like receptor 4.  
Irak proteins act as IKK complex stabilizers.  Finally, the protein product of nfkbib inhibits NF-
κB and traps it in the cytoplasm.  So, interestingly, down-regulation of nfkbib would actually 
increase the activity of transcription factors in the nucleus.  It seems evident that down-regulation 
of the expression of these genes serves to modulate the activity of the entire cascade in order to 
attenuate the effect, address the low level insult that certainly would have activated the pathway 
and still return to homeostasis. 
The hippocampus showed a number of changes in metabolites linked to glycolysis and 
the TCA cycle at 2 hr post dose (Fig. 31).  The decrease in succinate and increase in fumarate 
may indicate a shift in the equilibrium between the two metabolites towards fumarate.  Cis-
aconitate, the intermediate formed from the 2-step conversion of citrate to isocitrate was also 
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increased.  Unfortunately, it was not possible to detect citrate or iso-citrate in the NMR spectra.  
However, cis-aconitate is in equilibrium with citrate and should reflect levels of this metabolite.  
Similar to the cortex, the two BCAAs, valine and isoleucine, were increased after DFP exposure.  
As essential amino acids, the increase in valine and isoleucine must be caused by decreased 
metabolism.  As previously stated, both valine and isoleucine can serve an anaplerotic function to 
the TCA cycle at the point of succinyl-CoA (Murin et al., 2009a,b).  Impairment of  BCAA 
metabolism potentially reduces this point of entry into the TCA cycle.  If decreased metabolism 
of valine and isoleucine was reducing a source of succinyl CoA, this may explain the decrease in 
succinate.  However, it seems unlikely that fumarate would be increased following a decrease in 
succinate caused by loss of anaplerotic functions.  Finally, the amino acid alanine is in 
equilibrium with pyruvate, catalyzed by aminotransferase.  An increase in alanine, which is an 
important glucogenic amino acid, would disrupt the equilibrium with pyruvate which, 
unfortunately, we were unable to measure from the NMR spectrum.  However, if the increase in 
alanine was independent of any change in pyruvate, the equilibrium reaction could be shifted 
towards pyruvate, once again disrupting the TCA cycle and the glycolytic energy production 
pathway in the hippocampus.  Overall, it appears that the hippocampal cells were increasing 
glucose metabolism in order to meet higher energy demands.  Just as with the brainstem and 
cerebellum, future studies should investigate later time points to determine if the metabolic 
perturbation persists or even progresses, as seen in the cortex.  Indeed, several studies with 
individuals exposed to low levels of nerve agents have reported deficits in learning and memory 
that still manifest long after the initial exposure (Proctor et al., 2006; Yanagisawa et al., 2006; 
Yokoyama et al., 1998), suggesting that long term disruption in the hippocampus has occurred.  It 
is important to note that the lipid profile did not change at 2 hr post DFP exposure.  At later time 
points, the lipid metabolites may provide additional information to determine the mechanistic 
basis of neuronal dysfunction in the hippocampus. 
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Figure 31.  Schematic representation of glycolytic pathway and TCA cycle, showing changes in small 
molecule metabolites in the hippocampus at 2 hr post DFP exposure.  Increases in measured 
metabolites are shaded red and decreases are shaded green.  Metabolites that were measured from the NMR 
spectra but did not change after DFP exposure are shaded grey.  Unshaded metabolites were not measured.    
Abbreviations:  G6P – glucose-6-phosphate; GA3P – glyceraldehyde-3-phosphate; DHAP – 
dihydroxyacetone phosphate; G3P – glycerol-3-phosphate; OAA – oxaloacetate; αKG – α-ketoglutarate. 
 
4.9  Summary 
 While many studies have shown diverse effects of low level exposure to OPs, little is 
understood about the mechanistic basis of the off-target toxicity of this class of compounds.  This 
study was an initial attempt to characterize the effects of non-cholinergic toxicity of a model OP, 
DFP.  The –omic approach was selected in order to provide a global view of the changes 
occurring in each brain region investigated, giving a snapshot in time of the early metabolic and 
gene expression changes.  Integration of transcriptomic and metabolomic data is challenging, at 
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best, and a full time-course study would improve the ability to link differential gene expression 
with altered metabolic phenotypes.  However, by focusing on initial cellular responses to insult 
we have shown that a low dose of DFP induced early changes in metabolite and gene expression 
profiles that indicated a response of protection and repair of the neuronal environment. 
One of the most interesting findings of this research effort was the uniqueness of 
response from each of the four brain regions investigated.  Table 17 summarizes the significant 
effects for both gene expression and metabolite results.  Some of the regions showed similarities 
in the biological interactions, such as the down-regulation of apoptotic pathways in both the 
cortex and cerebellum and the decrease in gene expression associated with synaptic function in 
the cortex and brainstem.  Additionally, a depression in gene expression related to protein 
movement, folding and synthesis was seen in the cortex, brainstem and the cerebellum.  The 
cortex and hippocampus had metabolic phenotypes that suggested a perturbation in energy 
metabolism.  However, each region had many differences in gene expression and metabolic 
profile changes that reflected the distinct structure, chemistry and function of each region.  
Indeed, PCA of the 
1
H spectra, the full profile of the very compounds carrying out the 
biochemical reactions of the cell, revealed complete separation of each region in PC space.  This 
was compelling evidence regarding the importance of examining the brain as many subsystems, 
rather than as a whole.  In the search for better neuroprotectants, it is vital to consider the unique 
sensitivity of each brain region to OP insult. 
 While the apparent response of each brain region was to protect and repair the neuronal 
environment from the low level DFP exposure, evidence also exists for the potential for 
dysregulation.  In particular, the cortex showed down-regulation of processes to minimize 
damage and reduce excitotoxicity.  In spite of this there was some indication of neuronal distress 
at 2 hr manifested by changes in the lipid and phospholipid profile, followed by a perturbation in 
glycolysis at a later time point.  In the CNS, where the demand for energy is high, a disruption in 
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energy producing pathways has the potential to prolong recovery efforts and lead to sustained 
damage.  Increases in gene expression of prostaglandin synthesis linked with loss of phospholipid 
metabolites also suggests a response that may go from neuroprotective to neurotoxic, with the 
possibility of leading to long term dysfunction.  These metabolomic and transcriptomic 
approaches can increase the knowledge base and improve understanding of the mechanistic basis 
of adverse effects of low level DFP exposure, providing targets for novel therapeutics for 
neuroprotection. 
Table 17.  Summary of gene expression and metabolic effects in cortex, brainstem, cerebellum 
and hippocampus after 1 mg/kg DFP exposure. 
Brain region Gene Effects Metabolite Effects
a 
CX 
Apoptosis ↓ 
Synaptic function ↓ 
     RIM binding  proteins ↓ 
     Glutamate receptor ↓ 
Protein transport ↓ 
ATP binding ↓ 
GLUT3 (neuronal)↓ 
LDH (astrocyte) ↓ 
MCT1 (astrocyte, BBB) ↓ 
MCT2 (neuronal) ↓ 
Ptgds ↑ 
NAA: 2 hr ↓  48 hr  normal 
All lipids except PA, CL ↓ 
Phosphocholine ↓ 
Glucose, G6P, G3P, DHAP ↓ 
BCAA ↑ 
BS 
Ascorbate transport ↑ 
Protein localization ↓ 
Exocytosis ↓ 
ATP binding ↓ 
CL ↓ 
CB 
Phosphatase activity ↓ 
ATPase activity ↓ 
DNA repair ↓ 
Ribosome synthesis ↓ 
Anti-apoptosis ↑ 
Response to oxidative stress ↑ 
     Myeloperoxidase ↑ 
     Mitochondrial function ↓ 
Npas4 (neuroprotection) ↑ 
PtdI ↓ 
n3 FA ↓ 
Alanine ↑ 
Succinate ↑ 
HP 
Wnt signaling pathway ↓ 
I-κB kinase/NF-κB pathway ↓ 
BCAA ↑ 
Alanine ↑ 
Cis-aconitate ↑ 
Fumarate ↑ 
Nicotinate ↑ 
Succinate ↓ 
GABA ↓ 
a
Metabolite effects are at 2 hr unless otherwise noted. 
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VI. APPENDIX I 
 
6.1  RNA isolation gel electrophoresis images 
 
Figure 32.  Agarose gel images of RNA isolation quality check.  Top band is the 28S fragment and the 
bottom band is the 18S fragment.  Abbreviations:  CX – cortex; BS – brainstem; CB – cerebellum; HP – 
hippocampus. 
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Figure 33.  Agarose gel images of RNA isolation quality check for cortex sample re-isolated. 
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6.2  Quantification of total RNA 
 Table 18.  RNA isolation log with A260/280 and A260/230 ratios to detect degradation.  
Tube # Sample ID Brain region 260/280 260/230 ng/µL 
1 31 CX 2.06 .64 152.8 
2 40 CX 2.07 .24 82.4 
3 45 CX 2.05 1.29 182.5 
4 46 CX 2.07 0.3 101.3 
5 55 CX 2.09 1.95 740.8 
6 67 CX 2.07 0.20 50.7 
7 71 CX 2.07 0.42 182.0 
8 72 CX 2.18 1.30 35.8 
9 77 CX 2.04 0.29 147.8 
10 84 CX 2.03 0.27 104.2 
11 31 BS 2.06 1.67 225.3 
12 40 BS 2.03 2.02 393.3 
13 45 BS 2.13 0.15 75.4 
14 46 BS 2.17 0.09 42.5 
15 55 BS 2.05 1.26 208.3 
16 67 BS 2.05 0.91 180.8 
17 71 BS 2.05 1.51 276.1 
18 72 BS 2.06 1.19 131.0 
19 77 BS 2.04 1.61 154.1 
20 84 BS 2.02 0.68 81.6 
21 31 CB 2.06 2.02 744.5 
22 40 CB 2.01 1.34 205.7 
23 45 CB 1.99 1.24 114 
24 46 CB 2.06 1.71 320.6 
25 55 CB 2.15 0.36 185.2 
26 67 CB 1.99 0.41 216.3 
27 71 CB 2.03 1.63 283.9 
28 72 CB 1.99 0.29 147.3 
29 77 CB 2.05 0.33 107.1 
30 84 CB 2.11 0.28 152.0 
31 31 HP 2.05 1.08 111.4 
32 40 HP 2.11 1.68 129.3 
33 45 HP 2.03 1.25 451.3 
34 46 HP 2.1 1.67 87.2 
35 55 HP 2.06 2.00 324.0 
36 67 HP 2.06 1.83 228.0 
37 71 HP 2.02 1.99 461.9 
38 72 HP 2.02 1.29 101.9 
39 77 HP 2.14 0.06 26.3 
40 84 HP 2.02 1.68 444.2 
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6.3  cDNA fragmentation gel electrophoresis images 
 
Figure 34.  cDNA fragments from cortex samples at 1 hr post 1mg/kg DFP exposure.  Exposure was 
extremely light but evidence of fragmented cDNA at bottom is clear. 
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Figure 35.  cDNA fragments from brainstem samples at 1 hr post 1mg/kg DFP exposure.  Exposure 
was extremely light but evidence of fragmented cDNA at bottom is clear. 
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Figure 36.  cDNA fragments from cerebellum and hippocampus samples at 1 hr post 1mg/kg DFP 
exposure.   
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VII.  Appendix II 
 
7.1  Quality control analysis of cortex gene array 
Raw Data 
The tabular text report for the raw data shows that sample 8 has the lowest pm_mean value 
among all the samples, while the raw signals of samples 3 and 5 exceed 400. 
 
The signal histogram for the raw data is very uneven throughout.  Sample 8 is really shifted to the 
left with a 2- to 3-fold lower signal overall. 
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Figure 37.  Signal histogram of raw cortex data. 
 
The relative signal box plot of the raw data is very uneven. Samples 10, 2, and 8 fall below the 
median line, with sample 8 being the lowest and standing out more than the rest of the data set.  
Samples 3, 5, and 9 fall above the median line with sample 5 being the furthest away. Overall 
sample 8 looks like an outlier in this graph. 
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Figure 38.  Relative signal box plot of raw cortex data. 
 
The Pearson’s correlation plot of the raw data shows all samples with correlation 0.966 or greater.  
Consistent with the result of the box plot, sample 8 shows the lowest correlation with the rest of 
this dataset, suggesting that it is probably an outlier.  
 
 
Figure 39.  Pearson’s correlation plot of raw cortex data. 
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The tabular report for the normalized data shows that the %P of sample 8 is significantly lower 
than that of other samples, probably due to the overall low signal of this chip.  Although sample 3 
has the second highest overall signal level, it has the lowest pos_control_mean and 
dabg_pos_vs_neg_auc among all samples.  
 
The signal histogram for the normalized data is much smoother than the raw signal histogram. 
There is some unevenness around the peak signal area but no chip seems to really stand out more 
than the others. 
 
 
Figure 40.  Signal histogram of normalized cortex data. 
 
The relative signal box plot for the normalized data shows that after normalization most the 
samples are very close to the median line.  Sample 3 is slightly below and sample 8 is much lower 
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than the rest of the samples and has a broader distribution.  Sample 4 and 6 are slightly above the 
median line. 
 
 
Figure 41.  Relative signal box plot of normalized cortex data. 
 
The Pearson’s correlation plot shows that all samples have correlation 0.967 or greater.  
However, sample 8 has the lowest correlation with other samples in the dataset, followed by 
sample 3 with a slightly lower correlation with others. 
 
 
 
Figure 42.  Pearson’s correlation plot of normalized cortex data. 
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Comment and Suggestion 
The signal of sample CX_1hr_8 is significantly lower than that of other chips even after 
normalization.  Additionally, it shows the lowest correlation with other chips.  As the quality of 
CX_1hr_8 is low, it should be excluded from the dataset.  Sample CX_1hr_3 also shows a 
decreased correlation with other chips.  However, considering the Pearson’s correlation 
coefficient and the number of samples of the DFP treatment group left after exclusion of 
CX_1hr_8, it is decided to include CX_1hr_3 in the dataset.  
 
7.2  Quality control analysis of brainstem gene array 
Raw Data 
The tabular text report for the raw data shows that the pm_mean values of samples BS_2hr_14 
and BS_2hr_20 are less than 300.  Other metrics appear to be okay. 
 
The signal histogram for the raw data is somewhat uneven with several samples shifting slightly 
away from the main peak area.  The peak of sample BS_2hr_20 has shifted noticeably to the left 
of the graph, indicating a weaker signal overall. 
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Figure 43.  Signal histogram of raw brainstem data. 
 
The relative signal box plot for the raw data is somewhat uneven with the majority of samples 
falling above or below the average median line.  Samples BS_2hr_20 has a broader signal 
distribution than the rest of the data set. 
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Figure 44.  Relative signal box plot of raw brainstem data. 
 
The Pearson’s Correlation plot for the raw signals indicates that all samples have a good 
correlation with the lowest correlation coefficient being 0.977.  Samples BS_2hr_14 and 
BS_2hr_20 appear to have a weaker correlation than the rest of the data set. 
 
 
Figure 45.  Pearson’s correlation plot of raw brainstem data. 
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The tabular text report shows that after normalization samples BS_2hr_14 and BS_2hr_20 have 
signal values very close to that of other chips.  The background-corrected signal (pm_mean - 
bgrd_mean) of most samples (except BS_2hr_14 and BS_2hr_20) is >100.  The quality of 
BS_2hr_20 is lower than that of other chips, based on the values of %P, pos_vs_neg_auc and 
dabg_pos_vs_neg_auc. 
 
The signal histogram for normalized data is improved from the raw data histogram, however it is 
still a little uneven.  The graph shows a significant amount of variation in the signal strength, 
particularly around the peak area. 
 
 
Figure 46.  Signal histogram of normalized brainstem data. 
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The relative signal box plot for the normalized data is quite even with all samples falling closely 
to the median line.  Sample BS_2hr_20 is the furthest from the median line, falling slightly below 
average.  It also has the broadest signal distribution among all samples. 
 
 
Figure 47.  Relative signal box plot of normalized brainstem data. 
 
 
The Pearson’s Correlation plot for the normalized signals shows that all samples have a good 
correlation with the lowest correlation coefficient being 0.977.  Samples BS_2hr_14 and 
BS_2hr_20 appear to have a lower correlation with other samples than the rest of the data set. 
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Figure 48.  Pearson’s correlation plot of normalized brainstem data. 
 
 
Comment and Suggestion 
After normalization the signals of the chips look reasonably consistent.  The quality of 
BS_2hr_20 is lower than that of others.  However, considering the Pearson’s correlation 
coefficient and the number of samples in the DFP treatment group, it is recommended to include 
this sample in the dataset.  
 
7.3  Quality control analysis of cerebellum gene array 
Raw Data 
The tabular text report for the raw data shows that sample CB_1hr_28 has a pm_mean value of 
175 that is significantly lower than that of other samples.   
 
The signal histogram for the raw data is somewhat uneven.  It also shows multiple peaks 
suggesting variation in the signal intensity.  Sample CB_1hr_28 has shifted noticeably away from 
the main peak to the left indicating a lower signal (it is at least 5-fold lower than other chips). 
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Figure 49.  Signal histogram of raw cerebellum data. 
 
 
The relative signal box plot for the raw is uneven with the majority of samples falling above or 
below the median line.  Samples CB_1hr_28 and CB_1hr_29 have shifted the furthest from the 
median line with sample CB_1hr_28 showing the lowest signals, as well as a broad signal 
distribution. 
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Figure 50.  Relative signal box plot of raw cerebellum data. 
 
 
The Pearson’s correlation signal plot of the raw data shows that all samples have a good 
correlation with the lowest correlation coefficient being 0.972.  Sample CB_1hr_28 has the 
lowest correlation of the data set, while sample CB_1hr_21 has a lower correlation than most of 
the data set.   
 
 
Figure 51.  Pearson’s correlation plot of raw cerebellum data. 
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The tabular report for the normalized data shows that the sample CB_1hr_28 has a %P of 69.1, a 
value that is significantly lower than that of other samples.  This is probably due to the low signal 
of CB_1hr_28.  However, its pos_vs_neg_auc is about the same as that of other samples, while it 
has the highest dabg_pos_vs_neg_auc among all the samples. 
 
The signal histogram for the normalized data is greatly improved from the plot of the raw data.  
However it is still a little uneven and shows a lot of variance in signal intensity. 
 
 
Figure 52.  Signal histogram of normalized cerebellum data. 
 
The relative signal box plot of the normalized data is quite even with most samples falling well 
on the median line.  Sample CB_1hr_28 falls somewhat below this line and has the broadest 
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signal distribution among all samples.  Sample CB_1hr_21 also has a slightly increased signal 
distribution in comparison to the rest of the data set. 
 
 
Figure 53.  Relative signal box plot of normalized cerebellum data. 
 
The Pearson’s correlation plot for the normalized data shows that all samples have a good 
correlation with the lowest correlation coefficient being 0.972.  Samples CB_1hr_21 and 
CB_1hr_28 appear to have lower correlations than the rest of the dataset. 
 
 
Figure 54.  Pearson’s correlation plot of normalized cerebellum data. 
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Comment and Suggestion 
The signal of sample CB_1hr_28 is significantly lower than that of other chips even after 
normalization.  Additionally, it shows the lowest correlation with other chips.  Sample 
CB_1hr_21 also shows a decreased correlation with other chips.  These two samples should 
probably be excluded from the dataset. 
 
7.4  Quality control analysis of hippocampus gene array 
Raw Data 
The tabular text report for the raw data shows that although there are variations in the raw signals 
among the samples, the difference between the highest and the lowest samples is less than that 
observed in other brain regions.  
 
The signal histogram for the raw data has some uneven peaks throughout but only one sample 
(HP_1hr_38) stands out significantly.  This sample is shifted to the left of the rest and is an 
indicator of a weaker signal. 
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Figure 55.  Signal histogram of raw hippocampus data. 
 
The relative signal box plot for the raw data has some variation throughout with most of the 
sample staying close to the median line.  Sample 38 is most noticeably below the median.  
Sample 37 is slightly below the median and samples 36 and 40 are slightly above the median. 
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Figure 56.  Relative signal box plot of raw hippocampus data. 
 
The Pearson’s correlation plot of the raw data shows that all samples have correlation coefficient 
of 0.964 or above.  Sample 38 however shows much lower correlation values than the rest of the 
data set. 
 
 
Figure 57.  Pearson’s correlation plot of raw hippocampus data. 
 
 
Normalized Data 
The tabular report for the normalized data shows that sample HP_1hr_38 has the lowest %P 
(~72), while that of HP_1hr_31 is the highest (>77).  However, other QC metrics of HP_1hr_38 
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(including pos_vs_neg_auc and dabg_pos_vs_neg_auc, etc.) are very similar to that of other 
chips.  HP_1hr_38 does show a lower correlation with other samples (the lowest being 0.964). 
The signal histogram for the normalized data is much smoother then the raw signal histogram.  
Sample 32 is slightly shifted to the left but may not be considered as an outlier.   
 
 
Figure 58.  Signal histogram of normalized hippocampus data. 
 
The relative signal box plot for the normalized data shows all samples falling very close to the 
median line.  Sample 38 has a broader signal distribution when compared to the rest of the 
samples. 
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Figure 59.  Relative signal box plot of normalized hippocampus data. 
 
The Pearson’s correlation plot of the normalized data looks much like that of the raw data.  All 
samples have 0.965 or more and sample 38 shows the lowest correlation than the rest of the 
samples. 
 
 
Figure 60.  Pearson’s correlation plot of normalized hippocampus data. 
 
Comment and Suggestion 
Although the raw signal of sample HP_1hr_38 is significantly lower than that of other chips, the 
normalization step did bring it up to the median line.  However, it has a somewhat broader signal 
distribution than that of the others, as well as a lower correlation with other samples (especially 
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HP_1hr_31 and HP_1hr_32).  Considering the quality of HP_1hr_38 and the numbers of samples 
in the control and DFP groups, HP_1hr_38 should probably be excluded from the dataset.  
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VIII. APPENDIX III 
 
8.1  Differential gene expression in cortex 
 
Table 19.  List of significantly up- and down-regulated genes in the cortex at 1 hr post 1 
mg/kg DFP exposure (p<0.05). 
Gene Symbol 
Transcript 
Cluster ID 
Control 
P Call
a 
DFP P 
Call
a 
Fold 
Change
b 
Differential Gene 
Expression (p-val) 
ly6g6e 7220633 A P 1.2710 0.0062 
rgd1563319_predicted 7058913 A P 1.1680 0.0479 
nmur2 7077638 A P 1.0475 0.0183 
clca2 7215247 A P 1.0381 0.0091 
pcolce 7101091 P P 1.2000 0.0074 
ptgds 7236819 P P 1.1777 0.0492 
ppapdc2 7040998 P P -1.1503 0.0068 
chd6_predicted 7247512 P P -1.1503 0.0500 
ppp1r9a 7250817 P P -1.1503 0.0212 
stau1 7248027 P P -1.1503 0.0269 
b3galt5_predicted 7087139 P P -1.1511 0.0041 
ikbkap 7286561 P P -1.1511 0.0226 
lats2_predicted 7138580 P P -1.1511 0.0487 
ddx24 7309953 P P -1.1511 0.0232 
gabrg3 7051876 P P -1.1511 0.0422 
rgd1565966_predicted 7259993 P P -1.1511 0.0451 
tparl 7124803 P P -1.1519 0.0279 
arid4b 7165280 P P -1.1519 0.0222 
rgd1311340_predicted 7060851 P P -1.1519 0.0364 
loc315676 7345882 P P -1.1519 0.0486 
rps6ka2 7027386 P P -1.1519 0.0154 
loc500392 7282942 P P -1.1519 0.0351 
ung 7103033 P P -1.1519 0.0132 
mme 7194580 P P -1.1519 0.0014 
crhr1 7072608 P P -1.1519 0.0425 
lsm14a_predicted 7050065 P P -1.1519 0.0319 
zc3h8 7244736 P P -1.1527 0.0497 
loc682082 7120010 P P -1.1527 0.0415 
map3k4_predicted 7027136 P P -1.1527 0.0040 
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cttnbp2 7262584 P P -1.1527 0.0321 
olr59 7034855 P P -1.1527 0.0293 
uble1a 7048375 P P -1.1535 0.0383 
rgd1564821_predicted 7313538 P P -1.1535 0.0399 
mtf2 7122533 P P -1.1535 0.0317 
fcmd_predicted 7275208 P P -1.1535 0.0005 
rab3c 7203733 P P -1.1543 0.0215 
zfml_predicted 7255517 P P -1.1551 0.0452 
fbxo34_predicted 7131094 P P -1.1551 0.0058 
rgd1559742_predicted 7175146 P P -1.1551 0.0243 
slco2b1 7054899 P P -1.1551 0.0277 
loc499258 7190524 P P -1.1551 0.0024 
anxa11 7142829 P P -1.1551 0.0482 
cul5 7345821 P P -1.1551 0.0047 
usp24_predicted 7278018 P P -1.1559 0.0415 
rnf19_predicted 7326587 P P -1.1567 0.0159 
slc16a7 7326050 P P -1.1567 0.0415 
grik2 7224361 P P -1.1567 0.0150 
rgd1308284_predicted 7201429 P P -1.1567 0.0422 
tlk1_predicted 7240022 P P -1.1575 0.0042 
rgd1308133_predicted 7328693 P P -1.1575 0.0127 
psme4 7122317 P P -1.1575 0.0318 
ppp3r1 7121341 P P -1.1583 0.0011 
loc682319 7238202 P P -1.1583 0.0353 
jmjd1a 7265928 P P -1.1591 0.0152 
slc2a3 7269356 P P -1.1591 0.0487 
ppp1r12a 7314682 P P -1.1591 0.0159 
tcerg1_predicted 7169917 P P -1.1599 0.0312 
ptgfrn 7212112 P P -1.1599 0.0219 
pcdh8 7140465 P P -1.1599 0.0146 
rgd1563278_predicted 7087855 P P -1.1599 0.0115 
sdad1 7116943 P P -1.1599 0.0102 
actr8_predicted 7143057 P P -1.1599 0.0313 
mgc112775 7278605 P P -1.1607 0.0075 
sorcs1_predicted 7063716 P P -1.1607 0.0091 
rgd1564304_predicted 7233239 P P -1.1615 0.0229 
mina 7092362 P P -1.1615 0.0327 
pip3ap 7190771 P P -1.1615 0.0008 
scyl2_predicted 7323630 P P -1.1615 0.0051 
rgd1564243_predicted 7229382 P P -1.1623 0.0071 
fxna 7061738 P P -1.1631 0.0214 
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rab11fip2_predicted 7064282 P P -1.1639 0.0184 
pde4b 7277759 P P -1.1639 0.0001 
rgd1561597_predicted 7231650 P P -1.1639 0.0338 
appbp2 7080918 P P -1.1647 0.0159 
loc361929 7193056 P P -1.1655 0.0171 
rgd1560157_predicted 7263015 P P -1.1655 0.0251 
gpr22_predicted 7305518 P P -1.1655 0.0281 
asns 7262054 P P -1.1655 0.0463 
hps6 7042520 P P -1.1663 0.0056 
gabrd 7293733 P P -1.1663 0.0417 
adam17 7305030 P P -1.1663 0.0182 
klhl22_predicted 7095327 P P -1.1663 0.0005 
snx13_predicted 7297384 P P -1.1672 0.0290 
cybasc3 7039697 P P -1.1672 0.0004 
ythdf3_predicted 7192186 P P -1.1672 0.0330 
slc16a1 7197677 P P -1.1672 0.0235 
pitrm1_predicted 7166245 P P -1.1672 0.0150 
slc25a30 7140153 P P -1.1680 0.0443 
rgd1308297 7141456 P P -1.1680 0.0137 
loc294560 7367579 P P -1.1688 0.0122 
ldha 7031732 P P -1.1688 0.0342 
xpo1 7121841 P P -1.1688 0.0212 
centb2 7088946 P P -1.1688 0.0221 
strn4_predicted 7029119 P P -1.1696 0.0465 
rgd1560288_predicted 7061550 P P -1.1696 0.0133 
eif5b 7353614 P P -1.1696 0.0033 
prpf31_predicted 7047524 P P -1.1704 0.0272 
gyk 7381764 P P -1.1704 0.0156 
ruvbl1 7255986 P P -1.1704 0.0324 
rgd1308745_predicted 7230611 P P -1.1704 0.0291 
loc686794 7107406 P P -1.1704 0.0282 
rabep1 7069295 P P -1.1712 0.0265 
rab14 7237876 P P -1.1720 0.0161 
ets2 7087083 P P -1.1728 0.0002 
sfrs8 7101643 P P -1.1736 0.0275 
gdap1_predicted 7282454 P P -1.1736 0.0326 
foxo1a 7193959 P P -1.1745 0.0434 
rgd1309765_predicted 7145510 P P -1.1745 0.0035 
csrp2bp_predicted 7233359 P P -1.1753 0.0181 
zfp46_predicted 7280640 P P -1.1761 0.0005 
unc13b 7274462 P P -1.1761 0.0254 
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tmem32_predicted 7384334 P P -1.1761 0.0061 
actn1 7308330 P P -1.1761 0.0039 
btbd15 7334334 P P -1.1769 0.0317 
rgd1563920_predicted 7190584 P P -1.1769 0.0283 
nfx1 7274267 P P -1.1769 0.0097 
sema4f 7266506 P P -1.1777 0.0220 
stxbp5l_predicted 7088544 P P -1.1785 0.0269 
garnl1 7306743 P P -1.1785 0.0491 
smpd3 7185072 P P -1.1794 0.0190 
loc688502 7269834 P P -1.1794 0.0064 
trpc5 7374009 P P -1.1794 0.0148 
polr2b_predicted 7124650 P P -1.1794 0.0101 
rad50 7077420 P P -1.1802 0.0389 
slc25a29 7310462 P P -1.1802 0.0451 
rgd1560891_predicted 7375722 P P -1.1802 0.0134 
hes1 7094386 P P -1.1810 0.0044 
acsl4 7374114 P P -1.1810 0.0001 
bbs2 7178810 P P -1.1810 0.0332 
ddx5 7083616 P P -1.1810 0.0021 
cacna2d3 7148574 P P -1.1810 0.0036 
rgd1562456_predicted 7204917 P P -1.1818 0.0100 
ctns_predicted 7079678 P P -1.1818 0.0263 
vps16 7232578 P P -1.1818 0.0381 
rgd1563620_predicted 7158419 P P -1.1818 0.0462 
smarca5_predicted 7180178 P P -1.1818 0.0438 
rgd1304687_predicted 7311646 P P -1.1818 0.0266 
txnl1 7176469 P P -1.1826 0.0267 
slc4a11_predicted 7244936 P P -1.1826 0.0315 
tmem33 7125361 P P -1.1835 0.0023 
ocrl 7377457 P P -1.1843 0.0154 
brd8 7174341 P P -1.1843 0.0201 
ifnar1_predicted 7086751 P P -1.1843 0.0123 
vps35 7179671 P P -1.1843 0.0019 
rgd1309821_predicted 7285358 P P -1.1851 0.0053 
phtf1 7197646 P P -1.1851 0.0415 
wrnip1 7163963 P P -1.1851 0.0064 
bhlhb9 7377146 P P -1.1859 0.0027 
psip1 7288108 P P -1.1859 0.0104 
wdsof1_predicted 7316378 P P -1.1867 0.0004 
loc302855 7384409 P P -1.1867 0.0226 
epha6_predicted 7087282 P P -1.1867 0.0091 
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tomm70a 7092521 P P -1.1876 0.0016 
klf5 7134502 P P -1.1876 0.0441 
neto2_predicted 7179618 P P -1.1876 0.0180 
rgd1561347_predicted 7280055 P P -1.1884 0.0304 
pik3c3 7168785 P P -1.1884 0.0222 
usp11 7379200 P P -1.1884 0.0103 
dcp2_predicted 7170052 P P -1.1892 0.0053 
cdh8 7178411 P P -1.1892 0.0074 
rgd1563192_predicted 7170080 P P -1.1900 0.0222 
senp2 7094920 P P -1.1900 0.0196 
sypl 7297253 P P -1.1909 0.0047 
pank3_predicted 7066268 P P -1.1909 0.0098 
loc362994 7320536 P P -1.1917 0.0387 
ncoa6ip_predicted 7272299 P P -1.1917 0.0223 
matk 7322009 P P -1.1917 0.0344 
rgd1308916_predicted 7331805 P P -1.1925 0.0272 
klhl9_predicted 7288433 P P -1.1925 0.0129 
rgd1560736_predicted 7339286 P P -1.1925 0.0230 
mtmr4_predicted 7070858 P P -1.1925 0.0226 
herc3_predicted 7254229 P P -1.1925 0.0432 
dapk1_predicted 7161563 P P -1.1925 0.0192 
atp2c1 7349651 P P -1.1925 0.0027 
ppil4_predicted 7024728 P P -1.1933 0.0018 
cast 7201367 P P -1.1933 0.0493 
rgd1560909_predicted 7353732 P P -1.1933 0.0283 
lrrtm3_predicted 7222712 P P -1.1942 0.0153 
smarca1_predicted 7384017 P P -1.1942 0.0467 
hps3_predicted 7206804 P P -1.1942 0.0150 
loc685009 7054929 P P -1.1942 0.0422 
clcc1 7198031 P P -1.1950 0.0101 
ddx46 7161974 P P -1.1950 0.0187 
rgd1305020_predicted 7234434 P P -1.1950 0.0282 
rpo1-2 7232482 P P -1.1958 0.0108 
cdh9_predicted 7190970 P P -1.1958 0.0323 
rtn4 7122174 P P -1.1958 0.0019 
plk2 7189518 P P -1.1958 0.0120 
agtpbp1_predicted 7155116 P P -1.1958 0.0097 
nup155 7190518 P P -1.1966 0.0008 
nol9 7281877 P P -1.1966 0.0265 
pafah1b2 7345103 P P -1.1966 0.0289 
cntn4 7256986 P P -1.1975 0.0066 
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loc606294 7222960 P P -1.1975 0.0102 
cand1 7325522 P P -1.1975 0.0096 
rgd1566090_predicted 7111046 P P -1.1975 0.0360 
arntl 7035625 P P -1.1983 0.0096 
bai3_predicted 7360518 P P -1.1983 0.0330 
crlz1 7124168 P P -1.1983 0.0269 
cspg6 7043235 P P -1.1991 0.0233 
lnp_predicted 7240346 P P -1.1991 0.0053 
loc682552 7370477 P P -1.1991 0.0492 
zdhhc13 7031771 P P -1.2008 0.0459 
rgd1307325 7151422 P P -1.2008 0.0115 
ehmt2 7220672 P P -1.2008 0.0374 
wbp4 7140489 P P -1.2016 0.0041 
rgd1564397_predicted 7384188 P P -1.2016 0.0249 
pcdhb13 7169550 P P -1.2033 0.0336 
thap1 7152707 P P -1.2033 0.0045 
grm8 7262990 P P -1.2050 0.0431 
ctps_predicted 7290659 P P -1.2058 0.0111 
stx7 7044991 P P -1.2066 0.0406 
uck2 7113627 P P -1.2066 0.0198 
epha7 7273556 P P -1.2066 0.0145 
itch 7234287 P P -1.2066 0.0456 
loc297530 7257651 P P -1.2075 0.0079 
lmo7 7134690 P P -1.2075 0.0048 
myo1b 7354333 P P -1.2075 0.0016 
lzts1 7144503 P P -1.2075 0.0146 
kpna3 7138937 P P -1.2083 0.0058 
tollip_predicted 7058842 P P -1.2100 0.0165 
rgd1307724_predicted 7104052 P P -1.2108 0.0012 
rps6kb1 7081292 P P -1.2117 0.0392 
gspt1 7064697 P P -1.2142 0.0118 
atp5a1 7172368 P P -1.2142 0.0056 
apaf1 7323725 P P -1.2150 0.0480 
tgfbr1 7274897 P P -1.2159 0.0194 
adss_predicted 7114537 P P -1.2159 0.0453 
gpr88 7213152 P P -1.2167 0.0237 
bhlhb5_predicted 7192231 P P -1.2176 0.0005 
kremen1 7127825 P P -1.2176 0.0033 
rgd1305255_predicted 7325674 P P -1.2184 0.0273 
efnb2_predicted 7147985 P P -1.2193 0.0125 
taok1 7070080 P P -1.2193 0.0338 
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col4a3bp_predicted 7188638 P P -1.2201 0.0044 
tax1bp1 7253847 P P -1.2201 0.0461 
gpr17 7174148 P P -1.2218 0.0041 
cyp11b1 7328953 P P -1.2218 0.0414 
clpx 7337301 P P -1.2226 0.0318 
trpc4ap 7246986 P P -1.2235 0.0146 
abcf2_predicted 7249579 P P -1.2235 0.0338 
rgd1563798_predicted 7236146 P P -1.2243 0.0343 
rgd1305386 7213641 P P -1.2286 0.0027 
creld1 7257415 P P -1.2294 0.0205 
loc362264 7235058 P P -1.2303 0.0442 
aven_predicted 7231165 P P -1.2303 0.0369 
yipf4 7303624 P P -1.2303 0.0054 
kcnab1 7194678 P P -1.2329 0.0094 
slc2a5 7281641 P P -1.2371 0.0164 
plcl1 7354667 P P -1.2380 0.0353 
dnajc10 7229289 P P -1.2406 0.0164 
st8sia5 7172334 P P -1.2414 0.0463 
papolg_predicted 7128938 P P -1.2414 0.0384 
loc691335 7372942 P P -1.2431 0.0204 
il1rapl1 7381802 P P -1.2475 0.0344 
rdx 7336159 P P -1.2475 0.0075 
loc306096 7140946 P P -1.2492 0.0111 
wdr47 7198029 P P -1.2492 0.0056 
tspan2 7197536 P P -1.2518 0.0122 
hnrpr 7280644 P P -1.2527 0.0235 
papd5_predicted 7183613 P P -1.2535 0.0139 
rgd1305110_predicted 7128921 P P -1.2535 0.0190 
atpaf1_predicted 7278598 P P -1.2553 0.0235 
zbtb25 7308021 P P -1.2561 0.0254 
dnaja2 7179628 P P -1.2561 0.0267 
actn2_predicted 7159027 P P -1.2561 0.0068 
ssb 7228467 P P -1.2570 0.0376 
accn2 7320698 P P -1.2588 0.0026 
pacsin3 7229978 P P -1.2614 0.0101 
gucy1a3 7210088 P P -1.2614 0.0000 
rgd1308557_predicted 7272431 P P -1.2623 0.0374 
strn 7302571 P P -1.2640 0.0212 
psmd11_predicted 7070233 P P -1.2675 0.0187 
spock3_predicted 7150497 P P -1.2684 0.0121 
loc683283 7266023 P P -1.2710 0.0245 
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rab3gap2 7108733 P P -1.2746 0.0247 
ephb6 7253088 P P -1.2746 0.0426 
gpc4 7384216 P P -1.2754 0.0094 
idh3a 7336340 P P -1.2781 0.0335 
rgs8 7106406 P P -1.2790 0.0340 
vcpip1 7272087 P P -1.2843 0.0023 
ap1g1 7180943 P P -1.2852 0.0249 
rgd1563860_predicted 7381372 P P -1.2870 0.0255 
zfyve20_predicted 7267350 P P -1.2906 0.0156 
chordc1_predicted 7333276 P P -1.2941 0.0351 
rgd1306526_predicted 7197758 P P -1.2941 0.0249 
thumpd1 7056723 P P -1.3013 0.0270 
akap5 7299483 P P -1.3022 0.0040 
loc303067 7076750 P P -1.3041 0.0019 
cse1l_predicted 7235503 P P -1.3068 0.0156 
mtdh 7316024 P P -1.3077 0.0376 
rgs9 7083866 P P -1.3077 0.0005 
rbm34 7186753 P P -1.3095 0.0301 
pdap1 7096516 P P -1.3213 0.0052 
hrmt1l3 7031833 P P -1.3250 0.0271 
ugt8 7213846 P P -1.3296 0.0170 
scn4b 7335651 P P -1.3351 0.0232 
st8sia1 7271000 P P -1.3435 0.0160 
nlgn1 7206998 P P -1.3510 0.0034 
pdyn 7244787 P P -1.5052 0.0441 
rgd1564914_predicted 7294851 P P -1.6632 0.0153 
rgd1308113 7138227 P A -1.0098 0.0086 
card15_predicted 7183538 P A -1.0182 0.0459 
syk 7162313 P A -1.0295 0.0309 
mgam_predicted 7252877 P A -1.0353 0.0214 
isg20l1_predicted 7033277 P A -1.0403 0.0150 
cd80 7093567 P A -1.0497 0.0443 
rhov 7243592 P A -1.0519 0.0289 
ddx59 7105549 P A -1.0688 0.0480 
arhgap27 7083177 P A -1.0703 0.0432 
chd1_predicted 7027824 P A -1.0830 0.0247 
rgd1564792_predicted 7249737 P A -1.0860 0.0081 
cldn22_predicted 7151316 P A -1.1057 0.0020 
rgd1563090_predicted 7172373 P A -1.1204 0.0235 
chaf1b 7086975 P A -1.1212 0.0151 
zfp294 7091191 P A -1.1258 0.0098 
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rgd1306565_predicted 7025395 P A -1.1527 0.0411 
sart3_predicted 7099072 P A -1.1769 0.0179 
aste1 7339953 P A -1.1835 0.0199 
a
Label refers to the presence call determined by Affymetrix software.  For the signal detected by each probe 
set, the Affymetrix software uses 2 pieces of information: the level of the signal (expression level) and the 
quality of the signal (real signal versus background noise caused by cross hybridization).  If the signal 
quality is low (detection p value > 0.05) then the software will make an absolute call of whether or not the 
gene is expressed regardless of the signal strength.  A – absent; P – present. 
b
The Affymetrix software will make a fold change calculation based solely on the signal levels without 
consideration of the detection p values.  Therefore, genes that are turned off or on will also show a fold 
change, although it is meaningless for these genes and can be ignored. 
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8.2  Differential gene expression in brainstem 
 
Table 20.  List of significantly up- and down-regulated genes in the brainstem at 1 hr post 1 mg/kg 
DFP exposure (p<0.05). 
Gene Symbol 
DFP 
Present 
(p-val) 
Control P 
Call
a 
DFP P 
Call
a 
Fold 
Change
b 
Differential 
Gene 
Expression 
(p-val) 
ccl11 0.0410 A P 1.2518 0.0363 
hpd 0.0484 A P 1.1983 0.0340 
slc23a1 0.0463 A P 1.1696 0.0102 
espn 0.0445 A P 1.1423 0.0031 
btnl8 0.0499 A P 1.1127 0.0055 
loc680712 0.0357 A P 1.0996 0.0013 
gucy2e 0.0272 A P 1.0762 0.0467 
slc2a2 0.0500 A P 1.0519 0.0008 
smyd1_predicted 0.0403 A P 1.0432 0.0403 
mgam_predicted 0.0323 A P 1.0310 0.0139 
hdmcp 0.0464 A P 1.0288 0.0031 
slc26a4 0.0433 A P 1.0260 0.0081 
kif12 0.0384 A P 1.0210 0.0444 
rgd1561153_predicted 0.0304 A P 1.0161 0.0329 
aanat 0.0401 P P 1.2075 0.0020 
olr1451_predicted 0.0107 P P 1.1843 0.0149 
gchfr 0.0148 P P 1.1810 0.0321 
rgd1566127_predicted 0.0022 P P 1.1712 0.0483 
oraov1_predicted 0.0243 P P 1.1704 0.0060 
ppig 0.0003 P P -1.4631 0.0432 
zmpste24_predicted 0.0000 P P -1.3204 0.0382 
rgd735140 0.0006 P P -1.3131 0.0377 
rgd1307966_predicted 0.0013 P P -1.3022 0.0174 
rgd1305001_predicted 0.0000 P P -1.2897 0.0116 
stx1a 0.0223 P P -1.2861 0.0306 
peflin 0.0026 P P -1.2746 0.0207 
mip1 0.0090 P P -1.2702 0.0198 
lypla1 0.0114 P P -1.2693 0.0160 
adprtl1 0.0013 P P -1.2684 0.0306 
loc499563 0.0016 P P -1.2658 0.0234 
loc317279 0.0342 P P -1.2649 0.0009 
tor1aip1 0.0000 P P -1.2640 0.0215 
loc304725 0.0014 P P -1.2457 0.0184 
atp11c_predicted 0.0017 P P -1.2329 0.0037 
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rgd1563556_predicted 0.0043 P P -1.2303 0.0063 
cdh18_predicted 0.0006 P P -1.2286 0.0095 
pctk2 0.0000 P P -1.2226 0.0465 
oprk1 0.0015 P P -1.2226 0.0286 
cacna2d3 0.0000 P P -1.2209 0.0185 
rgd1562284_predicted 0.0047 P P -1.2150 0.0218 
cntn6 0.0133 P P -1.2134 0.0419 
trhr 0.0374 P P -1.2125 0.0368 
rgd1306256_predicted 0.0060 P P -1.2066 0.0275 
pgr 0.0173 P P -1.2066 0.0263 
anapc4 0.0002 P P -1.2025 0.0296 
lrrc7 0.0000 P P -1.2025 0.0407 
loc679564 0.0021 P P -1.2016 0.0457 
mllt3 0.0005 P P -1.2000 0.0098 
ddx50 0.0014 P P -1.1991 0.0406 
calb1 0.0000 P P -1.1983 0.0148 
gabrg3 0.0000 P P -1.1975 0.0217 
galnt13 0.0000 P P -1.1975 0.0286 
rgd1310810 0.0005 P P -1.1966 0.0431 
cul5 0.0000 P P -1.1950 0.0469 
ppm1a 0.0000 P P -1.1942 0.0203 
zc3h6_predicted 0.0002 P P -1.1925 0.0064 
car7_predicted 0.0026 P P -1.1917 0.0455 
sgtb 0.0001 P P -1.1900 0.0368 
loc688502 0.0001 P P -1.1892 0.0051 
jak2 0.0004 P P -1.1876 0.0444 
tlk2 0.0010 P P -1.1867 0.0308 
txndc4 0.0004 P P -1.1867 0.0310 
taf5l 0.0085 P P -1.1867 0.0414 
ipo7_predicted 0.0022 P P -1.1851 0.0336 
csnk1g1 0.0008 P P -1.1843 0.0092 
smarca1_predicted 0.0361 P P -1.1843 0.0213 
hspa14 0.0069 P P -1.1826 0.0245 
loc678810 0.0057 P P -1.1810 0.0281 
rgd1307084 0.0167 P P -1.1810 0.0391 
snapc1_predicted 0.0046 P P -1.1794 0.0055 
slc30a1 0.0229 P P -1.1785 0.0237 
cdkl1_predicted 0.0000 P P -1.1761 0.0480 
rgd1306259_predicted 0.0064 P P -1.1753 0.0122 
fkbp5 0.0032 P P -1.1753 0.0363 
cnksr2 0.0000 P P -1.1745 0.0333 
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kcnt2 0.0031 P P -1.1736 0.0232 
rgd1309058_predicted 0.0044 P P -1.1712 0.0301 
rgd1563465_predicted 0.0000 P P -1.1704 0.0182 
rgd1549725 0.0283 P P -1.1696 0.0138 
lrrtm3_predicted 0.0000 P P -1.1696 0.0424 
arf2 0.0194 P P -1.1688 0.0178 
stk32c_predicted 0.0002 P P -1.1688 0.0275 
loc689617 0.0072 P P -1.1688 0.0394 
mobk1b 0.0011 P P -1.1672 0.0324 
loc367153 0.0118 P P -1.1663 0.0096 
gpr22_predicted 0.0002 P P -1.1655 0.0131 
grpca 0.0471 P P -1.1655 0.0319 
pigh_predicted 0.0159 P P -1.1631 0.0404 
ahctf1_predicted 0.0000 P P -1.1623 0.0360 
fez2 0.0190 P P -1.1615 0.0203 
arntl 0.0114 P P -1.1591 0.0316 
ift74 0.0006 P P -1.1591 0.0472 
srm 0.0000 P P -1.1583 0.0152 
papd4 0.0000 P P -1.1583 0.0336 
pafah1b2 0.0000 P P -1.1567 0.0070 
rab5a 0.0004 P P -1.1551 0.0034 
rab3b 0.0016 P P -1.1551 0.0420 
ssx2ip 0.0001 P P -1.1543 0.0167 
loc682303 0.0124 P P -1.1535 0.0176 
rgd1310137 0.0232 P P -1.1527 0.0036 
lrfn5_predicted 0.0001 P P -1.1527 0.0153 
xrn1_predicted 0.0040 P P -1.1519 0.0223 
oxr1 0.0000 P P -1.1519 0.0103 
soat 0.0477 P P -1.1511 0.0337 
rgd1560796_predicted 0.0011 P P -1.1511 0.0092 
klhl8_predicted 0.0000 P P -1.1511 0.0254 
ckm 0.0530 P A -1.2702 0.0068 
nov 0.1610 P A -1.2596 0.0359 
loc361473 0.0531 P A -1.2371 0.0118 
rnf6_predicted 0.0514 P A -1.1975 0.0260 
usp12_predicted 0.0578 P A -1.1583 0.0439 
dnmt2 0.0564 P A -1.1282 0.0431 
daxx 0.0521 P A -1.1127 0.0282 
camlg 0.0604 P A -1.1119 0.0270 
zcchc11_predicted 0.0883 P A -1.1034 0.0404 
rgd1308632 0.0538 P A -1.0981 0.0029 
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kcnn4 0.0705 P A -1.0762 0.0394 
mrps9 0.0524 P A -1.0417 0.0052 
loc288750 0.0518 P A -1.0217 0.0483 
rgd1311358 0.0526 P A -1.0084 0.0425 
rgd1564727_predicted 0.0512 P A -1.0014 0.0180 
a
Label refers to the presence call determined by Affymetrix software.  For the signal detected by each probe 
set, the Affymetrix software uses 2 pieces of information: the level of the signal (expression level) and the 
quality of the signal (real signal versus background noise caused by cross hybridization).  If the signal 
quality is low (detection p value > 0.05) then the software will make an absolute call of whether or not the 
gene is expressed regardless of the signal strength.  A – absent; P – present. 
b
The Affymetrix software will make a fold change calculation based solely on the signal levels without 
consideration of the detection p values.  Therefore, genes that are turned off or on will also show a fold 
change, although it is meaningless for these genes and can be ignored. 
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8.3  Differential gene expression in cerebellum 
 
Table 21.  List of significantly up- and down-regulated genes in the cerebellum at 1 hr post 1 mg/kg 
DFP exposure (p<0.05). 
Gene Symbol 
Transcript 
Cluster ID 
Control P 
Call
a 
DFP P 
Call
a 
Fold 
Change
b 
Differential 
Gene 
Expression (p-
val) 
npas4 7059690 A P 1.4409 0.0230 
prss1 7253051 A P 1.1851 0.0321 
npy5r 7144617 A P 1.1487 0.0358 
loc682898 7373679 A P 1.1479 0.0157 
ubxd3 7292372 A P 1.1400 0.0108 
pex11c_predicted 7096062 A P 1.1368 0.0104 
rom1 7060215 A P 1.1034 0.0019 
mpo 7070870 A P 1.1004 0.0197 
loc686178 7152914 A P 1.0981 0.0275 
loc686966 7142343 A P 1.0935 0.0190 
loc682124 7115871 A P 1.0468 0.0470 
dusp2 7232331 A P 1.0353 0.0124 
col27a1 7275821 A P 1.0154 0.0445 
nr4a2 7239111 P P 1.5476 0.0346 
fos 7300295 P P 1.5021 0.0359 
rgd1305207 7320961 P P 1.4113 0.0319 
nr4a3 7274931 P P 1.3232 0.0333 
dusp1 7066011 P P 1.2843 0.0289 
tessp5 7340732 P P 1.2518 0.0208 
tnfrsf4 7282381 P P 1.1892 0.0176 
mafg 7085198 P P 1.1769 0.0161 
zfp206_predicted 7065316 P P 1.1753 0.0026 
trib1 7317342 P P 1.1623 0.0383 
heyl_predicted 7279240 P P 1.1599 0.0189 
rgd1560065_predicted 7200445 P P -1.3822 0.0007 
eif3s6 7327087 P P -1.3794 0.0259 
cbr4 7150589 P P -1.3538 0.0119 
morf4l2 7383689 P P -1.3351 0.0074 
rgd1304686 7039157 P P -1.3268 0.0106 
pin1_predicted 7333428 P P -1.3186 0.0395 
jtb 7196390 P P -1.3113 0.0146 
hbxip_predicted 7197893 P P -1.3013 0.0055 
cmpk 7290094 P P -1.2977 0.0323 
idi1 7166170 P P -1.2941 0.0013 
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tmem22 7349372 P P -1.2941 0.0326 
atox1 7077604 P P -1.2941 0.0380 
cox4i2 7233997 P P -1.2843 0.0430 
arl4a 7305953 P P -1.2781 0.0109 
mki67ip 7104286 P P -1.2719 0.0269 
rps7 7305265 P P -1.2605 0.0168 
sult1a1 7057289 P P -1.2579 0.0176 
tmem49 7081108 P P -1.2509 0.0125 
crtam_predicted 7344444 P P -1.2501 0.0134 
gnmt 7352038 P P -1.2492 0.0250 
loc499779 7237617 P P -1.2466 0.0416 
loc363484 7376206 P P -1.2457 0.0299 
rnut1 7336565 P P -1.2440 0.0457 
rgd1565441_predicted 7376584 P P -1.2431 0.0256 
ssr3 7209291 P P -1.2423 0.0018 
chic2_predicted 7117936 P P -1.2414 0.0044 
rnf138 7168316 P P -1.2406 0.0036 
akr7a2 7280974 P P -1.2397 0.0036 
ttpa 7273147 P P -1.2388 0.0428 
paip1_predicted 7190069 P P -1.2337 0.0093 
march2 7322862 P P -1.2286 0.0225 
cldn12_predicted 7250545 P P -1.2243 0.0112 
rgd1563459_predicted 7068965 P P -1.2218 0.0249 
tmco1 7107464 P P -1.2218 0.0388 
txnl2 7037921 P P -1.2209 0.0398 
timp1 7379138 P P -1.2176 0.0398 
slc2a10_predicted 7235412 P P -1.2167 0.0183 
mettl6 7148827 P P -1.2159 0.0084 
taf11 7221138 P P -1.2150 0.0244 
loc362129 7238414 P P -1.2142 0.0020 
loc301117 7370407 P P -1.2125 0.0498 
mnat1 7299267 P P -1.2117 0.0147 
znf593_predicted 7291854 P P -1.2117 0.0149 
loc362304 7249784 P P -1.2108 0.0043 
rgd1310794 7250681 P P -1.2100 0.0281 
alkbh3 7242031 P P -1.2100 0.0480 
cbx7 7329878 P P -1.2075 0.0313 
fcgr3 7113955 P P -1.2075 0.0377 
sub1 7205179 P P -1.2050 0.0061 
cldnd1 7092399 P P -1.2025 0.0159 
cyb5 7172808 P P -1.2016 0.0129 
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rgd1562933_predicted 7371886 P P -1.2008 0.0220 
rgd1562794_predicted 7173122 P P -1.2008 0.0445 
dap3 7210715 P P -1.1991 0.0242 
loc498396 7120252 P P -1.1983 0.0199 
gclm 7198646 P P -1.1975 0.0409 
tsc22d3 7383864 P P -1.1950 0.0274 
tmem19 7325131 P P -1.1942 0.0275 
ppil3 7362531 P P -1.1942 0.0360 
psma6 7298286 P P -1.1925 0.0446 
bbs4_predicted 7346390 P P -1.1917 0.0053 
wdr12 7362759 P P -1.1917 0.0109 
eef1b2_predicted 7355235 P P -1.1909 0.0069 
ms4a6b 7060488 P P -1.1884 0.0083 
orc4l 7238623 P P -1.1876 0.0308 
hsf2 7219178 P P -1.1876 0.0396 
il13ra1 7378996 P P -1.1867 0.0319 
rgd1563824_predicted 7027009 P P -1.1851 0.0477 
atp5f1 7212517 P P -1.1843 0.0209 
rgd1307449 7365763 P P -1.1835 0.0254 
rsbn1_predicted 7197644 P P -1.1818 0.0148 
lrrc35 7344567 P P -1.1818 0.0164 
mrpl46 7053246 P P -1.1810 0.0063 
rchy1 7117001 P P -1.1810 0.0409 
rap2ip 7072450 P P -1.1802 0.0024 
slc25a20 7340393 P P -1.1802 0.0125 
metrn 7075592 P P -1.1802 0.0364 
trim50 7101332 P P -1.1794 0.0438 
atp5c1 7159732 P P -1.1785 0.0155 
ilkap 7365239 P P -1.1761 0.0047 
hmgn1 7092107 P P -1.1761 0.0201 
tmem138 7060322 P P -1.1761 0.0353 
cdh7 7104008 P P -1.1753 0.0144 
eif4a1 7079103 P P -1.1753 0.0425 
cd74 7170979 P P -1.1736 0.0303 
d123 7159989 P P -1.1720 0.0087 
gsbs 7254092 P P -1.1712 0.0283 
gabra4 7118216 P P -1.1704 0.0176 
rgd1310320 7110414 P P -1.1704 0.0195 
psma3 7299062 P P -1.1704 0.0338 
resp18 7363941 P P -1.1696 0.0168 
rgd1304748 7142414 P P -1.1696 0.0291 
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tprkb 7255679 P P -1.1696 0.0432 
nme2 7081660 P P -1.1688 0.0027 
rgd1311925_predicted 7085130 P P -1.1688 0.0231 
bap1_predicted 7143236 P P -1.1688 0.0358 
tada2l 7080793 P P -1.1680 0.0141 
rgd1311161 7151445 P P -1.1680 0.0185 
ercc8_predicted 7189404 P P -1.1672 0.0371 
galnt11 7260392 P P -1.1663 0.0330 
pcmt1 7043913 P P -1.1663 0.0377 
mrps12_predicted 7049346 P P -1.1647 0.0467 
atp1b3 7349069 P P -1.1631 0.0122 
fbxo22 7336427 P P -1.1623 0.0052 
loc293589 7038162 P P -1.1623 0.0414 
surf1 7237053 P P -1.1623 0.0446 
morf4l1 7114379 P P -1.1623 0.0405 
rgd1306583 7203374 P P -1.1615 0.0263 
rgd1309784 7337926 P P -1.1615 0.0206 
taldo1 7038449 P P -1.1607 0.0119 
dhx40 7081133 P P -1.1607 0.0450 
rgd1559909_predicted 7290921 P P -1.1599 0.0031 
isgf3g 7131960 P P -1.1599 0.0490 
rgd1304890 7208620 P P -1.1599 0.0195 
dnajc9_predicted 7129918 P P -1.1583 0.0495 
rgd1310953 7181438 P P -1.1583 0.0140 
cops3 7078117 P P -1.1583 0.0377 
tpst1 7101571 P P -1.1567 0.0033 
za20d3 7053926 P P -1.1567 0.0134 
rgd1565289_predicted 7375643 P P -1.1567 0.0292 
khdrbs3 7317826 P P -1.1559 0.0157 
rgd1304592_predicted 7271008 P P -1.1543 0.0337 
dnaja2 7179628 P P -1.1535 0.0160 
yipf4 7303624 P P -1.1527 0.0124 
rgd1563352_predicted 7050869 P P -1.1527 0.0212 
eif3s4 7342899 P P -1.1511 0.0264 
rgd1559901_predicted 7033268 P P -1.1511 0.0094 
lmcd1_predicted 7257290 P P -1.1511 0.0004 
cct4 7121804 P P -1.1511 0.0020 
prei3 7354648 P P -1.1511 0.0253 
loc500947 7333100 P P -1.1503 0.0367 
loc685243 7349579 P A -1.2380 0.0206 
glipr1 7324926 P A -1.2252 0.0056 
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pi4k2b 7126173 P A -1.2075 0.0121 
loc500893 7318137 P A -1.1313 0.0077 
rgd1560328_predicted 7039654 P A -1.1235 0.0282 
apoh 7073093 P A -1.0920 0.0240 
chek1 7344093 P A -1.0770 0.0426 
rgd1304719 7301961 P A -1.0267 0.0155 
a
Label refers to the presence call determined by Affymetrix software.  For the signal detected by each probe 
set, the Affymetrix software uses 2 pieces of information: the level of the signal (expression level) and the 
quality of the signal (real signal versus background noise caused by cross hybridization).  If the signal 
quality is low (detection p value > 0.05) then the software will make an absolute call of whether or not the 
gene is expressed regardless of the signal strength.  A – absent; P – present. 
b
The Affymetrix software will make a fold change calculation based solely on the signal levels without 
consideration of the detection p values.  Therefore, genes that are turned off or on will also show a fold 
change, although it is meaningless for these genes and can be ignored. 
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8.4  Differential gene expression in hippocampus 
 
Table 22.  List of significantly up- and down-regulated genes in the hippocampus at 1 hr 
post 1 mg/kg DFP exposure (p<0.05). 
Gene Symbol 
Transcript 
Cluster ID 
Control 
P Call
a 
DFP P 
Call
a 
Fold 
Change
b 
Differential 
Gene 
Expression 
(p-val) 
pex11c_predicted 7096062 A P 1.1511 0.0315 
rgd1564139_predicted 7226812 A P 1.1352 0.0327 
cpa6_predicted 7271972 A P 1.1251 0.0299 
rgd1307392_predicted 7300366 A P 1.0951 0.0027 
rgd1311565 7149614 A P 1.0815 0.0129 
slc1a6 7322521 A P 1.0607 0.0282 
rgd1560814_predicted 7131980 P P 1.3068 0.0132 
rragd_predicted 7273845 P P 1.1591 0.0253 
ptges2_predicted 7226278 P P -1.1503 0.0219 
rgd1561074_predicted 7338955 P P -1.1503 0.0385 
hrmt1l1 7217751 P P -1.1519 0.0313 
dhrs7b 7068301 P P -1.1535 0.0249 
tmie_predicted 7350260 P P -1.1535 0.0037 
loc307798 7184960 P P -1.1535 0.0125 
rgd1560783_predicted 7319486 P P -1.1543 0.0215 
rgd1305276 7169645 P P -1.1551 0.0347 
rgd1305110_predicted 7128921 P P -1.1559 0.0364 
trpc3 7207698 P P -1.1567 0.0296 
birc2 7341989 P P -1.1567 0.0123 
loc500392 7282942 P P -1.1575 0.0126 
armcx6 7383569 P P -1.1599 0.0025 
cdh22 7247856 P P -1.1599 0.0109 
vps45 7211615 P P -1.1607 0.0159 
heyl_predicted 7279240 P P -1.1607 0.0121 
fastk 7249610 P P -1.1615 0.0397 
loc503000 7281575 P P -1.1623 0.0461 
nfkbib 7049352 P P -1.1623 0.0165 
rab34 7080062 P P -1.1639 0.0416 
dvl1 7282328 P P -1.1655 0.0126 
rgd1311433_predicted 7074692 P P -1.1688 0.0377 
dffa 7281533 P P -1.1696 0.0237 
erp29 7098469 P P -1.1704 0.0135 
mfng 7329632 P P -1.1704 0.0016 
sdhb_predicted 7281072 P P -1.1712 0.0367 
184 
 
ppm1f 7095530 P P -1.1753 0.0075 
loc298018 7275427 P P -1.1769 0.0262 
il3ra 7100909 P P -1.1769 0.0100 
ctbp2 7058050 P P -1.1769 0.0435 
abo 7237043 P P -1.1785 0.0112 
moap1 7309897 P P -1.1818 0.0345 
rps6ka4_predicted 7059970 P P -1.1818 0.0214 
rgd1564019_predicted 7237711 P P -1.1818 0.0396 
map2k2 7322049 P P -1.1859 0.0237 
rgd1311900_predicted 7120197 P P -1.1867 0.0443 
dpp10 7110544 P P -1.1909 0.0084 
gli1 7326245 P P -1.1958 0.0225 
rgd1305631_predicted 7096970 P P -1.1983 0.0071 
cd320 7312950 P P -1.2050 0.0016 
arv1_predicted 7182053 P P -1.2100 0.0226 
abhd14a 7349759 P P -1.2117 0.0084 
loc499798 7227487 P P -1.2125 0.0170 
zfp207 7070228 P P -1.2193 0.0485 
psmb8 7220914 P P -1.2235 0.0018 
crip2 7302155 P P -1.2260 0.0131 
prkg2 7116627 P P -1.2269 0.0258 
ddx47 7259105 P P -1.2277 0.0404 
sult1a1 7057289 P P -1.2294 0.0300 
tmem22 7349372 P P -1.2303 0.0072 
ubadc1 7236927 P P -1.2329 0.0480 
irak1bp1_predicted 7338594 P P -1.2337 0.0476 
hdgfrp3 7053729 P P -1.2397 0.0453 
mrps12_predicted 7049346 P P -1.2406 0.0166 
rgd1307475 7137537 P P -1.2466 0.0230 
rab3b 7278266 P P -1.2475 0.0059 
fabp3 7279978 P P -1.2501 0.0184 
pcbp2 7373866 P P -1.2509 0.0355 
znf593_predicted 7291854 P P -1.2509 0.0127 
mrpl9 7196794 P P -1.2561 0.0275 
mgc94555 7135395 P P -1.2588 0.0081 
loc498029 7073939 P P -1.2614 0.0497 
rgd1562933_predicted 7371886 P P -1.2684 0.0410 
ke2 7217033 P P -1.2799 0.0350 
exosc5_predicted 7029832 P P -1.2816 0.0027 
loc499947 7248407 P P -1.2852 0.0275 
camk2d 7198855 P P -1.2861 0.0175 
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ndn 7032357 P P -1.2950 0.0040 
igfbp6 7321003 P P -1.2977 0.0046 
mpst 7318588 P P -1.3086 0.0498 
bri3 7100296 P P -1.3140 0.0498 
ahcy 7246923 P P -1.3296 0.0210 
rgd1563497_predicted 7051164 P P -1.3538 0.0390 
resp18 7363941 P P -1.3890 0.0410 
map1lc3a 7234297 P P -1.4006 0.0279 
aqp11 7054680 P P -1.4152 0.0273 
stard10 7034633 P P -1.4499 0.0438 
unc119 7079952 P P -1.4917 0.0354 
coch_predicted 7298004 P A -1.2277 0.0141 
mafk 7100653 P A -1.1591 0.0126 
syde1_predicted 7312686 P A -1.1527 0.0114 
eif1b_predicted 7341468 P A -1.1503 0.0187 
rgd1566118_predicted 7216807 P A -1.1400 0.0219 
umps 7088755 P A -1.1329 0.0260 
myocd 7078672 P A -1.1282 0.0089 
rgd1307688 7267004 P A -1.1196 0.0404 
mppe1_predicted 7176727 P A -1.1165 0.0020 
zcchc11_predicted 7278195 P A -1.1127 0.0158 
ankrd32_predicted 7201470 P A -1.1042 0.0431 
cdc25a 7340628 P A -1.1019 0.0177 
rgd1308612 7236250 P A -1.0845 0.0097 
ltk_predicted 7243627 P A -1.0845 0.0143 
traf2_predicted 7236836 P A -1.0519 0.0067 
rgd1564500_predicted 7339142 P A -1.0475 0.0166 
ormdl2_predicted 7321465 P A -1.0417 0.0384 
rnf125_predicted 7168309 P A -1.0295 0.0242 
sfrp4 7164977 P A -1.0182 0.0289 
a
Label refers to the presence call determined by Affymetrix software.  For the signal detected by each probe 
set, the Affymetrix software uses 2 pieces of information: the level of the signal (expression level) and the 
quality of the signal (real signal versus background noise caused by cross hybridization).  If the signal 
quality is low (detection p value > 0.05) then the software will make an absolute call of whether or not the 
gene is expressed regardless of the signal strength.  A – absent; P – present. 
b
The Affymetrix software will make a fold change calculation based solely on the signal levels without 
consideration of the detection p values.  Therefore, genes that are turned off or on will also show a fold 
change, although it is meaningless for these genes and can be ignored. 
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IX. APPENDIX IV 
 
The analyses of cortex lipid extracts from the 48 hr time point were compromised by faulty proton 
decoupling, creating spectra that contained signals with incomplete or absent decoupling.  Therefore, it was 
impossible to quantify the lipid signals accurately.  Because the PtdC signal was quantified from the 
13
C 
spectra and used as the internal standard for the 
31
P spectra signal quantification, the values derived from 
the phospholipid spectra were also suspect.  The decoupling parameters were adjusted and decoupling was 
restored.  The CDCl3 from the small amount of lipid extract that was unused from the initial analysis was 
evaporated, vials were re-weighed and the remaining lipid was reconstituted with 550 µL of CDCl3.  Five 
hundred microliters were transferred to 5 mm NMR tubes and re-analyzed.  Metabolite concentrations were 
normalized back to the original weight of tissue, although the full amount of lipid from the tissue was not 
available.  Results from the first, non-decoupled analysis and second, decoupled analyses are shown in 
Table 22.  These results are qualitative and are only meaningful relative to the samples that were run 
together (i.e. control and DFP for the first analysis).  The data suggest that, at 48 hr post DFP exposure, the 
lipid profiles did not change significantly from control. 
  
187 
 
Table 23.  Changes in lipid metabolite concentrations in the cortex 48 hr post 1 mg/kg DFP dose. 
 Metabolite Concentration (µmol/g tissue) 
 First Analysis
a 
Second Analysis
b 
Metabolite Control DFP Control DFP 
Total Tissue Weight (g) 0.81 ± 0.03 0.78 ± 0.04 0.81 ± 0.03 0.78 ± 0.04 
Phosphatidic acid 0.5 ± 0.06 0.6 ± 0.1 0.09 ± 0.06 0.09 ± 0.03 
Cardiolipin 4.0 ± 0.6 3.4 ± 1.7 0.23 ± 0.12 0.22 ± 0.06 
Ethanolamine  
plasmalogen 
41.0 ± 2.9 47.9 ± 12.5 2.7 ± 1.4 2.7 ± 1.0 
Choline plasmalogen 2.3 ±  1.8 
e 
0.14 ± 0.11 0.12 ± 0.05 
Phosphatidylserine 30.8 ± 3.4 40.0 ± 9.2 1.4 ± 0.5 1.5 ± 0.6 
Phosphatidyl- 
ethanolamine 
64.4 ± 8.3 75.7 ± 13.0 2.6 ± 0.8 2.5 ± 0.9 
Phosphatidylinositol 6.8 ± 1.0 9.5 ± 2.6 0.3 ± .1 0.3 ± 0.1 
Phosphatidylcholine 111.7 ± 9.8 132.6 ± 29.1 5.9 ± 2.2 5.7 ± 2.1 
Sphingomyelin 14.6 ± 3.3 24.7 ± 12.8 0.5 ± 0.2 0.5 ± 0.2 
Cholesterol
c 
172.2 ± 22.1 207.6 ± 32.1 8.4 ± 4.3 9.4 ± 2.9 
n3 Fatty acids 40.8 ± 8.9 52.4 ± 12.5 3.5 ± 1.3 3.2 ± 1.3 
n6 Fatty acids 52.1 ± 7.0 75.2 ± 28.8 5.3 ± 1.8 5.0 ± 2.2 
Polyunsaturated  
fatty acids
d 430.7 ± 52.4 529.8 ± 107.0 28.7 ± 10.1 28.0 ± 11.2 
Total fatty acids 440.3 ± 56.1 518.6 ± 96.5 36.5 ± 12.0 35.5 ± 14.1 
a
First analysis denotes initial NMR analysis of lipid extract where decoupling parameters were 
faulty. 
b
Second analysis denotes subsequent NMR analysis of remaining lipid extract after decoupling 
parameters were corrected.  Lipid concentration was low, resulting in poor signal to noise ratio. 
c
Average of 2 cholesterol carbon signals for the first analysis (C18 at 12.5 ppm and C19 at 19.7 
ppm ) and 3 cholesterol carbon signals for the second analysis (C18 at 12.5 ppm, C19 at 19.7 ppm 
and C14 at 57.2 ppm). 
d
Polyunsaturated fatty acid signal intensity is subject to changes in both concentration and 
composition  
e
Unable to quantify signal because of poor resolution 
